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Mast cells release potent mediators upon degranulation, including serine proteinases.
These proteinases play a pivotal role in the pathogenesis of human asthma. Due to
the similarities between human asthma and equine heaves, a similar role for the mast
cell in equine heaves is proposed.
Antibodies directed against equine tryptase and equine mast cell proteinase-1
(eq.MCP-1) were purified, validated and used to develop ELISAs for determination
of proteinase concentrations in bronchoalveolar lavage fluid (BALF) from controls,
clinical heaves horses, heaves horses in remission and horses with other pulmonary
diseases. Clinical heaves horses had significantly increased BALF tryptase
concentrations compared to controls or heaves horses in remission, whereas BALF
tryptase concentrations of controls and heaves horses in remission did not
significantly differ. Horses with other pulmonary diseases also had significantly
elevated BALF tryptase concentrations compared to controls. Very low eq.MCP-1
concentrations were detected in all samples. Likewise, eq.MCP-1 immunoreactive
cells were scarcely observed in equine lung tissue or BALF cytospins suggesting that
eq.MCP-1 may be unimportant in the healthy and heaves affected equine lung.
Cloning and sequencing of these proteinases revealed an alanine 216 substitution in
equine tryptase, which confers increased arginine substrate specificity and may
restrict fibrinogenolysis in vivo. The deduced eq.MCP-1 Aa sequence differed from
that isolated from equine mastocytoma tissue and it appears that a similar, but novel,
chymase was sequenced. Probing of tryptase mRNA transcript regulation in control
and heaves susceptible horses revealed no significant change in airway luminal cell
pellet tryptase expression following hay/straw challenge of control or heaves horses.
However, bioiicliiolar tissue from heaves horses in early resolution phase had
significantly down-regulated tryptase transcripts compared to controls. Furthermore,
immunohistochemistry revealed significant intra-epithelial recruitment of tryptase
positive mast cells in heaves horses compared to controls, suggesting involvement of
tissue mast cells in response to challenge.
in
In vitro hay dust suspension (HDS) challenge induced significant airway luminal
mast cell degranulation in heaves susceptible horses, however a similar dose
response trend was also evident in control horses. The increased number of intra¬
epithelial mast cells in heaves horses may explain the divergent mast cell response to
in vivo and in vitro challenges. HDS-induced mast cell degranulation in both control
and heaves horses may suggest non-IgE mediated degranulation. Alternatively, both
control and heaves horses may have been sensitised to HDS allergens and phenotypic
diversity may ultimately determine response to challenge. Collectively, these results
provide evidence for mast cell involvement in the pathogenesis of equine heaves and
warrant further studies into the potential roles ofmast cell mediators.
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Chapter 1: Review of the Literature
1.1. Introduction
As a result of domestication, horses are commonly exposed to deleterious stable
environments that have long been associated with respiratory disease (Clarke, 1788).
Consequently heaves (also termed recurrent airway obstruction, formerly chronic
obstructive pulmonary disease), which is induced by inhalation of organic stable
dusts, is the most common cause of chronic pulmonary disease in the horse in the
United Kingdom (Dixon et al., 1995a). Heaves is characterised by reversible
neutrophilic airway inflammation and airway obstruction primarily due to
bronchospasm and mucus hypersecretion following exposure of susceptible
individuals to poor quality hay and straw (Robinson et al., 1996) and as such, shares
many similarities with human occupational dust induced asthma. Whilst great
advances in knowledge have been made in recent years regarding the aetiological
components of organic dusts that can produce clinical signs of equine heaves
(McPherson et al., 1979a; Halliwell et al., 1993; McGorum et al., 1993d;
Schmallenbach et al., 1998; Pirie, 2002); the pathogenesis of the pulmonary
inflammatory response to inhaled dust is still poorly understood. Similarly, due to the
characteristic neutrophil influx into the pulmonary airspace following challenge of
heaves susceptible horses, it is the neutrophil that has been the focus of most
research, whilst the cellular events orchestrating this neutrophilic response have
received comparatively little attention.
The cell population of the healthy airway comprises macrophages, lymphocytes and
occasional mast cells, neutrophils and eosinophils. The mast cell has tremendous
ability to react rapidly to inhaled stimuli releasing many potent mediators, including
serine proteinases, biologic amines and cytokines, with potential to influence a wide
range of effector cells. These mediators are believed to be biologically important in
the lung (Caughey, 1991) with mast cell degranulation acting as a key event in
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initiating and maintaining airway response to challenge in human asthma (Holgate,
2000). By analogy, a similar role for the mast cell may exist in equine heaves.
Current treatment protocols for heaves include preventative measures, such as
environmental control to remove the inciting dusts (which is often impractical in
temperate climates), or symptomatic therapy such as anti-inflammatories and
bronchodilators. It has become increasingly evident over recent years that the clinical
features of heaves are consequences of the underlying pulmonary inflammatory
response. Effective management of heaves therefore centres upon a fuller
understanding of the inflammatory pathway to allow more rational, directed therapies
for the treatment of this disease.
1.2. Equine Heaves
1.2.1. Aetiology
Although agents have been recognised that produce the clinical signs of heaves, the
definitive aetiologic agents or mechanisms that induce disease are not yet defined. It
is likely that heaves is multifactorial in aetiology, however the most commonly
implicated factor is exposure of the horse to environmental respiratory allergens,
predominantly in the stable environment (McPherson et al., 1979a; McPherson et al.,
1979b; Derksen et al., 1985; Tremblay et al., 1993; McGorum et al., 1993d).
Although the term 'respiratory allergen' has been used in many studies, the role of
allergy in equine heaves is still equivocal and poorly understood, as discussed
furthered in section 1.2.4.1.
1.2.1.1. Organic Stable Dust
Horses are exposed to a myriad of airborne pollutants in stable dust which can act as
allergens or direct irritants to the lung. These agents include inorganic dusts, fungal
and actinomycete spores, endotoxin, bacteria and viral aerosols, noxious gases such
as ammonia, plant material and dust mites and their metabolites (Clarke, 1987;
McGorum et al., 1998; May and Robinson, 2004). A genetic predisposition of
susceptibility to these environmental dusts has been described (Marti et al., 1991).
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The primary sources of airborne stable dusts are hay and straw and microbial growth
in situ on deep litter bedding materials such as wood shavings or newspaper
(McPherson et al., 1979b; Clarke, 1987; Spendlove et al., 2004). Agitation of food
and bedding due to foraging behaviour by the horse results in the dust concentrations
around the muzzle ('the breathing zone') being much higher than that in the overall
stable environment (Woods et al., 1993). Some degree of fungal contamination is
present in all hays. However, severe fungal growth occurs in hay that is baled with a
high moisture content, which can result in respirable challenges of up to 1010 fungal
and actinomycete propagules per breath in the horses' breathing zone (Clarke, 1987).
Dust concentrations in the stable vary with the feed and bedding products used
(Woods et al., 1993; Vandenput et al., 1997; McGorum et al., 1998; Spendlove et
al., 2004). A conventional stable with straw and visibly mouldy hay may have
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breathing zone dust concentrations as high as 17.5mg/m total dust and 9.3mg/m
respirable dust (Woods et al., 1993). In contrast, the current recommended threshold
limiting value for humans with an average 8h exposure period to grain dust is
4mg/m3 total dust (Chan-Yeung et al., 1992) and grain workers with repeated 8h
exposure to total dust concentrations of 5mg/m3 have suffered serious loss of
pulmonary function (Enarson et al., 1985). Considering that permanently housed
horses may be almost continuously exposed to the aforementioned much higher
levels of dust, ensuing airway dysfunction would seem highly probable in these
horses.
Clinical remission of heaves can be achieved by reduction of the environmental dust
burden, optimally by turning the horse out to pasture (McPherson et al., 1978;
Derksen et al., 1985). Keeping horses permanently outdoors however is frequently
impossible or impractical for owners in cold or temperate climates and therefore
environmental control is often instigated by improving stable ventilation and the use
of low dust feed substitutes such as haylage, haymax, silage or complete pelleted diet
and of beddings such as paper, shavings or rubber mats. Low dust stable
environments using wood shavings bedding and feeding a pelleted diet contain up to
97% less respirable dust burden in the equine breathing zone compared to that in
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conventional, poorly ventilated stables containing hay and straw (Woods et al., 1993;
McGorum et al., 1998). However, horses in low dust management stables have
significantly higher dust concentrations in the breathing zone than those at pasture
(McGorum et al., 1998). As mould spores are a large component of stable dust,
concentrations of these spores are also significantly lower in a low dust stable
environment (Woods et al., 1993). Vandenput et al. (1998) were able to maintain
heaves horses in clinical remission in a well ventilated stable bedded with good
quality straw and by feeding grass silage. However, when silage was replaced by
good quality hay, deterioration of pulmonary function was evident after several days
suggesting that, at least in this study, the hay was more capable of producing clinical
signs of heaves than the straw.
1.2.1.2. Mould Spores
Potential allergens that have frequently been implicated in the aetiology of equine
heaves include the mould spores Faenia rectivirgula, Aspergillus fiumigatus and
Thermoactinomyces vulgaris (McPherson et al., 1979a; Derksen et al., 1988; Woods
et al., 1993; McGorum et al., 1993d). These mould spores are respirable, i.e. have an
aerodynamic diameter <5jam and as such are small enough to be inhaled into the
terminal airways. Inhalation challenge of heaves susceptible horses with Faenia
rectivirgula and Aspergillus fumigatus extracts have been reported to result in
increased maximum trans-pulmonary pressure change (APpl), decreased arterial
oxygen pressure (PaC^) (McPherson et al., 1979a), deterioration in pulmonary
mechanics (Derksen et al., 1988) and intraluminal neutrophil recruitment (McGorum
et al., 1993d), consistent with a heaves-like response. Although Derksen et al. (1988)
found that inhalation challenge with Faenia rectivirgula increased bronchoalveolar
lavage fluid (BALF) neutrophil counts in both control and heaves susceptible horses,
the high challenge concentrations of antigen used were within the ranges which have
induced false positive responses in humans with no history of respiratory disease
(Cavannagh et al., 1977). Aspergillus fumigatus and Faenia rectivirgula are further
implicated by the observation that heaves susceptible horses have increased levels of
BALF IgE to these agents compared to control horses (Halliwell et al., 1993;
Schmallenbach et al., 1998). The role of Thermoactinomyces vulgaris is less clear, as
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inhalation studies with this potential allergen caused a neutrophilic influx into the
airway lumen in both control and heaves susceptible horses (McGorum et al.,
1993d). Inhalation challenge with these three mould extracts induced less severe
intraluminal neutrophilic influx than following natural hay / straw exposure and no
significant deterioration in lung function occurred following challenges (McGorum
et al., 1993d). This suggests that the duration of exposure to these fungal extracts, or
inhalation of a combination of antigens and pro-inflammatory agents is likely to be
important in reproducing clinical heaves.
On reflection of more recent literature however, it is possible that response to these
fungal extracts may have been at least partly due to non-specific responses to
contaminant endotoxin, rather than the fungal antigens themselves (Pirie, 2002).
Furthermore, the former studies utilised only soluble fungal antigens and the
presence of combined soluble antigens and particulate matter have proven important
in simulating the features of natural challenge (Pirie, 2002).
1.2.1.3. StorageMites
Large numbers of storage mites have been found in poorly saved forage and are
clinically important allergens in some forms of occupational asthma (Hallas and
Gudmundsson, 1985; Solarz et al., 1997). However, heaves horses do not have
elevated BALF IgE or IgG specific for these mites (B.C. McGorum, personal
communication) suggesting that hypersensitivity to these mites is unlikely to play a
role in the heaves response.
1.2.1.4. Endotoxin
Airborne endotoxin concentrations correlate with environmental dust concentrations
and have recently been implicated as an auxiliary aetiological agent causing
pulmonary inflammation in heaves (McGorum et al., 1998; Pirie et al., 2001; Pirie,
2002). Certainly, conventional hay / straw stables have been shown to contain
endotoxin concentrations in excess of those which can induce bronchial hyper-
responsiveness and pulmonary inflammation in control human subjects and
bronchoconstriction in humans with pre-existing pulmonary inflammation
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(McGorum et al., 1998). Inhalation challenge with endotoxin induces a dose
dependent neutrophilic airway inflammatory response in both heaves susceptible and
control horses; however heaves susceptible horses have a lower response threshold
(Pirie et al., 2001). Lung dysfunction was only observed in heaves susceptible horses
and only following higher challenge doses (Pirie et al., 2001). Comparison of natural
hay / straw exposure and nebulised endotoxin challenges suggests that whilst inhaled
endotoxin may contribute to airway inflammation, or even act synergistically with
other dust components, it is not the sole cause of the clinical signs in heaves affected
horses when exposed to hay / straw (Pirie et al., 2001).
1.2.2. Pathology
The main pathological finding in equine heaves is bronchiolitis (Nicholls, 1978;
Winder and von Fellenberg, 1988; Beech, 1991) characterised by diffuse epithelial
hyperplasia, increased numbers of goblet cells and goblet cell metaplasia, decreased
numbers of non-ciliated (Clara) cells, mucus plugging of airways and peribronchiolar
infiltration of neutrophils, lymphocytes and plasma cells (Thurlbeck and Lowell,
1964; Nicholls, 1978; Winder and von Fellenberg, 1988). In more severely affected
chronic cases, peribronchiolar fibrosis and alveolar emphysema may result (Winder
and von Fellenberg, 1988; Kaup et al., 1990a; Derksen, 1991). Eosinophilic
infiltration may be present in occasional animals (Thurlbeck and Lowell, 1964).
Despite similarities between equine heaves and human asthma, these diseases differ
in the predominant inflammatory cell recruited into the airway lumen. Thus, whilst
heaves is characterised by neutrophil influx into the airway lumen following
challenge of heaves susceptible horses (Winder and von Fellenberg, 1988; Dixon et
al., 1995b; Freeman and Roszel, 1997), classical asthma is characterised by
recruitment of predominantly eosinophils (Coyle et al., 1996). Heaves is therefore
more analogous to human occupational dust induced asthma, which also has a
predominantly neutrophilic cellular influx into the airway lumen. The mechanism for
inducing this neutrophilic rather than eosinophilic influx is not definitively known
but has been suggested to result from the key transcription factor nuclear factor-icB
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(NF-kB) in bronchial epithelial and airway luminal cells from heaves affected horses
being composed mainly of p65 homodimers, rather than classical p65-p50
heterodimers (Bureau et al., 2000). These p65 homodimers induce expression of
intercellular adhesion molecule-1 (ICAM-1), a cell surface ligand required for
neutrophil migration (Ledebur and Parks, 1995), and the potent neutrophil
chemokine IL-8 (Schulte et al., 2000), in contrast to the p65-p50 heterodimers which
induce expression of the eosinophil chemoattractant eotaxin (Matsukura et al., 1999).
However, mast cell mediators could provide an alternative explanation for this
neutrophil recruitment as mast cell derived tryptase, tumour necrosis factor-a (TNF-
a), interleukin-4 (IL-4), IL-8 and extractable nuclear antigen-78 (ENA-78) are all
potent chemokines with numerous other additional effects on mechanisms of
neutrophil recruitment as discussed in section 1.4. In addition, grain dust has been
demonstrated to induce both direct and indirect neutrophil chemotaxis via several
different pathways (section 1.3.1) and therefore in a similar mechanism, it is possible
that organic stable dust also plays a role in neutrophil recruitment to the airway.
Ultrastructural studies of the larger airways confirm that the principal change in
heaves affected horses is a hyperplastic epithelium with focal loss of ciliated
epithelial cells replaced by undifferentiated cells (Kaup et al., 1990b). Dilated
intercellular clefts and accumulations of mast cells, considered to be indicative of
non-specific mucosal hyper-reactivity, are also present (Kaup et al., 1990b). There
are degenerative changes in the terminal airways, including lack of differentiation
and loss of granulation of Clara cells and metaplasia of goblet cells. Alveolar regions
show necrosis of type I epithelial cells, alveolar fibrosis of varying degrees and type
II epithelial transformation and emphysema with an increase in Kohn's pores (Kaup
et al., 1990a).
The pathological lesions of heaves, although of a diffuse nature, are not homogenous
in distribution (Derksen, 1991). Whilst cytological composition of BALF samples
collected from 4 different lung regions in heaves affected horses showed no
significant difference (McGorum et al., 1993e), inflammatory markers indicative of
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oxidative stress and oxidative damage may show regional differences (D. Marlin,
personal communication).
1.2.3. Pathophysiology
Heaves is characterised by reversible small airway obstruction, airway hyper¬
reactivity and inflammation in response to inhalation of organic dusts. Airway
obstruction and subsequent deterioration of pulmonary function is predominantly the
result of bronchospasm of the bronchiolar smooth muscle, largely due to activation
of M3 muscarinic receptors by acetylcholine (Broadstone et al., 1988; Robinson et
al., 1996). The in vitro response of airway smooth muscle to acetylcholine is
unaltered, and therefore this increased smooth muscle tone is thought to be due to
activation of airway reflexes by inflammatory mediators, decreases in inhibitory
mechanisms such as the intrapulmonary nonadrenergic noncholinergic nervous
system and the production of PGE2 in affected horses (Robinson et al., 1996).
Pulmonary function indices of heaves affected horses at peak bronchodilator
response are significantly impaired relative to those of control horses suggesting that
residual obstruction is due to peribronchiolar cellular infiltration and luminal mucus
accumulation (Thurlbeck and Lowell, 1964; Murphy et al., 1980).
Diffuse airway obstruction leads to ventilation / perfusion mismatching and a
normocapnic hypoxaemia (McPherson and Thomson, 1983). The increased
respiratory drive caused by hypoxaemia in the presence of airway obstruction leads
to affected horses adopting a characteristic breathing pattern in which very high peak
flows at the start of exhalation rapidly diminish as expiration proceeds (Robinson et
al., 1996). With severe disease, horses develop a pronounced abdominal end
expiratory effort; the so-called 'heave'. Heaves susceptible horses exhibit reduced
dynamic compliance and increased pulmonary resistance, which increase the work of
breathing and APpl, following exposure to natural challenge environments (Muyulle
and Oyaert, 1973; McPherson et al., 1978; Thomson and McPherson, 1984;
McGorum et al., 1993d; Vandenput et al., 1998). Respiratory rate, minute volume,
maximum inspiratory flow rate and ratio of expiratory to inspiratory time are also
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significantly increased whilst inspiratory time and PaC>2 decrease in symptomatic
heaves horses (Muyulle and Oyaert, 1973; Thomson and McPherson, 1984).
Intraluminal airway cytology, airway reactivity and pulmonary function values return
to normal following removal of inhalational challenge. Remission of clinical signs
occurs 8.4 ± 4.8d (mean ± s.d., range 4 - 24d) following implementation of
environmental control (Thomson and McPherson, 1983; Thomson and McPherson,
1984; Armstrong et al., 1986; McGorum et al., 1993d). The time taken for horses to
become asymptomatic has been correlated with age, duration of illness and severity
of disease, as judged by the non-elastic work of breathing (Thomson and McPherson,
1984). Some structural airway changes such as epithelial metaplasia and hyperplasia
and smooth muscle hyperplasia take longer to resolve (Robinson et al., 1996).
Excessive and disordered mucus secretion and / or delayed mucokinesis may also
persist for prolonged periods following removal of allergens from the environment
(Dixon et al., 1995b).
1.2.4. Pathogenesis
Despite much research, the specific pathways which result in pulmonary
inflammation and obstruction in equine heaves remain ill-defined. In particular, the
role of allergy in the pathogenesis still remains somewhat speculative.
Collectively, the presented evidence suggests involvement of an IgE-mediated
hypersensitivity, but that it is unlikely to be the sole mechanism responsible for the
equine heaves response. Phenotypic diversity of heaves affected horses, as has been
described for occupational human asthmatics, is suggested by the individual
variability of response to challenge and the contrasting reports of IgE and T-helper
cell 2 (Th2) responses in affected horses. Consequently, phenotypic variation may be
an important determinant of the individual horse's response to inhalational challenge.
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1.2.4.1. Hypersensitivity to Moulds and Other Allergens
There is credible evidence from inhalational challenge studies to support the role of
hypersensitivity to the previously mentioned mould species in the pathogenesis of
heaves. Challenge with Faeni rectivirgula and Aspergillus fumigatus extracts
resulted in intraluminal neutrophilic influx in heaves susceptible but not control
horses, suggestive of a pulmonary hypersensitivity to specific antigens rather than a
non-specific response to dusts and irritants in the stable environment (McGorum et
al., 1993d). Increased levels of BALF IgE antibodies to Faeni rectivirgula and
Aspergillus fumigatus in asymptomatic and symptomatic heaves susceptible horses
also support a type I (IgE mediated) hypersensitivity response (Halliwell et al., 1993;
Schmallenbach et al., 1998). These studies reported IgE involvement to be restricted
to a localised pulmonary response as systemic antigen specific IgE levels were not
elevated in affected animals. More recent evidence however, suggests that serum IgE
to grain dust and grass pollens is in fact increased in a significant proportion of
heaves susceptible horses (L. Monreal, personal communication). An increase in IgE
positive cells in bronchiolar tissue and pulmonary blood vessels has also been found
in heaves affected horses as compared to controls, although this effect was
predominantly caused by very high numbers of positive cells found in two of the five
heaves horses (van der Haegen et al., 2001).
The selective recruitment of CD4+ T (helper) lymphocytes from peripheral blood
into the airway lumen following natural hay / straw challenge of heaves susceptible
horses also supports the role of allergy in the pathogenesis of heaves (McGorum et
al., 1993b). Similarly, the cytokine profile of increased IL-4 and IL-5 and decreased
interferon-y (INF- y) expression in airway luminal cells from heaves affected horses
as compared to controls is consistent with a local pulmonary Th2 response (Lavoie et
al., 2001). Other cytokine studies however, have suggested that heaves is not
characterised by a Th2 response (Giguere et al., 2002; Ainsworth et al., 2003b).
As airway obstruction and intraluminal neutrophil accumulation occur several hours
after antigen exposure, the response is most typical of a late phase, rather than an
immediate phase, type I hypersensitivity (McGorum et al., 1993d; Robinson et al.,
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1996). Involvement of a late phase response is also suggested by elevated pulmonary
epithelial lining fluid (PELF) histamine concentrations in heaves susceptible ponies
at 5h, but not at 0.5h, post natural challenge (McGorum et al., 1993c). However,
histamine release from mast cells is not necessarily IgE mediated as discussed further
in section 1.2.4.2.
Halliwell et al. (1979) previously suggested that IgE (type I), IgG (type III) and
possibly cell mediated (type IV) hypersensitivities were involved in the pathogenesis
of heaves. However that study was based upon skin wheal response to intradermal
antigens which, subsequent studies have shown do not correlate with pulmonary
responses to mould extracts (McGorum et al., 1993a).
1.2.4.2. Evidencefor a Mast Cell Role
The aforementioned studies demonstrating evidence of IgE mediated type I
hypersensitivity support mast cell participation in the pathogenesis of heaves.
Increased histamine release following in vitro Aspergillus fumigatus challenge of
airway luminal cells from symptomatic and asymptomatic heaves horses compared
to controls suggests that mast cells from heaves susceptible horses may be sensitised
to these fungal allergens (Hare et al., 1999). Furthermore, in vivo hay / straw
challenge caused significantly elevated PELF histamine concentrations in heaves
susceptible horses but not in controls, with concentrations correlated to numbers of
metachromatically stained intraluminal cells (McGorum et al., 1993c).
Histological and ultrastructural studies have demonstrated large numbers of mast
cells in the normal equine lung, with approximately 20% of these present in the
bronchiolar walls, the primary site of histological change in horses with heaves (Mair
et al., 1988). Mast cells are also located in the airway epithelium (Mair et al., 1988)
and the airway and alveolar lumina where they are strategically placed to interact
with inhaled antigens (Kaup et al., 1990a). Increased numbers of peribronchiolar
mast cells are reported in horses with mild, moderate and severe chronic bronchiolitis
(Nicholls, 1978; Winder and von Fellenberg, 1990). Furthermore, ultrastructural
studies have shown intraepithelial accumulations of mast cells in heaves affected
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horses in varying stages of degranulation (Kaup et al., 1990b). Degranulated mast
cells have also been identified in normal human bronchial mucosa however, and
therefore it is likely that some degranulation is physiological, rather than
pathological in nature (Lamb and Lumsden, 1982).
Some studies have also found increased numbers of intraluminal mast cells in
symptomatic heaves horses (Yashamiro et al., 1986; Winder et al., 1990; Vrins et al.,
1991) or horses with airway hyper-reactivity (Hoffman et al., 1998). Indeed, in this
latter study, intraluminal mast cell counts were significantly correlated with airway
hyper-reactivity. Degranulated mast cells have also been observed in BALF
preparations from horses with heaves (Yashamiro et al., 1986; Vrins et al., 1991)
suggesting release of mast cell mediators may occur in the airway lumen. Mast cell
granules contain mediators capable of causing many of the pathophysiological
effects of heaves as discussed in section 1.4. Indeed, Olszewski et al. (1999)
demonstrated that mast cell mediators increase cholinergic small airway tone in vitro
suggesting a potential role for these agents in the development of bronchospasm and
airway obstruction (Olszewski et al., 1999).
The apparent effectiveness of sodium cromoglycate, which is reputed to have mast
cell stabilising effects, in the prophylaxis of heaves may provide further evidence for
a mast cell role (Murphy et al., 1979; Thomson and McPherson, 1981). However,
studies in man have shown that the beneficial effects of this drug are more likely to
be attributable to its other anti-inflammatory effects (Richards et al., 1986).
Although mast cell participation in the pathogenesis of equine heaves is consistent
with a type I hypersensitivity response, mast cell degranulation is not necessarily IgE
mediated. It is now recognised that mast cells may also degranulate following non-
immunological activation by complement, neuropeptides, cytokines, endotoxin,
adenosine, lectins, opioids, hypoxia and changes in osmolality (da Silva et al., 1967;
Church et al., 1989; White, 1990; Bingham and Austen, 2000; Crummy et al., 2004).
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1.2.4.3. Previous Viral Injury
Several studies have shown that a significant proportion of heaves horses (19.2-
65.8%) have a history of respiratory infection in the immediate time period prior to
onset of heaves (McPherson et al., 1978; Halliwell et al., 1993; Dixon et al., 1995a).
Thorsen et al. (1983) found increased levels of anti-haemagglutination antibodies in
respiratory secretions from horses with heaves as compared to controls. Increased
levels of BALF IgE for Faeni rectivirgula and Aspergillus fumigatus have also been
identified in horses with a prior history consistent with respiratory viral infection and
which continued to cough after the expected resolution of the infectious disease
(Halliwell et al., 1993). Furthermore, inflammatory airway disease in young horses,
in which respiratory infections may have an aetiological role, has been hypothesised
to progress into heaves in the older animal (Moore et al., 1995; Hare and Viel, 1998)
Although the specific method by which viral or bacterial lung disease acts as a
trigger for the induction of heaves is unknown, it appears that prior infection may
increase the subsequent immune response to potential antigens.
1.3. Occupational Dust Induced Asthma
Occupational dust induced asthma (hereafter termed occupational asthma) is
characterised by reversible bronchiolitis and airway obstruction, as a result of
inhalation of environmental dusts in the workplace. In contrast to the intraluminal
influx of eosinophils in classical asthma, occupational asthma is characterised by
neutrophilic recruitment into the pulmonary airspace (Von Essen et al., 1988; Park et
al., 1999). Occupational asthma therefore shares many similarities with equine
heaves, which itself has been described as an occupational lung disease as it is a
consequence of the environment in which horses are kept in order to perform
(Derksen, 1993).
Human occupational asthma has been reported in work environments associated with
chronic inhalation of many types of organic dusts including grain dust (Do Pico et
al., 1984; Chan-Yeung et al., 1992; Park et al., 1999), red cedar sawmill dust (Vedal
et al., 1986; Frew et al., 1993; Chan-Yeung, 1994), cotton (Schachter et al., 1984;
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Zuskin et al., 1997), toluene diisocyanate (Di Stefano et al., 1993), storage mites
(Alvarez et al., 1999), vegetable gums (Bush, 1990) and fish processing (Rodriguez
et al., 1997). These multiple subtypes of occupational asthma do not appear to share
a universal pathogenesis for induction of pulmonary inflammation. Therefore, due to
the aetiological similarities between grain dust induced human occupational asthma
and equine heaves, this review will focus upon literature regarding grain dust
associated occupational asthma. Although the interstitial lung disease extrinsic
allergic alveolitis (Farmer's Lung) occurs in humans exposed to mouldy hay and
straw, this is a hypersensitivity pneumonitis (involving the alveoli and pulmonary
interstitium) rather than a type of occupational asthma (involving airways) and
therefore will not be reviewed.
1.3.1. Grain Dust Associated Occupational Asthma
The composition of grain dust is variable but is predominantly composed of fractured
grain kernels, fractured weed seeds, husks, storage mites, insects, bacteria, moulds,
inorganic matter and chemicals (Chan-Yeung et al., 1992). The effects of grain dust
inhalation have long been associated with respiratory ill health, with up to 88% of
grain workers reported to experience respiratory symptoms in the 1970's (Do Pico et
al., 1977). This high disease prevalence has lead to much research in recent decades,
with progressive reductions in the recommended threshold limiting value for
"7
environmental dust exposure (currently 4mg/m total grain dust for an average 8h
exposure period) (Chan-Yeung et al., 1992).
The prevalence of respiratory symptoms among grain workers is positively
correlated with length of employment in the grain industry (Do Pico et al., 1984).
Predisposing host factors such as atopy and smoking increase the severity of disease
and are important determinants of the individual's response to grain dust exposure
(Do Pico et al., 1984; Chan-Yeung et al., 1992; Park et al., 1998a). Skin reactivity to
common allergens is not associated with this disease (Enarson et al., 1985; Park et
al., 1998a). Grain dust specific IgE is present in the serum of 40% of symptomatic
subjects compared to only 11% of asymptomatic subjects (Park et al., 1998a)
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suggesting that grain dust can induce a systemic IgE-mediated response in some
individuals. However, as the majority of sufferers do not have serum specific IgE,
other non-IgE-mediated responses are also likely to be involved in the pathogenesis
of grain dust occupational asthma.
A strong dose-response relationship exists between grain dust concentration and both
respiratory symptoms and physiological lung dysfunction (Enarson et al., 1985; Huy
et al., 1991) with chronic exposure to 5mg/m total grain dust resulting in a serious
reduction in lung function (Enarson et al., 1985). Wheat grain extract causes a direct,
dose dependent constriction of guinea pig tracheal smooth muscle in vitro, possibly
by activation of cholinergic receptors (Schachter et al., 2004). Direct, dose-
dependent histamine release from human lung mast cells occurs following in vitro
grain dust challenge (Chan-Yeung et al., 1987; Alam et al., 1988) suggesting mast
cell involvement in the induction of this pulmonary dysfunction. This direct
histamine release has been shown to occur independently of IgE, complement and
cell cytotoxicity (Chan-Yeung et al., 1987). Grain dust also induces indirect
histamine release by stimulating the production of a histamine releasing factor from
lymphocytes (Alam et al., 1988). This lymphocyte derived degranulating factor is
suggested to be of greater physiological significance in vivo as its release occurs with
much lower grain dust concentrations than are required to induce direct mast cell
degranulation (Alam et al., 1988).
Grain dust is capable of inducing both direct and indirect neutrophil chemotaxis in
vitro, which may be important mechanisms for neutrophil recruitment into the airway
lumen in vivo. Aqueous extracts of grain dust are capable of activating both classical
and alternative complement pathways (Olenchock et al., 1980) such that indirect
chemotaxis occurs via release of the potent neutrophil chemotactic factor C5a (Von
Essen et al., 1988). Grain dust also induces the release of a neutrophil
chemoattractant factor from both bronchial epithelial cells (Von Essen et al., 1994)
and alveolar macrophages (Von Essen et al., 1988). IL-8 has been suggested as the
inducible neutrophil chemokine and its concentration is significantly increased from
baseline in the sputum of occupational asthmatics following in vivo grain dust
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challenge (Park et al., 1998b). Increased serum neutrophil chemotactic activity is
also evident in occupational asthmatics 30min following grain dust challenge (Park
et al., 1999). This serum neutrophil chemotactic activity can be divided into heat
stable and heat labile factors (Atkins et al., 1977) which are believed to originate
from mast cells and monocytes / macrophages, respectively (Nagy et al., 1982). The
numbers of mast cells in the bronchial mucosa are significantly increased in grain
dust occupational asthmatics compared to allergic asthma sufferers (Park et al.,
1998b) further supporting their involvement in pathogenesis of this disease.
1.4. Mast Cells in Airway Disease
1.4.1. Mast Cell Activation
Mast cells are strategically located close to blood vessels and nerves in tissues that
interface with the external environment, for example the lung, to encounter and
respond to foreign antigens. Mast cell activation is traditionally described as the
result of crosslinkage of allergen specific IgE to high affinity FcsRI receptors on the
mast cell surface (Kinet, 1990). However, as previously mentioned, degranulation
can also be mediated by endotoxin, complement, neuropeptides, adenosine, opioids,
hypoxia, changes in osmolality and lectins (Eggleston et al., 1987; Church et al.,
1989; White, 1990; Heaney et al., 1995; Bingham and Austen, 2000; Polosa et al.,
2002). Therefore allergy is not a prerequisite for mast cell activation. Following
activation via immunoglobulin receptors, polypeptide ligands (Bingham and Austen,
2000) or c-kit receptors (Bischoff and Dahinden, 1992) mast cells exocytose
preformed mediators stored in secretory granules such as the proteinases tryptase and
chymase and the biologic amine histamine. Activated mast cells also synthesise
substantial quantities of newly formed lipid mediators, such as leukotrienes (LT) and
prostaglandins (PG), and express multi-functional cytokines (Church et al., 1989;
Bingham and Austen, 2000). These mediators have a wide range of effector cells and
in asthma are believed to play a role in increasing vascular permeability and causing
bronchoconstriction, mucus hypersecretion and cellular recruitment, to amplify the
inflammatory response and ultimately contribute to tissue remodelling (Bingham and
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Fig.1.1 : Schematic diagram to show the integrated role of mast cell products in the
development of allergic airway inflammation, lym = lymphocyte, IL = interleukin,
LTC = leukotriene C; PGD = prostaglandin D; PAF = platelet activating factor; ENA
= extractable nuclear antigen, TNF-a = tumour necrosis factor-a. Taken from Hart
(2001).
1.4.2. Mast Cell Heterogeneity
Mast cells can be defined by their tissue location into mucosal mast cells (MMC) and
connective tissue type mast cells (CTMC). They have also been classified according
to their proteinase content into mast cells containing only tryptase (MCt), mast cells
containing both tryptase and chymase (MCtc) and mast cells containing only
chymase (MCc). Mast cell heterogeneity has been demonstrated in many species
with regard to their proteinase and cytokine content and also their function, with
these being dependent upon their tissue location (Bienenstock et al., 1985; Irani et
al., 1986; Barrett and Metcalfe, 1987; Shanahan et al., 1987; Chen et al, 1990; Sture
et al., 1995; Kube et al., 1998; Kuther et al., 1998). In rodents, mast cell
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heterogeneity is particularly notable with regard to their chymase content. For
example, the chymase mouse mast cell proteinase-4 (mMCP-4) is found in CTMC
and chymases mMCP-1 and mMCP-2 are found in MMC (Bienenstock et al., 1985;
Barrett and Metcalfe, 1987). However, there is also mast cell heterogeneity among
species such that mast cell proteinase composition in particular tissue locations
differs with the species studied. For example, in humans, MCt are found in the lung
and intestinal mucosa whilst MCtc are characteristically found in connective tissue
locations such as skin, lymph nodes and intestinal submucosa and occasional MCc
are found in human lung and intestinal tissue (Irani et al., 1986; Weidner and Austen,
1990; Weidner and Austen, 1991). In contrast, the majority of sheep mast cells are
MCt however gastrointestinal and lung nematodes induce a chymase (sheep mast
cell proteinase-1 [SMCP-1]) containing mast cell population. Parenchymal mast cells
are then MCtc but airway MMCs are predominantly MCt U- Brown, personal
communication). A preliminary study of the tissue distribution and heterogeneity of
equine mast cells reported the presence of chymase containing cells in connective
tissue and MCt in both mucosal and connective tissue locations (Pemberton et al.,
2001). Chymases are divided into a- and P- chymases according to their ability or
inability respectively to catalyse the conversion of angiotensin I to angiotensin II
(Wintroub et al., 1984; Chandrasekharan et al., 1996). Homologous a-chymases are
expressed in human and canine mast cells whereas rodent and ruminant mast cells
can contain both a- and p-chymases (Miller and Pemberton, 2002). It may be
inappropriate to compare chymase mast cell heterogeneity between species
expressing a- and P-chymases, which could have differing tissue distributions and
functions.
The characteristic metachromatic staining of mast cell granules seen with toluidine
blue is due to their content of heavily sulphated anionic proteoglycans, heparin and
chondroitin sulphate glycosaminoglycan, which act to stabilise proteinases in the
granule (Bingham and Austen, 2000). CTMC synthesise heparin whereas MMC of
most species produce little or no heparin and instead synthesise lower sulphated
chondroitin sulphates. MMC do not stain well with toluidine blue following aldehyde
fixation, although the reason for this is not clear (Walls et al., 1990).
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1.4.3. Evidence for Mast Cell Involvement in Human Asthma
It has been increasingly recognised over recent years that the release of mast cell
mediators may play a central role in inflammatory disorders such as allergic and
occupational asthma (Kaliner, 1984; Marone, 1985; Kay, 1987; Hart, 2001). As
previously mentioned, mast cell density in the lung is highest around blood vessels,
nerves and mucus glands; key areas where they are able to effect a rapid response to
a noxious insult. Allergen challenge in sensitised asthmatics induces both mast cell
infiltration into the airway mucosa and subsequent degranulation (Casale et al.,
1987b; Pesci et al., 1993; Montefort et al., 1994). Similarly, intra-epithelial
accumulations of mast cells have been observed in the airways of heaves affected
horses (Kaup et al., 1990b), inviting speculation of a similar mast cell response to
challenge in equine heaves and human asthma.
Compared to control subjects, asthmatics have increased numbers of mast cells in
their sputum (Pizzichini et al., 1996) and bronchial mucosa (Lozewicz et al., 1988;
Crimi et al., 1991; Pesci et al., 1993; Gibson et al., 1993; Laitinen et al., 1993;
Bradding et al., 1994). These bronchial mucosal mast cells demonstrate progressive
degranulation towards the airway lumen (Pesci et al., 1993; Koshino et al., 1995).
Increased numbers of intraluminal mast cells are inconsistently reported in
asthmatics, however if present, a positive correlation with airway hyper-reactivity
may exist (Kirby et al., 1987). The number of mast cells in asthmatic airway
epithelium have also been reported to correlate with the number of intraluminal mast
cells and airway reactivity (Gibson et al., 1993).
Mast cell numbers are also increased in bronchial smooth muscle of human
asthmatics compared to controls, suggesting they may play a role in bronchial hyper-
responsiveness (Ammit et al., 1997; Brightling et al., 2002; Carroll et al., 2002a).
Indeed, passive sensitisation of human bronchi with asthmatic serum in vitro induced
mast cell degranulation with an associated increase in measurable tryptase and
airway hyper-responsiveness (Berger et al., 2002). Mast cells appear essential to the
19
development of this hyper-reactive airway as previously sensitised control mice and
mast cell reconstituted mast cell deficient mice show allergen induced airway hyper-
responsiveness, whereas mast cell deficient mice are incapable of this response
(Kobayashi et al., 2000b). The increased cholinergic smooth muscle tone observed in
response to incubation of equine small airways with mast cell mediators suggests a
similar role for mast cells in inducing bronchospasm in equine heaves (Olszewski et
al, 1999).
Mast cell participation in the late phase response of allergic asthma is implicated by
normal numbers of bronchial tissue mast cells in asthmatics at 4h, but increased
numbers at 24h following allergen exposure, with the count at 24h significantly
correlated with severity of response (Crimi et al., 1991). Mast cell derived neutrophil
and eosinophil chemotactic factors have also been associated with the development
of the late phase inflammatory response (Nagy et al., 1982). These findings are of
interest given the apparent predominance of a late phase response in equine heaves,
with intraluminal neutrophil accumulation not occurring until several hours
following challenge.
1.4.4. Mast Cell Mediators
1.4.4.1. Tryptase
Tryptase, a neutral serine endopeptidase, is the predominant mast cell proteinase and
exhibits trypsin-like specificity, preferentially cleaving peptide bonds at the carbonyl
side of lysine or arginine residues, except when followed by a proline residue.
Tryptase is considered to be mast cell specific as, although basophils contain small
amounts of this proteinase, it is only approximately 0.2-0.4% of that present in mast
cells (Castells et al., 1987; Schwartz et al., 1987).
The enzymatically active form of tryptase is a tetramer of 120-140kDa, consisting of
four tryptase monomer subunits of 31-34kDa in a ring-like structure with a central
pore (Pereira et al., 1998). The protected location of the active sites facing inwards
towards the central pore makes tryptase resistant to endogenous mammalian
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proteinase inhibitors. The tryptase tetramer is stabilised by heparin and other
negatively charged proteoglycans with the monomers becoming inactive upon
dissociation. The tetrameric form of tryptase is also stabilised in vitro by
hydrophobic interactions at high salt concentrations (>0.5M). The stability of the
tetramer is thought to govern tryptase activity in vivo such that if heparin is
scavenged by substances with a higher affinity, for example neutrophil lactoferrin,
the tetramer dissociates into inactive monomers (Schwartz and Bradford, 1986;
Addington and Johnson, 1996). Therefore, interestingly, neutrophil recruitment in
heaves affected horses may actually have a role in restricting tryptase activity in the
airway.
Multiple tryptase subtypes have been recognised in some species such as humans and
sheep and different functional roles have been elucidated for human a- (constitutive)
and (3- (inducible) tryptases (Miller et al., 1989; Miller et al., 1990; Huang et al.,
2001). An equine tryptase, which shows strong identity with human tryptase-P over
the first 20 residues of the N-terminal amino acid (Aa) sequence, has recently been
isolated from equine mastocytoma tissue (Pemberton et al., 2001).
As previously indicated, the majority of pulmonary mast cells are MCj making
tryptase abundantly available in the lung. A role for tryptase in human asthma has
been suggested by elevated sputum (Pizzichini et al., 1996) and BALF tryptase
concentrations in asthmatics compared to control subjects (Wenzel et al., 1988;
Broide et al., 1991; Bousquet et al., 1991). Asymptomatic asthmatics also have
higher BALF tryptase concentrations than control subjects, implying some degree of
ongoing mast cell activation in the asymptomatic asthmatic airway (Broide et al.,
1991; Jarjour et al., 1991). These tryptase concentrations in airway biological fluids
are positively correlated with level of challenge and severity of clinical symptoms
(Alvarez et al., 2000). Although some authors have reported increased numbers of
mast cells in the BALF compartment of asthmatic subjects (Tomioka et al., 1984;
Walls et al., 1990), most studies report elevated BALF tryptase concentrations
without a concurrent increase in the intraluminal mast cell count (Wardlaw et al.,
1986; Wenzel et al., 1988; Chan-Yeung et al., 1989; Broide et al., 1991). This
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suggests that the increased numbers of degranulating mast cells observed in the
bronchiolar epithelium of human asthmatics may contribute to BALF proteinase
concentrations.
Tryptase has potent biological activities, which are believed to contribute to the
inflammatory response and hyper-reactivity of the asthmatic airway. Incubation of
guinea pig skin with tryptase causes a dose-dependent increase in microvascular
permeability which is similar in magnitude, but has a longer duration of action, than
that induced by histamine (He and Walls, 1997). Despite this difference in time-
course, it seems likely that induction of microvascular leakage is mediated, at least in
part, by histamine because pre-treatment with histamine receptor antagonists
markedly inhibits both tryptase and histamine induced effects on guinea pig skin (He
and Walls, 1997).
Another potential role for tryptase in the asthmatic airway is in the development of
bronchospasm. Incubation of human bronchial tissue with tryptase in vitro causes
migration of mast cells from the epithelium into the airway submucosa and smooth
muscle (Berger et al., 1999). This is thought to be biologically significant as tryptase
has a potent direct and indirect agonist action on human airway smooth muscle cells
(Chambers et al., 2001; Berger et al., 2001b). The action of tryptase on equine
airway smooth muscle warrants investigation since other mast cell mediators
(histamine, serotonin and LTD4) have been shown to augment equine small airway
cholinergic tone (Olszewski et al., 1999). Tryptase has also been implicated in
chronic airway remodelling by inducing the proliferation of human airway smooth
muscle cells (Berger et al., 1999; Berger et al., 2001a; Brown et al., 2002; Cho et al.,
2003) and synthesis of type I collagen in human lung parenchyma and airway
fibroblasts in vitro at concentrations likely to be achieved in vivo (Cairns and Walls,
1997; Akers et al., 2000). These actions are thought to be mediated via the G-protein
coupled receptor proteinase activating receptor-2 (PAR-2), as similar magnitude
responses can be elicited using PAR-2 agonists (Akers et al., 2000; Chambers et al.,
2001; Berger et al., 2001a). In addition, immunohistochemical staining has localised
PAR-2 to the surface of human lung fibroblasts (Akers et al., 2000).
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Tryptase is also hypothesised to play a functional role in regulation of neurogenic
airway inflammation. Tryptase degrades the endogenous bronchodilator vasoactive
intestinal peptide (VIP) and is suggested to be responsible for the decreased levels of
VIP observed in the airway nerves of asthmatics and their consequent increased
bronchial responsiveness (Tarn and Caughey, 1990). The rapid rate of hydrolysis of
calcitonin gene related peptide by tryptase suggests that it may terminate the potent
effects of this neuropeptide on bronchial and vascular smooth muscle tone and
permeability (Tarn and Caughey, 1990). Activation of pre-kallikrein and generation
of kinins (endogenous peptides causing increased vascular permeability, smooth
muscle contraction and neutrophil chemotaxis), is also mediated by tryptase
(Pasquale et al., 1991; Imamura et al., 1996).
Actions of tryptase in the epithelial microenvironment suggest a pivotal role in
neutrophil recruitment. Biologically relevant concentrations of tryptase stimulate
bronchiolar epithelial cells to upregulate expression of ICAM-1 and to increase
secretion of IL-8 (Cairns and Walls, 1996). Furthermore, tryptase itself is also
reported to be chemotactic for human peripheral blood neutrophils (Walls et al.,
1995). Injection of tryptase into guinea pig skin and mouse peritoneum induced
marked neutrophil accumulation within 6h and this recruitment was prevented by co-
injection of tryptase inhibitors (He et al., 1997). This neutrophil recruitment over a
time course pertinent to that observed following challenge of heaves susceptible
horses invites speculation of a similar role for tryptase in equine heaves.
In a self-amplification role, tryptase induces further mast cell activation causing
concentration dependant histamine release from human tonsillar and lung mast cells
(He and Walls, 1997; He et al., 1998). Furthermore, tryptase has been shown to
potentiate histamine induced contraction of sensitised human (Johnson et al., 1997;
Berger et al., 1999), guinea pig (Barrios et al., 1998) and canine (Sekizawa et al.,
1989) bronchial smooth muscle in vitro and of allergic sheep in vivo (Molinari et al.,
1996). These studies provide strong evidence for a link between tryptase, histamine
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and airway hyper-responsiveness across different species such that a similar effect
may be present in equine heaves.
A number of studies have also investigated modification of the allergic airway
response with tryptase inhibitors. In a mouse model of asthma, Oh et al. (2002)
found that MOL 6131 (a potent specific tryptase inhibitor) reduced airway luminal
total cell count and eosinophilia, airway tissue eosinophilia, goblet cell hyperplasia,
mucus secretion and peribronchiolar oedema and also inhibited the release of IL-4
and IL-13 into BALF, although it did not alter airway hyper-reactivity. The tryptase
inhibitors, aprotinin, APC-366 [N-(l-hydroxy-2-napthoyl)-L-arginyl-L-prolinamide
hydrochloride], BABIM [bis(5-amidino-2-benzimidazolyl)methane], AMG-126737
[l,5-bis-{4-[(3-carbamimidoylbenzenesulfonylamino)-methyl]-phenoxy}-pentane]
and endogenous secretory leukocyte proteinase inhibitor (SLPI) and lactoferrin
decreased inducible bronchoconstriction and hyper-responsiveness in a model of
allergic asthma in sheep in vivo (Clark et al., 1995; Tanaka et al., 1995; Molinari et
al., 1996; Elrod et al., 1997; Barrios et al., 1998; Wright et al., 1999a; Wright et al.,
1999b). SLPI and APC 366 also inhibited tryptase mediated hyper-responsiveness of
isolated guinea pig bronchi and attenuated the hyper-responsiveness in airway
smooth muscle from antigen-sensitised animals subjected to antigen exposure in
vitro (Barrios et al., 1998). The inhibition of late phase airway responses by SLPI,
lactoferrin, APC 366 and AMG-126737 in allergic sheep in vivo (Clark et al., 1995;
Elrod et al., 1997; Wright et al., 1999a; Wright et al., 1999b; Krishna et al., 2001) is
particularly exciting given the suggested late phase response in equine heaves
indicated by elevated PELF histamine concentrations 5h following challenge of
heaves susceptible horses (McGorum et al., 1993c). Interestingly, endogenous
trypsin inhibitor activity of equine tracheal lavage fluid is reduced in horses with
heaves, suggesting increased consumption or decreased production of inhibitors
(Sandholm et al., 1990; Maisi et al., 1994). Although the specificity of these trypsin
inhibitors may not include tryptase, it does suggest that proteolytic systems are
involved in the pathogenesis of equine heaves.
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1.4.4.2. Chymase
The other major mast cell proteinase is chymase, which has chymotrypsin-like
activity preferentially cleaving C-terminal to aromatic and leucine residue sites.
Some chymases however, such as sheep mast cell proteinase-1 (SMCP-1) and human
cathespin G, possess dual specificity with both chymotryspin-like and trypsin-like
activity (Pemberton et al., 1997; Polanowska et ah, 1998). A P-chymase has recently
been purified from equine mastocytoma tissue and termed equine mast cell
proteinase-1 (eq.MCP-1) (Pemberton et ah, 2001). This proteinase shares 95%
identity over the first 20 residues of the N-terminal Aa sequence with the cytotoxic T
lymphocyte derived chymase human granzyme H (Pemberton et ah, 2001).
Mammalian mast cells may express multiple closely-related chymases which are
members of a family of proteinases with varying substrate specificities expressed by
granulocytes (Miller and Pemberton, 2002; Zamolodchikova et ah, 2003). This
review of the potential biological effects of chymase is focused upon human a-
chymase and therefore in the following section, 'chymase' refers to human a-
chymase, unless otherwise stated.
Within the airway, the distribution of chymase containing mast cells is greatest near
submucosal mucus glands (Matin et ah, 1992). This appears to be a pertinent
location as chymase markedly stimulates mucus secretion, in a concentration
dependent manner, from cultured bovine airway submucosal gland serous cells
(Sommerhoff et ah, 1989a). Indeed, chymase is the most potent secretagogue for
cultured serous cells, with respect to threshold concentration and magnitude of
response identified to date, and this response can be blocked by chymase inhibitors
(Sommerhoff et ah, 1989a). Furthermore, asthmatics have increased numbers ofmast
cells in close proximity to mucus glands compared to control subjects and mast cell
number is also significantly correlated with the extent of airway lumen mucus
plugging (Carroll et ah, 2002b). This potent secretagogue activity of chymase is
therefore thought to play an important role in the exaggerated mucus secretion in
asthma (Sommerhoff et al., 1989a) and by analogy, may be involved in mucus
hypersecretion in equine heaves.
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Chymase, like tryptase, has potent biological effects, which may be of significance in
the neuroregulation of airway secretion, vascular permeability and airway
bronchomotor tone. Canine mast cell chymase is capable of inactivating peptides
such as bradykinin (Reilly et al., 1985), VIP and substance P (Caughey et al., 1988).
Similarly, human lung and skin mast cell chymase converts angiotensin I to
angiotensin II with the same efficiency as angiotensin converting enzyme and this
appears to be a biologically significant alternative pathway of activation (Reilly et
al., 1982; Wintroub et al., 1984; Wintroub et al., 1986). Angiotensin II contracts
smooth muscle and enhances vascular permeability in vitro and may act to regulate
these processes in the airway tissue microenvironment. In contrast however,
eq.MCP-1 can hydrolyse substance P but can only very slowly cleave
angiotensinogen and has no effect on angiotensin I and bradykinin, such that its
substrate specificity appears to be highly restricted (Pemberton et al., 2001).
Although chymase does not directly induce microvascular leakage, it greatly
augments histamine induced cutaneous wheal formation in allergic dogs in a dose
dependent manner (Rubinstein et al., 1990). In contrast to the direct agonist action of
tryptase, chymase is postulated to potentiate wheal formation by degradation of
extracellular matrix components, thereby allowing freer flow of extravasated fluid
(Vartio et al., 1981; Briggaman et al., 1984; Rubinstein et al., 1990). However, this
degradation could also be explained by an indirect effect of chymase via activation of
matrix metalloproteinases (MMP) (Fang et al., 1997).
Chymase appears to have a complex role in the regulation ofmast cell degranulation,
as although pre-incubation of mast cells with purified chymase did not induce
histamine release, pre-incubation with specific chymase inhibitors decreased IgE
dependent histamine release by as much as 80% (He et al., 1999). This suggests a
role for endogenous chymase in promoting IgE dependent degranulation. In an
interesting contrast to the self amplification role of tryptase, chymase may also
provide negative feedback to restrict further mast cell degranulation, as incubation of
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human mast cells with purified chymase suppressed subsequent IgE dependent
activation (He et al., 1999).
1.4.4.3. Histamine
The biologic amine histamine is present in all mast cells but is not mast cell specific,
also being present in equal quantity in basophils. Histamine exerts potent pro¬
inflammatory actions such as capillary dilation, increased capillary permeability and
smooth muscle contraction which are generally mediated via type 1 histamine (Hi)
receptors (White, 1990). Additional immunoregulatory effects such as inhibition of
lymphocyte proliferation, neutrophil chemotaxis and increased mucus secretion are
mediated via histamine type 2 (H2) receptors (White, 1990; Tamaoki et al., 1997).
More recent evidence suggests a further role for histamine in cytokine regulation via
type 2 and 3 (H3) receptors (Jeannin et al., 1994; Delneste et al., 1994; Bissonnette,
1996; Krouwels et al., 1998; Sirois et al., 2000).
Elevated BALF histamine concentrations are present in asymptomatic and
symptomatic asthmatics compared to control subjects (Casale et al., 1987a; Wenzel
et al., 1988; Casolaro et al., 1989; Chan-Yeung et al., 1989; Broide et al., 1991;
Jarjour et al., 1991). Furthermore, these BALF histamine levels are correlated with
mast cell count, severity of disease and mechanical measurements of airway
obstruction (Wardlaw et al., 1988; Walls et al., 1990; Jarjour et al., 1991). Similarly,
increased PELF histamine concentrations have been demonstrated in heaves
susceptible horses following challenge (McGorum et al., 1993c). Furthermore, the
airways of both asthmatic (Casale et al., 1987a; Durham et al., 1988; Jarjour et al.,
1991) and heaves affected horses (Derksen et al., 1988) are hyper-responsive to
histamine, thereby increasing the biological relevance of any histamine release. The
use ofHi antagonists in asthmatics results in 30-50% attenuation in airway response
to allergen (Finnerty et al., 1989; Phillips and Holgate, 1989) suggesting that,
although histamine may contribute to pathogenesis of disease, it is not the sole
mediator of the asthmatic response.
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Histamine stimulates the release of neuropeptides, such as Substance P, which may
contribute to further mast cell activation via non-immunological means (Joos et al.,
2000). Interestingly, histamine also appears to be involved in cytokine regulation
increasing synthesis and release of IL-10 (Sirois et al., 2000), IL-5, IL-6 and IL-8
(Jeannin et al., 1994) and inhibiting the release of IL-1 (Dohlsten et al., 1988), IL-2,
IFN-y (Krouwels et al., 1998), and TNF-a (Bissonnette, 1996). Histamine also
stimulates CD8+ T cells and airway epithelial cells to produce IL-16, an early
chemotactic factor for CD4+ T lymphocytes, (Mashikian et al., 1998; Sirois et al.,
2000).
1.4.4.4. Cytokines
As can be seen from fig. 1.1, mast cells have the potential to produce a wide array of
cytokines. Unlike most other cells, the mast cell contains preformed cytokines in
granules ready for release upon mast cell activation. It appears that there is
heterogeneity of mast cells with regard to their cytokine, as well as proteinase,
content (Bradding et al., 1995). Furthermore, cytokine release may be restricted to
specific time periods (early, late or chronic phase) following stimulation (Kobayashi
et al., 2000a). Mast cell cytokines are predominantly type 2 cytokines, which are
critical to the development and maintenance of the asthmatic IgE driven response
(Hart, 2001) and in particular, are thought to be involved in the pathogenesis of the
late phase cellular allergic response (Kobayashi et al., 2000a). Mast cell cytokine
biology is extremely complex and is still incompletely defined and therefore, only a
brief overview of their putative involvement in airway inflammation is detailed
below.
Several mast cell cytokines have been demonstrated to play an pivotal role in
neutrophil recruitment, including IL-4, TNF-a, ENA and IL-8 (Boey et al., 1989;
Moller et al., 1993; Strieter et al., 1993; Teran et al., 1995; Echtenacher et al., 1996;
Malaviya et al., 1996; Girard et al., 1997). As well as stimulating neutrophil
recruitment, IL-4 also enhances neutrophil phagocytosis and increases neutrophil
longevity by delaying apoptosis (Girard et al., 1997). The importance of mast cell
derived cytokines in the asthmatic response is demonstrated by airway mucosa from
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asthmatics having greatly increased numbers of IL-4 and TNF-a positive mast cells
compared to control subjects (Bradding et al., 1994; Bradding, 1996). Furthermore,
elevated BALF TNF-a (Broide et al., 1992) and IL-8 (Teran et al., 1995)
concentrations have been reported in asthmatics. Interestingly, elevated BALF IL-8
concentrations have also been detected in heaves affected horses, with chemotactic
activity correlated to the level of dust exposure (Franchini et al., 1998). IL-8 is not
expressed constitutively by mast cells and maximal mRNA expression of IL-8 takes
up to 4h following mast cell activation (Moller et al., 1993). This lack of pre-formed
IL-8 may, in part, explain the time lag between challenge and cellular response in
neutrophil mediated respiratory diseases such as occupational asthma and heaves. IL-
8 can resist mild proteolytic degradation and therefore once released, is likely to have
prolonged biological action (Strieter et al., 1993). Mast cells are the only known cell
to store preformed TNF-a in cytoplasmic granules and in models of acute septic
peritonitis and pneumonia, mast cell derived TNF-a was critical in the rapid
recruitment of neutrophils (Echtenacher et al., 1996; Malaviya et al., 1996). The
release of preformed mast cell TNF-a has also been demonstrated to act as positive
feedback to augment NF-kB transcription and production of further mast cell
cytokines, including IL-8 (Coward et al., 2002). TNF-a also stimulates bronchial
epithelial cells and alveolar macrophages to upregulate IL-8 expression (Caims and
Walls, 1996). Lastly, TNF-a facilitates neutrophil recruitment by upregulating
expression of endothelial cell derived neutrophil adhesion molecules including
leukocyte adhesion molecule 1 (E-selectin) and ICAM-1 (Strieter et al., 1993).
There are several other proposed roles for mast cell cytokines in the airway. Mast
cell IL-4 and IL-5 mRNA and protein expression have been demonstrated in
asthmatic bronchial biopsies (Ying et al., 1997) where IL-5 is considered to have a
primary role in late phase airway eosinophilic influx in asthma (Jaffe et al., 1995).
TNF-a can activate MMP-9, which may be involved in the fibrotic response of
chronic asthma (Han et al., 2002), and can also induce bronchial hyper-
responsiveness (Wheeler et al., 1990). Mast cell derived IL-4 induces IgE production
from B cells independently of T cells, whereas maintenance of IgE synthesis in the
asthmatic airway is believed to be dependent on IL-13 derived both from mast cells
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and T lymphocytes (Pawankar et al., 1997). IL-13 is also believed to stimulate
mucus hypersecretion from goblet cells (Hart, 2001). Mast cell release of IL-4 and
IL-16, augmented by histamine stimulation of IL-16 secretion from other cells as
previously mentioned, also contribute towards T helper cell accumulation
(Mashikian et al., 1998).
1.5. Aims of This Project
Key roles for the mast cell, and in particular the mast cell proteinase tryptase, have
been elucidated in the pathogenesis of both human allergic asthma and occupational
asthma. Due to the similarities between these diseases and equine heaves, analogous
mast cell involvement in the pathogenesis of equine heaves is proposed. This project
was therefore designed to determine whether mast cells, and in particular mast cell
proteinases, play a role in heaves by:
• Cloning and sequencing the equine mast cell serine proteinases equine
tryptase and eq.MCP-1 in order to rationalise their enzymic activity and to
develop molecular tools to probe mast cell proteinase expression in tissues
from control and heaves affected horses
• Quantifying levels of mast cell serine proteinases in BALF from control
horses and heaves susceptible horses (during both disease exacerbation and
remission)
• Investigating the distribution and proteinase heterogeneity of equine mast
cells in pulmonary tissues from control and heaves affected horses
• Probing mast cell proteinase mRNA transcript regulation in airway luminal
and tissue mast cells from control and heaves susceptible horses in response
to inhalational challenge in vivo
• Determining if a suspension of hay dust can induce release of mast cell
proteinases from airway luminal cells from control and heaves susceptible
horses in vitro
• Determining the effects of mast cell proteinases on cultured equine tracheal
explants in vitro
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Chapter 2: Purification and Validation of
Antibodies
2.1. Summary
Previously produced polyclonal rabbit anti-equine tryptase and rabbit anti-eq.MCP-1
were cross-absorbed against albumin and affinity purified. These antibodies
recognised equine tryptase and eq.MCP-1 respectively when used to probe western
blots of mastocytoma extract or purified proteinases. Immunohistochemical staining
of tissues with these antibodies successfully demonstrated tryptase and eq.MCP-1
positive mast cells. Furthermore, dual immunofluorescent labelling of mast cells in
lung and colon tissue with these antibodies confirmed that these antibodies did not
co-localise in dual positive cells and therefore detected mast cell proteinases in
different granules.
2.2. Introduction
Mast cells contain many potent mediators including serine proteinases, biological
amines, prostaglandins, leukotrienes and cytokines. Serine proteinases are the major
protein constituents of the mast cell and are hypothesised to have a significant
biological effect in the lung and other tissues (Caughey, 1991). Indeed, there is now
considerable evidence confirming a role for the mast cell in the pathogenesis of
human asthma, including occupational dust induced asthma (Casale et al., 1987b;
Chan-Yeung et al., 1987; Wenzel et al., 1988; Crimi et al., 1991; Park et al., 1998b;
Park et al., 1999; Holgate, 2000; Hart, 2001; Carroll et al., 2002a). Equine heaves is
similar in many respects to occupational dust induced asthma, since both are
characterised by reversible neutrophilic pulmonary inflammation in response to
inhaled organic dust (Enarson et al., 1985; Huy et al., 1991; Chan-Yeung et al.,
1992; Pirie et al., 2002a). Consequently, speculation has arisen that mast cells may
also play a role in the pathogenesis of equine heaves (McGorum et al., 1993c; Hare
et al., 1999).
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The serine proteinases equine tryptase (trypsin-like) and eq.MCP-1 (chymotrypsin-
like) have previously been isolated from equine mastocytoma tissue and antibodies to
these proteinases raised in rabbits (Pemberton et al., 2001). Purification and
validation of these antibodies was performed to allow further investigation of the role
of the mast cell and their serine proteinases in equine heaves. Specifically, these
antibodies would allow development of ELISAs for quantification of proteinases in
equine BALF from control and heaves affected horses. Furthermore, these antibodies
would facilitate immunohistochemical detection and enumeration of mast cells in
lung tissue, to assess whether there is mast cell recruitment to the lung during clinical
disease.
2.3. Materials and Methods
2.3.1. Extraction of Mast Cell Proteinases from High Salt Extract of
Mastocytoma Tissue
2.3.1.1. Tryptase Extraction
A high salt extract (HSE) (2M NaCl, 50mM MES pH 6.1, 0.1% Brij 35) of equine
mastocytoma tissue containing mast cell proteinases had previously been prepared
and stored at -70°C (Pemberton et al., 2001). A 2ml aliquot of HSE was added to
6ml 50mM MES, pH 6.1, 0.1% Brij 35 (low salt buffer) to give a final salt
concentration of 0.5M and filtered through a 5pm membrane (Millex SV, Sigma). A
Hi Trap heparin affinity column (1ml, Pharmacia) was pre-equilibrated with low salt
buffer and then loaded with diluted HSE using a high performance liquid
chromatography system (Waters, Millipore). Tryptase in the mastocytoma extract
bound to the heparin column whilst the mobile phase was retained for later eq.MCP-
1 extraction. Heparin-bound tryptase was then eluted using a 0-2M salt gradient in
50mM MES, pH 6.1, 0.1% Brij 35. Tryptase activity of the eluted fractions and
chymase activity of the flow-through were measured chromogenically as described
in section 2.3.1.4. Samples showing high tryptase activity were concentrated using a
Centricon YM10 filter device (Millipore) at 6000g for 70min at 4°C.
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2.3.1.2. Eq.MCP-1 Extraction
Eq.MCP-1 had previously been extracted from the heparin column flow-through
generated during tryptase purification from equine mastocytoma HSE and was
available for use (Pemberton et al., 2001). This purified enzyme had given a double
band at 32.1kDa on SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and
hydrolysed the thioester chymotrypsin substrate succinyl-Phe-Leu-Phe thiobenzyl
ester (FLF-SBzl), indicating chymase activity.
2.3.1.3. SDS-PAGE ofElated Fractions
Samples of eluted fractions (5 pi) were heated to 95°C with 15pi of reducing buffer
for 5min and run on a 12% SDS separating gel, 0.375M Tris, pH 8.8, at 200V, for
40min with Tris / glycine pH 8.3 running buffer. The gel was stained with 0.25%
Coomassie Brilliant Blue R250 (Sigma) in 25% methanol, 5% acetic acid, 70% water
for 15min and then destained with 1 part acetic acid : 5 parts methanol : 1 part
deionised water until bands could be visualised.
2.3.1.4. Measurement ofProteinase Activity
Proteinase activity of eluted fractions was measured spectrophotometrically
(Beckmann DU650).
Tryptase fractions were diluted 1:10 in 0.1M Tris-HCl pH 8.0, 0.1M NaCl, 1.0M
glycerol and lOpl of diluted sample added to 180pl of the same buffer containing
lOpg/ml heparin. The spectrophotometer was blanked on this solution and then lOpl
chromogenic substrate 2.5mM pyroGlu-Pro-Arg-p-nitroanilide (S2366, Quadratech,
final concentration 0.125mM) in water added. The rate of activity was measured at
405nm.
Eq.MCP-1 activity was determined using lOpl of a 1:10 dilution of purified
proteinase in 0.1M HEPES pH 7.5. This diluted sample was added to 170pl 0.1M
HEPES pH 7.5, lOpl 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB, lOmM in DMSO)
and lOpl FLF-SBzl (lOmM in DMSO).
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2.3.1.5. Preparation ofTryptase Column
Tryptase isolated from mastocytoma HSE was used to prepare a tryptase column for
affinity purification of polyclonal anti-equine tryptase. Isopropanol was washed from
a 1ml Hi Trap NHS activated column (Pharmacia) using ImM ice cold HC1 at a rate
of approximately lml/min. Tryptase was loaded onto the column in binding buffer
(0.2M NaHCCE, 0.5M NaCl, pH 8.3) at the same rate and the column then sealed and
left for 30min at room temperature. The column was then washed three times with
2ml 0.5M ethanolamine, 0.5M NaCl, pH 8.3 (buffer A), three times with 2ml 0.1M
acetate, 0.5M NaCl, pH 4.0 (buffer B) and a further three times with buffer A. The
column was left for 30min at room temperature and then washed three times each
with buffer B, buffer A and again with buffer B. Finally the column was equilibrated
with 2ml PBS.
2.3.2. Purification of Antibodies
2.3.2.1. Cross-Absorption ofAntisera Against Albumin
Polyclonal antisera directed against equine tryptase or eq.MCP-1 had previously
been produced at R(D)SVS and stored at -20°C (Pemberton et al., 2001). An albumin
column (Hi Trap NHS activated 1ml column, Pharmacia), to which lOmg equine
albumin had previously been conjugated, was connected to the fast performance
liquid chromatography unit (FPLC; Pharmacia LCC 500) and washed with 0.1M
citric acid to release any protein pre-bound to the column. Rabbit anti-equine tryptase
or anti-eq.MCP-1 antisera was thawed, diluted 1:1 with phosphate buffered saline
(PBS) and fdtered through a 0.45pm cellulose acetate membrane (Millipore). The
diluted antisera was then loaded into the FPLC superloop and loaded onto the
albumin column in 1.5ml aliquots. Contaminating anti-albumin antibodies bound to
the albumin column, whilst anti-equine tryptase / anti-eq.MCP-1 antisera were
collected in the flow-through. Bound albumin antibodies were eluted with 0.1M
citric acid between loading of separate aliquots to prevent saturation of the column.
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2.3.2.2. Affinity Purification ofAntibodies
Albumin cross-absorbed anti-equine tryptase / anti-eq.MCP-1 serum was re-loaded
into the FPLC superloop and injected onto an equine tryptase / eq.MCP-1 column.
An eq.MCP-1 column was available from preliminary work leading up to this project
(Pemberton et al., 2001). Flow-through was discarded and affinity purified
antibodies eluted from the column with 0.1M citric acid. Eluted antibodies were
immediately buffered to approximately pH 7.0 with 1M Tris. The albumin-cross
absorbed, affinity purified antibodies were then either concentrated and stored, or
biotinylated.
2.3.2.3. Protein Concentration ofAntibodies
Albumin-cross absorbed, affinity purified antibodies were loaded into a centrifugal
filter device (Centricon YM10, Millpore) with a retention size of >10kDa and
centrifuged at 4500g, 4°C, 30min. Absorbance of the concentrated antibodies was
measured spectrophotometrically (Beckmann DU650) at 260 and 280nm and the
protein concentrations calculated using the equation:
Protein concentration (ng/ml) = (1.55 x A280) - (0.76 x A260)
Antibodies were then diluted 1:1 w/v with glycerol and stored at -20°C.
2.3.2.4. Biotinylation ofAntibodies
Buffer exchange of antibodies was performed using a Hi Trap desalting column
(Pharmacia) equilibrated with 0.1M NaHCCL, pH 8.5. Albumin-cross absorbed,
affinity purified antibodies in Tris buffer were loaded onto the column by syringe
and then eluted using 0.1M NaHCCL, pH 8.5. The protein concentration of eluted
antibodies was measured using a spectrophotometer. Biotin (Long Arm) N
hydroxysuccinimide ester (Vector Laboratories) (25mg/ml in DMSO) was added to
the antibody in a glass bijoux such that the final ratio was 10% biotimprotein and the
solution left at room temperature for 2h with occasional mixing by hand. Excess
biotin was then removed by HPLC gel filtration using a Hi Trap 5ml desalting
column (Pharmacia) with 5kDa cut off.
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2.4. Validation ofAntibodies
2.4.1. Western blotting of Mastocytoma HSE and Purified
Proteinases
Equine mastocytoma tissue HSE, purified equine tryptase or purified eq.MCP-1 were
diluted 1:10 with reducing buffer and heated to 95°C for 5min. Samples were run
(0.1 pg proteinase / lOpl diluted HSE per lane) on two 12% SDS separating gels,
0.375M Tris, pH 8.8, at 200V (Mini-Protean-II, Bio-Rad), for 40min with Tris /
glycine pH 8.3 running buffer. One gel was stained with Coomassie Brilliant Blue
R250 as previously described in section 2.3.1.3. The other gel was blotted (Trans-
Blot SD, Bio-Rad) onto polyvinylidenfluoride (PVDF) membrane (Immobilon P,
Millipore), 80mA for lh, blocked for lh with PBS / 0.5M NaCl, 0.5% Tween 80, 1%
skimmed milk powder and then probed with lpg/ml rabbit anti-equine tryptase /
rabbit anti-eq.MCP-1 for lh. The secondary antibody mouse monoclonal anti-rabbit
IgG-alkaline phosphatase conjugate (clone RG-96, Sigma) was applied at 1/20,000
dilution for lh, and then the reaction developed with substrate 5-bromo-4-chloro-3-
indolyl phosphate / nitro blue tetrazolium (BCIP / NBT) (Sigma).
2.4.2. Immunohistochemistry
2.4.2.1. Equine Tissue Sections
Sections of equine duodenum and ileum previously collected from horses euthanased
at R(D)SVS and fixed in 4% paraformaldehyde were available for
immunohistochemical testing of antibodies.
2.4.2.2. Antigen Retrieval Techniques
As very poor staining was observed following immunohistochemical labelling of
paraformaldehyde fixed tissue, several antigen retrieval methods were assessed.
a) Citrate Boiling
Following de-waxing in xylene and rehydration through graded alcohols, slides were
immersed in boiling lOmM citrate, pH 6.0 under pressure for 4min (Biomen pressure
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cooker, A. Menarini Diagnostics) in a microwave (Panasonic 800W D). This
technique was found to cause excessive tissue destruction and therefore a modified
technique using lOmin immersion in lOmM citrate, pH 6.0 heated to 95-100°C on a
magnetic stirring plate (Bibby Hotplate Stirrer B212) was also performed. Although
this resulted in positive labelling of cells, some tissue destruction was still evident
and therefore reduced exposure times of lmin and 5min and immersion in lOmM
citrate, pH 6.0 for lOmin at room temperature were employed. Whilst immersion in
cold citrate buffer did not result in any tissue destruction, there was also no positive
staining evident. Sections treated with even lmin boiling citrate buffer showed
excessive tissue destruction (data not shown).
b) Trypsin Digestion
A successful method of antigen retrieval was found using trypsin digestion.
Following de-waxing in xylene and rehydration through graded alcohols, slides were
immersed in 0.1, 0.5 or lmg/ml trypsin (Sigma) in PBS for 30min at 37°C. The
concentration deemed most successful was 0.lmg/ml as this achieved good antigen
retrieval without non-specific staining (data not shown).
2.4.2.3. Final Immunohistochemistry Protocol
All steps were performed at room temperature unless otherwise stated. Slides were
de-waxed in xylene, rehydrated through graded alcohol and washed with tap water.
Tissue sections were then incubated in 0.lmg/ml trypsin in PBS for 30min at 37°C,
washed twice in PBS and then immersed in 97% methanol / 3% hydrogen peroxide
for lOmin to block endogenous peroxidase activity. Following a further wash with
tap water, slides were placed in Sequenza carriers (Shandon) and incubated with
blocking buffer (PBS / 0.5M NaCl / 0.5% Tween 80 [Sigma]) for 30min. All
subsequent dilutions were made using this blocking buffer. Primary antibodies,
polyclonal rabbit anti-equine tryptase or anti-eq.MCP-1, were then applied at lpg/ml
for lh. Normal rabbit IgG (lpg/ml) was applied to control sections. Following
washing with PBS, slides were incubated with biotinylated goat anti-rabbit IgG
(1:400 dilution, Vector Laboratories) for 30min. Slides were again washed with PBS
and then avidin-horseradish peroxidase conjugate (ABC kit, Vector Laboratories)
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applied for 30min. Colour was developed using 3,3'-diaminobenzidine (DAB kit,
Vector Laboratories) and counterstaining with Mayer's haematoxylin (Sigma). Slides
were washed in Scott's tap water, dehydrated and mounted using DPX (Sigma).
2.4.3. Dual Immunofluorescent Labelling of Equine Tissues
Samples of colon and lung tissue were collected immediately post mortem from a
horse euthansed at R(D)SVS for orthopaedic disease. Tissues were immersed in
Carnoys Fixative for 24h and then transferred to 70% alcohol until further
processing. Carnoys fixative is reported to be the optimal fixative for preservation of
mast cells (Nicholls, 1978; Irani et al., 1986; Craig et al., 1986; Shanahan et al.,
1987; Winder and von Fellenberg, 1990; Kube et al., 1998; Kuther et al., 1998) and
its use in equine tissues is discussed further in Chapter 5. Fixed samples were
submitted to the Division of Veterinary Pathology at R(D)SVS for paraffin
embedding and cutting of 4pm thickness serial sections onto coated slides
(Surgipath).
Slides were de-waxed, rehydrated through graded alcohols and treated with DAB for
5min to quench eosinophil peroxidase. Non-specific binding was blocked by
incubation with PBS / 0.5M NaCl / 0.5% Tween 80 (Sigma) / 10% normal donkey
serum (Sigma) for 30min. Rabbit anti-equine tryptase was applied as the primary
antibody at lpg/ml with overnight (approx. 8h) incubation at 4°C. Normal rabbit IgG
(lpg/ml) was used for control sections. Following washing with PBS, slides were
incubated with donkey anti-rabbit IgG-Alexafluor 488 (Invitrogen) at 4pg/ml for
30min. This incubation and all subsequent steps were performed in the dark. Slides
were washed with PBS and then blocked with PBS / 0.5M NaCl / 0.5% Tween 80
(Sigma) / 10% normal rabbit serum (Sigma) for the rest of the day. Biotinylated
rabbit anti-eq.MCP-1 (2pg/ml) was applied overnight (approx. 8h) at 4°C.
Biotinylated normal rabbit IgG was used on control slides. Following washing with
PBS, slides were treated with ABC kit for 30min. Slides were again washed,
incubated with tyramide-Alexafluor 568 (1:200 dilution, Molecular Probes) for
lOmin and then washed again and mounted with Mowiol.
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Fluorescent images were acquired using an MRC-600 confocal laser scanning
microscope (CLSM: Bio-Rad Laboratories) mounted on an Axiovert 100 inverted
microscope equipped with Plan-Apochromat objective lenses (Carl Zeiss). Cells
labelled with anti-equine tryptase fluoresced green under 488nm excitation whereas
anti-eq.MCP-1 labelled cells fluoresced red under 568nm excitation.
2.5. Results
2.5.1. Tryptase Extraction from Mastocytoma HSE
Fractions eluted from the heparin affinity column that contained high levels of
trypsin-like activity with S2366 were combined. SDS-PAGE of this product showed
a triple band complex at approximately 32-35kDa, characteristic of equine tryptase
(Pemberton et al., 2001) (fig. 2.1).
Fig. 2.1 : Coomassie Brilliant Blue R250
stained SDS-gel showing the characteristic
triple band of tryptase at approximately
32kDa. MW = molecular weight markers.
T = lpg equine tryptase. kDa = size of
molecular weight markers in kilo Daltons.
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2.5.2. Purification of Antibodies
The protein concentration of albumin cross-absorbed affinity purified polyclonal
anti-eq.MCP-1 was 2.28mg/ml. The protein concentration of albumin cross-absorbed
affinity purified polyclonal anti-equine tryptase was 1.80mg/ml. Biotinylated anti-
eq.MCP-1 and biotinylated anti-equine tryptase had protein concentrations of










2.5.3. Validation of Antibodies
2.5.3.1. Western Blot Analysis
Affinity purified, albumin cross-absorbed, polyclonal rabbit anti-equine tryptase and
anti-eq.MCP-1 positively identified purified equine tryptase and eq.MCP-1,
respectively. The antibodies also detected these proteinases in equine mastocytoma






Fig. 2.2: Composite picture of the
Western blot of high salt extract (HSE)
97 of equine mastocytoma tissue. MW =
66 Coomassie blue stained molecular weight
markers. HSE = Coomassie blue stained
HSE showing the characteristic triple
band of tryptase at approximately 32kDa.
M = HSE probed with anti-eq.MCP-1, T
= HSE probed with anti-equine tryptase,
C = HSE probed with normal rabbit IgG.






Affinity purified, albumin cross-absorbed, polyclonal rabbit anti-equine tryptase and
anti-eq.MCP-1 successfully labelled mast cells in equine ileal sections following
trypsin digestion (figs. 2.3, 2.4). Positively labelled cells showed deep brown
colouration throughout the cell. For both anti-equine tryptase and anti-eq.MCP-1,
most positively labelled cells were present in the ileal submucosa with only






. ^ " J ■












,w ' <: ■ V" \
t- •
* ' • • "
„ 9 '




equine ileum. Size marker
= 10pm.
2.5.3.3. Dual Immunojluorescent Labelling
Colon sections showed many intensely labelled mast cells. Single and dual labelled
cells were present with single eq.MCP-1 positive cells being predominant (fig. 2.5).
In contrast, lung sections showed fewer positively labelled cells, with predominantly
tryptase positive mast cells, and only occasional dual positive or solely eq.MCP-1
positive cells observed. All control sections were negative. It was clear on confocal
microscopy that the two fluorescent labels did not co-localise.
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Fig. 2.5 : Dual immunofluorescent
labelling of equine colon. Cells
fluorescing green are tryptase
positive, cells fluorescing red are
eq.MCP-1 positive, yellow cells are
dual positive. Size marker = 10pm.
2.6. Discussion
2.6.1. Purification of Equine Tryptase
Tryptase purified from equine mastocytoma HSE hydrolysed the arginine containing
chromogenic substrate S2366. This activity is characteristic of trypsin-like
proteinases which cleave arginine and lysine residues unless followed by a proline
residue (Schwartz, 1994). Active tryptase is stable as a tetrameric structure composed
of four individual tryptase monomers of 31-34kDa (Schwartz, 1994). The purified
proteinase showed a triple band at approximately 32-35kDa following SDS-gel
electrophoresis representing multiple glycosylated forms of the tryptase subunit.
2.6.2. Purification and Validation of Antibodies
Cross-absorbed affinity purified anti-equine tryptase and anti-eq.MCP-1 successfully
recognised purified proteinases and proteinases in equine mastocytoma tissue HSE.
All bands visualised on SDS-gel electrophoresis were recognised on probing
Western blots with these antibodies. Validation of the biotinylated antibodies was
performed as part of the development process for the ELISAs, and as such is
described in Chapter 4.
The anti-equine tryptase and anti-eq.MCP-1 antibodies successfully detected tryptase
and eq.MCP-1 positive cells in equine tissues using immunohistochemical and
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immunofluorescent techniques. Antigen retrieval was required for the
immunohistochemical demonstration ofmast cells in paraformaldehyde fixed tissues.
Trypsin digestion was clearly superior to citrate boiling in improving epitope
recognition without resulting in tissue destruction. Antigen retrieval techniques
appear to be more successful in the submucosa than the mucosa, as positive mucosal
cells, which are reported in other species (Huntley et al., 1985), were rarely
observed, even following trypsin digestion. This was considered likely to be an
artefact due to fixation with paraformaldehyde because formalin based fixatives are
reported to result in underestimation of mucosal mast cells across species (Nicholls,
1978; Irani et al., 1986; Craig et al., 1986; Shanahan et al., 1987; Winder and von
Fellenberg, 1990; Kube et al., 1998; Kuther et al., 1998). Although not ideal,
paraformaldehyde fixed tissues were used in this instance as sections were readily
available and eliminated the necessity to procure tissues. Furthermore, the use of
antigen retrieval in paraformaldehyde fixed equine tissues had previously resulted in
successful recognition of tryptase and eq.MCP-1 positive mast cells with these
antibodies (Pemberton et al., 2001). Abundant mucosal tissue mast cells have been
identified by electron microscopy and other staining techniques in horses (Mair et
al., 1988) and other species (Guerzon et al., 1979; Fox et al., 1981; Huntley et al.,
1985; Jolly et al., 2000), therefore their absence from paraformaldehyde fixed tissue
was attributed to a fixative effect rather than a true absence of mast cells from this
location. This observation led to the use of Carnoys fixative for tissues intended for
dual immunofluorescent labelling. Plentiful mucosal mast cells were identified in
these Carnoys fixed tissues, further supporting their absence in paraformaldehyde
tissue being an artefact related to paraformaldehyde fixation.
Dual immunofluorescence was performed to confirm the cellular origin of eq.MCP-
1. Whilst tryptase is considered to be a mast cell specific proteinase (Schwartz,
1994), chymotrypsin-like proteinases have been isolated from both mast cells and T
lymphocytes (Peitsch and Tschopp, 1994). The mast cell origin of eq.MCP-1 was
therefore confirmed by dual labelling of cells with both proteinases. The presence of
single labelled cells and the lack of co-localisation of labels in dual positive cells
demonstrated that the antibodies recognised proteinases in separate storage granules.
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2.7. Conclusion
Albumin cross-absorbed, affinity purified anti-equine tryptase and anti-eq.MCP-1
were validated to successfully recognise their respective proteinases in equine
mastocytoma extracts and in equine tissues. These antibodies were purified to allow
further investigation into the role of the mast cell in the pathogenesis of equine
heaves. Their use in the development of ELISAs allowed determination of BALF
proteinase concentrations for control and heaves horses (Chapter 4). Furthermore,
possible mast cell recruitment to the lung in heaves affected horses was investigated
(Chapters 4 and 5) by immunohistochemistry and immunofluorescence of equine
mast cells in lung tissue and BALF cytospin preparations.
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Chapter 3: Cloning and Sequencing of Equine
Mast Cell Proteinases and their Expression in Equine
Tissues
3.1. Summary
It was attempted to clone and sequence the mast cell proteinases equine tryptase and
eq.MCP-1 from equine tissues. The amino acid (Aa) sequence deduced from the
cDNA nucleotide sequence for equine tryptase shared strong identity with other
tryptases; 77% with human tryptase pi and 73% with sheep tryptase-2. The deduced
N-terminal Aa sequence corresponded exactly with that determined from tryptase
purified from equine mastocytoma tissue and the peptide mass fingerprint of
mastocytoma derived equine tryptase was consistent with the cloned equine tryptase
sequence. Unusually for a trypsin-like proteinase, equine tryptase has alanine at
residue 216, rather than glycine, which confers increased arginine substrate
specificity and may restrict fibrinogenolysis in vivo. Cloned putative eq.MCP-1 has
an uncharged residue (glutamine) at 226 conferring chymase (chymotrypsin-like)
substrate specificity. The cloned Aa sequence shared greatest identity (65%) with the
cytotoxic T lymphocyte associated serine esterase human granzyme B, 57% identity
with the putative chymase sheep mast cell proteinase-3 and 56% identity with dual
specific sheep mast cell proteinase-1. The N-terminal Aa sequence of eq.MCP-1
isolated from mastocytoma tissue differed from that determined from the cDNA
nucleotide sequence by 2 residues. Furthermore, peptide mass fingerprinting of
eq.MCP-1 isolated from equine mastocytoma tissue shared only 3 peptides with the
cloned putative eq.MCP-1 sequence. Granulocytes of most mammalian species
express multiple closely-related proteinases and therefore it is likely that a similar
but novel chymase was sequenced. Expression of the cloned proteinases in equine
tissues was assessed by reverse transcriptase polymerase chain reaction (RT-PCR).
Both tryptase and putative eq.MCP-1 were expressed in bronchial tissue, bronchiolar
tissue, liver, skin and colon.
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3.2. Introduction
Two neutral serine proteinases have previously been extracted from equine
mastocytoma tissue, namely equine tryptase, which has trypsin-like activity, and
eq.MCP-1 which has chymotrypsin-like specificity. Eq.MCP-1 demonstrated
extremely restricted substrate specificity, which most closely resembled that of the
cytotoxic T lymphocyte serine proteinase human granzyme H (Pemberton et al.,
2001).
Tryptases and chymases possess a wide range of potent biological effects which
contribute to inflammatory processes, particularly in allergic disease (Denburg et al.,
1989; Holgate, 2000). Equine tryptase and eq.MCP-1 positive mast cells have
previously been identified in the equine lung (Pemberton et al., 2001) and therefore
these proteinases may have relevance in the equine airway with regard to the
pathogenesis of heaves.
The aim of this study was to clone and sequence equine tryptase and eq.MCP-1 and
to assess their expression in various equine tissues. Cloning and sequencing of these
proteinases will allow further rationalisation of their enzymic activity and the
development of molecular tools to probe transcription of mast cell proteinases in
control and heaves-affected horses.
3.3. Materials and Methods
3.3.1. Samples for Cloning and Sequencing of Proteinases
Colonic tissue was collected into RNA-Later (Ambion) immediately post mortem
from one horse euthanased for orthopaedic disease. Tissue was stored at 4°C
overnight and then -20°C until further processing. Cell pellets were harvested (400g,
lOmin) from BALF samples collected from 2 horses referred to R(D)SVS clinical
hospital for poor exercise performance. Cells were resuspended in 1ml TRI Reagent
(Sigma) by vortexing vigorously and then incubated at room temperature for 5min
before repeated vortexing. Cell pellets were stored at -70°C prior to RNA extraction.
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3.3.2. RNA extraction
Approximately lOOmg colon tissue was homogenised on ice with 2ml of TRI
Reagent (Sigma). The homogeniser probe was soaked in Neutracon (Decon
Laboratories Ltd.) overnight prior to use and cleaned thoroughly between samples.
Molecular biology grade chloroform (0.2ml, Sigma) was added to homogenised
tissue or thawed BALF cell pellets in 1.5ml eppendorfs. Samples were vortexed for
30s, allowed to stand at room temperature for 5min and then centrifuged at
13,000rpm, 15min (Biofuge, Kendro Laboratory Products). The upper aqueous phase
was carefully collected and 650pl isopropanol added to precipitate total RNA.
Following incubation at room temperature for lOmin, RNA was pelleted by
centrifugation at 13,000rpm, 15min. Isopropanol was removed and the RNA pellet
washed with 1ml 75% ethanol by vortexing and then centrifugation at 8,000rpm, for
5min. The RNA pellet was air-dried following removal of ethanol and then dissolved
in lOOpl RNase free water (Ambion). RNA concentration and purity were measured
by spectrophotometer (Beckmann DU650).
DNase treatment of TRI Reagent extracted RNA was performed using DNA-free
DNase treatment kit (Ambion). RNA (5pg in a volume of 41 pi) was incubated for 1-
2h, at 37°C, with 4pl DNase I and 5pi DNase I buffer and then 5pi DNase I
inactivation reagent was added and the reaction incubated at room temperature for
2min. The inactivation reagent was then pelleted by centrifugation for lmin, at
13,000rpm.
3.3.3. Reverse Transcription of RNA
DNA free total RNA was reverse transcribed using random hexamer primers and
avian myeloblastosis virus (AMV) reverse transcriptase (Reverse Transcription
System, Promega). The following reaction was set up on ice; 4pl 25mM MgC^, 2pl
lOx reverse transcription buffer (lOOmM Tris HC1, pH 8.8), 2pl lOmM dNTPs, 0.5pl
(20u) RNase inhibitor, 0.5pl (15u) AMV-RT, lpl (0.5pg) random hexamers and
lOpl RNA. The reaction mixture was incubated for lOmin at room temperature, 50
min at 42°C and finally 5min at 99°C to stop the reaction (Technegene, Techne). The
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mixture was cooled on ice, diluted to lOOpl with RNase free water and the cDNA
concentration measured by spectrophotometry.
3.3.4. Design of Primers
Sheep tryptase primers (kindly donated by S. McAleese, R[D]SVS) in a highly
conserved region of the proteinase were used for initial isolation of an equine
tryptase sequence fragment. Eq.MCP-1 primers were designed from well conserved
areas of other known chymases using alignment analysis (Clustal W, EMBL EBI).
Following sequencing of these initial fragments, specific primers for the 3' and 5'
regions of each proteinase could be designed using the software programme Primer
3, which is freely available on the internet at the website http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi. All primers were manufactured by TAGN (VH Bio
Ltd). Primers used for cloning and sequencing equine tryptase and eq.MCP-1 are
shown in tables 3.1 and 3.2 respectively. The location and direction of these primers







PT1 sense TGG CCC TGG CAG GTG AGC CTG AGA 60
PT2 antisense GGG ACA TAG TGG TGG ATC CA 60
PT3 sense GAG TCA GTC TGC CAC CTC CGT TTC 55
PT4 sense CAT TGT GGA AAA CAG CGT TTG TGA 60
PT5 antisense TGT CTC TGA AAT CTT CAA TGT CCG 55
PT6 antisense AAC ACA GTG CGC CGC CGT CAG CAC 62
PT7 antisense TAG GGA GCC CCC GCA GAA GTG TTT 62
PT8 sense CCA AGA TGC CAA ATC TGC TG 55
PT9 antisense ATG TTG ACA GGG TCC TGG AG 55
PT10 sense TCA GAG ACA TCA GGG TGC AG 55
PT11 antisense GAC GGG GCT CAA GAG TCC TT 55
Table 3.1: Primers used in cloning and sequencing equine tryptase
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PM1 sense CAC TCC CGT CCC TAC ATG GC 60
PM2 antisense CAG AAG AGG GCC CCC AGA GTC TCC 60
PM3 sense CAG ACA CAC TGC AGG AGG TGG 60
PM4 sense GAG GTG TGC GAA TCC TAC TTC CGC 62
PM5 antisense CCC AAG GGT GAC ATT CAT TA 55
PM6 antisense GCA GTG AGC TGC CGT CAG 55
PM7 antisense GCA CGA GGA CAC CAC CAC AAC TGT 62
PM8 sense CCA GAG GAG CAC AGG TCT AG 55
PM9 antisense AGT TCC ACC TCC TGC AGT GT 55
PM10 sense GGA GAA GAC CCA GCA AGT CA 55
PM11 antisense GGG TGT TTC TGG ATC AGC TC 55
Table 3.2: Primers used in cloning and sequencing eq.MCP-1
nrrsnroa i—
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Fig. 3.1 : Generic strategy for cloning and sequencing equine tryptase and
eq.MCP-1 showing the direction and location of primers used. The heavy black
line depicts the protease cDNA sequence whilst the open black lines depict PCR
products.
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3.3.5. Reverse transcriptase PCR (RT-PCR)
PCR was performed in lOmM Tris-HCl, 1.5mM MgCl2 buffer with 5ju.l 2mM
dNTPs, 10pl 2pM primers and 2.5 units Taq DNA polymerase (Roche). Reactions
were performed in a Gene Amp PCR System 2400 (Perkin Elmer) with the following
conditions: initial denaturation at 95°C for 5min, followed by 30 cycles of 95°C 40s,
annealing temperature 30s (tables 3.1, 3.2), 72°C lmin and a final extension step of
20min at 72°C. PCR products were analysed on 1.2% agarose gels, containing 0.1%
ethidium bromide, by electrophoresis at 120-160V for 30min and imaged under UV
(Image Station 440 CF, Kodak Digital Science). Gels were then blotted and
subjected to subsequent Southern blot analysis with digoxigenin (DIG) labelled
probes (section 3.3.13). If clear, distinct bands were obtained on gel electrophoresis,
PCR products were sequenced directly (ABI Prism, Durham Sequencing Service,
Durham University). If a clear band was not obtained, PCR products were ligated
into a vector for subsequent transformation of cells.
3.3.6. Rapid amplification of cDNA ends (RACE)
The 3' and 5' ends of sequences were obtained using a 573' RACE kit (Boehringer
Mannheim) as per the manufacturer's recommendations. Briefly, for 3' RACE, first
strand cDNA synthesis was initiated at the RNA polyA-tail with the oligo dT-anchor
primer. The resulting cDNA was amplified by PCR using P3 and the 3'-dT-anchor
primer and then re-amplified using P4 and the 3'anchor. For the 5' end, total RNA
was reverse transcribed using P5 and avian myeloblastosis virus reverse
transcriptase. The synthesised cDNA was purified using High Pure PCR Product
Purification Kit (Roche) and a 3' homopolymeric A-tail added using dATP and
terminale transferase, allowing nested PCR using the 5'-dT-anchor primer and
primers P6 and P7. The thermal cycle profile used was 94°C for 5min followed by 30
cycles of 95°C 40s, annealing temperature 30s (tables 3.1, 3.2), 72°C lmin, followed
by a final extension of 72°C lOmin. RACE PCR products were subjected to Southern
blot analysis and positive products ligated into a vector.
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3.3.7. Ligation of PCR products into Plasmid Vector
PCR products were ligated into the TA cloning vector pCR 2.1 (Invitrogen)
according to the manufacturer's directions. Briefly, 2pl of fresh PCR product was
incubated overnight at 14°C with lpl ligation buffer, 2pl pCR 2.1 vector (25ng/pl),
lpl DNA ligase and 4pl sterile water.
3.3.8. Transformation of Competent Cells
The ligated vector was used to transform One Shot INVaF Competent Cells
(Invitrogen). A vial of competent cells was thawed on ice and 2pl of ligation reaction
added by gentle stirring with a pre-cooled pipette tip. The cells were incubated on ice
for 30min and then subjected to a heat shock of 42°C for 30s. The cells were then
immediately placed on ice and 250pl room temperature SOC medium (Invitrogen)
added. Vials were incubated at 37°C, 225rpm for lh in a shaking incubator
(Gallenkamp, Sanyo) and then 50 and lOOpl of the cell suspension plated out onto
pre-warmed LB agar containing X-Gal (Promega) and lOOpg/ml ampicillin. Agar
plates were incubated at 37°C overnight after which small colonies could be seen
growing. Colonies of transformed cells were white whereas colonies not transformed
by the plasmid were blue. The incubated plates were then stored at 4°C until colony
selection.
3.3.9. Isolation of Plasmid DNA
White colonies were transferred using sterile toothpicks into 10ml LB broth
containing 100pg/ml ampicillin and incubated overnight at 220rpm, 37°C, after
which the LB broth was cloudy from colony growth. Plasmid DNA was isolated
from broth medium using Wizard Plus SV Minipreps DNA Purification System
(Promega). All steps were performed at room temperature. Cells were pelleted from
3ml broth by centrifugation at 13,000rpm for 5min (Biofuge, Kendro Laboratory
Products) and resuspended in 250pl cell resuspension solution. Cells were then lysed
by addition of 250pl cell lysis solution and incubated for 5min with lOpl alkaline
protease solution to inactivate endonucleases released during cell lysis.
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Neutralisation solution (350pl) was then added and the bacterial lysate centrifuged at
13,000rpm for lOmin. Plasmid DNA was then bound to a spin column filter by
centrifuging the cleared lysate at 13,000rpm for lmin. DNA was washed with 750pl
wash solution followed by centrifugation at 13,000rpm for lmin and then a further
250pl of wash solution with centrifugation at 13,000rpm for 2min. Plasmid DNA
was then eluted with lOOpl nuclease free water (Ambion) and centrifugation at
13,000rpm for lmin.
3.3.10. Restriction Enzyme Analysis of Plasmid DNA
Inserted DNA was cut out of the plasmid using the restriction enzyme Eco R1
(Roche). Plasmid DNA (2pl) was added to 2pl Buffer H (Roche) and 16pl of sterile
water. To lOpl of this mixture, lpl of Eco R1 was added; the other lOpl served as an
uncut control. Samples were incubated at 37°C for 2h and then subjected to gel
electrophoresis on a 1.2% agarose gel containing 0.1% ethidium bromide at 120V for
45min. After imaging, the gel was blotted for subsequent Southern blot analysis.
3.3.11. Complete Sequence RT-PCR Products
Attempts to amplify the whole cDNA sequence for each proteinase from one PCR
reaction were unsuccessful (data not shown). Therefore the cDNA sequence obtained
from the three overlapping segments using the protocols above was confirmed by
sequencing the whole proteinase in two halves using primers P8 and P9 to amplify
the 5' end and P10 and PI 1 to amplify the 3' end. These products were cloned and
sequenced as described above.
3.3.12. DIG-Labelling of Oligonucleotides
Complementary oligonucleotides (oligos) to the DNA sequence of interest were
labelled with DIG using the Oligo End Labelling Kit (Roche). The following reaction
was set up on ice; 4pl tailing buffer, 4pl cobalt chloride solution, lOpl lOOpmol
oligonucleotide, lpl DIG ddUTP solution and 1 jul terminale transferase. The reaction
was incubated at 37°C for 15min, placed on ice and 2pi stop solution (lpl glycogen
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solution and 200pl 0.2mM EDTA) added. The DIG-labelled oligo was then added to
10ml Rapidhyb buffer (Amersham) to be used as a probe for Southern blot analysis
of PCR products / clones.
3.3.13. Southern Blot Analysis
Agarose gels of PCR products and restriction digests of cloned products were
washed briefly with distilled water and denatured in 1.5M NaCl, 0.5M NaOH twice
for 15min. Gels were again washed briefly with distilled water and then neutralised
with 1.5M NaCl, 0.5M Tris, 0.001M EDTA twice for 20min. The gel was placed
face down on a plastic tray and a piece of nitrocellulose membrane (Amersham) pre-
wetted with 1.5M NaCl, 0.5M Tris, 0.001M EDTA placed on top of the gel. Three
layers of blotting paper, a thick layer of absorbent paper towels and then a 500g
weight were positioned on top of the nitrocellulose membrane. Following overnight
capillary transfer of DNA to the nitrocellulose membrane from the gel, the
membrane was washed briefly with 6 x SSC (where 1 x SSC is 0.15M NaCl /
0.015M sodium citrate). DNA was fixed to the membrane by 2 UV light cycles of
12s each (Template Tamer, Qbiogene). The size markers were excised and stained by
lOmin immersion in 5% glacial acetic acid followed by 30min in 0.04% methylene
blue (pH 5.2) and final washing with distilled water. The DNA impregnated
membrane was pre-hybridised with 10ml Rapidhyb buffer in hybridisation bottles
(Techne) in a hybridisation oven (Techne Hybridiser HB-1D) at 40°C for 30min.
DIG-labelled oligo probes in Rapidhyb buffer were then hybridised to the membrane
for 3h at 40°C. The membrane was washed with 2 x SSC, 0.1% SDS for 2 x 5min,
followed by 0.1 x SSC, 0.1% SDS for 2 x 15min. Following a brief rinse with maleic
acid buffer (0.15M NaCl, 0.1M maleic acid, pH 7.5), the membrane was incubated
with blocking buffer (1% blocking reagent, [Roche] in maleic acid buffer) for 30min
followed by anti-digoxigenin-alkaline phosphatase-conjugate (Roche) diluted 1:5000
in blocking buffer for 30min. The membrane was washed twice for 15min with
maleic acid buffer, 0.3% Tween 20 (Sigma) and rinsed in lOOmM Tris-HCl, lOOmM
NaCl, 50mM MgCh, pEl 9.5. The reaction was then developed by incubating with
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substrate 5-bromo-4-chloro-3-indolyl phosphate / nitro blue tetrazolium (BCIP /
NBT) (Sigma) in the dark until positive bands appeared.
3.3.14. Peptide Mass Fingerprinting
Eq.MCP-l and tryptase (2pg) previously isolated from equine mastocytoma tissue
(Pemberton et al., 2001) were heated to 95°C for 3min with an equal volume of
reducing buffer. The reduced proteinases were subject to SDS-PAGE and the gel
stained as previously described (section 2.3.1.3). A band was excised for each
proteinase, cut into 1mm sections and sent for tryptic peptide mass fingerprinting
(Moredun Institute, Midlothian).
3.3.15. Enzyme Kinetics of Equine Tryptase
The enzyme kinetics of equine tryptase with the arginine containing substrate N-(p-
Tosyl)-Gly-Pro-Arg p-nitroanilide acetate (GPR, Sigma) and the lysine containing
substrate N-(p-Tosyl)-Gly-Pro-Lys 4-nitroanilide acetate (GPK, Sigma) were
assessed to investigate possible preferential activity for one substrate over another.
A single concentration of equine tryptase was incubated at room temperature with a
range of concentrations of each substrate (0.25-2.0mM) in 1M glycerol, 0.1M NaCl,
0.1M Tris-HCl, pH 8.0. Analyses were performed in duplicate. The specific activity
of equine tryptase in this buffer system has previously been determined with S2366
(Pemberton et al., 2001). Equine tryptase was therefore standardised against S2366
and the final active tryptase concentration in the diluted sample determined to be
3.35x10"9M. The rates of activity for the given substrate concentrations were fitted to
a Michaelis-Menten plot using non-linear regression (Graph Pad Prism). Regression
analysis determined the kinetic parameters Km (a measure of the affinity of the
enzyme for the substrate) and Vmax (maximum velocity). Vmax values (AUmin"1) were
converted to Ms"1 using the extinction coefficient of 15000M"'cm"1 for
paranitroaniline under these conditions (Pemberton et al., 2001). kca, values, a direct
measure of the catalytic production under optimum conditions (saturated enzyme),




kCat /Km ratios were then calculated for each substrate as a measure of overall enzyme
efficiency to allow comparison of their suitability as substrates for equine tryptase.
3.3.16. Samples for Expression of Proteinases in Tissues
Tissue samples of liver, colon, skin, bronchus and bronchiole were collected from 3
horses euthansed at R(D)SVS for non-medical reasons. Samples were stored in
RNA-Later at 4°C overnight and then at -20°C until further processing. RNA was
extracted and reverse transcribed as described in sections 3.3.2 and 3.3.3,
respectively.
3.3.17. RT-PCR for Proteinase Expression
RT-PCR was performed as described in section 3.3.5 except that an annealing
temperature of 55°C was used over 40 cycles. Each sample was amplified for equine
tryptase, eq.MCP-1 and the house-keeping gene |3-actin. Primers were designed using







Tryptase CTC CAG GAC CCT GTC
AAC AT
ACG CCA GTG TGG TAT
TTC CT
209
Eq.MCP-1 AAG CCA TAC ACC ACC
CAG AC
TGC ACA GTC AGT TCC
ACC TC
226
fi-actin TGG GCC AGA AGG ACT
CAT AC
CTT GAT GTC ACG CAC
GAT TT
500
Table 3.3: Primers used in RT-PCR reactions to demonstrate protease expression in
various equine tissues.
PCR products were subjected to electrophoresis at 160V, for 30min on a 1.6%
agarose gel with 0.1% ethidium bromide and visualised under UV light. Southern





The cDNA sequence for equine tryptase from start to stop codons was 828 base pairs














Fig. 3.2: Equine tryptase cDNA nucleotide sequence from start to stop codon.
This cDNA nucleotide sequence translated into a 275 Aa long protein, consisting of a
30 Aa leader sequence and a 245 Aa mature protein. The cloned sequence
corresponded exactly with that determined by N-terminal Aa sequencing of the first
20 residues of tryptase purified from equine mastocytoma tissue (Pemberton et al.,
2001). Theoretical trypsin cleavage of the cloned equine tryptase sequence (Peptide
Mass, ExPASy) gave 11 peptides in the optimal 600-2000Da range detectable by
peptide mass fingerprint MALDI-TOF instrumentation. Peptide mass fingerprint
analysis (Mascot, Matrix Science) of equine mastocytoma derived tryptase matched
9 out of these possible 11 peptides, scoring highest compatibility with the above
equine tryptase sequence, with a Mascot probability of 0.006 and covering 33% of
the mature protein sequence (fig. 3.3).
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IVGGQEASGS KWPWQVSLRK NTEYWKHFCG GSLIHPQWVL TAAHCVGPDI
EDFRDIRVQL REQHLYYRDQ LLPVSRILPH PYYYTVENGA DIALLELQDP
VNISSHVQVV TLPPASETFP PGTPCWVTGW GDVDNGVSLP PPFPLKEVKV
PIVENSVCDR KYHTGVSTKn NTRTVQADMT. CAGNRRHOSC QGDSGGPLVC
KVKGTWLQAG VVSWANSCAQ PNRPGIYTRV TYYLDWIYQY VPKDS
Fig. 3.3: Coverage map of matched peptides from peptide mass
fingerprinting of tryptase isolated from equine mastocytoma tissue
to the cloned equine tryptase sequence. Nine out of a possible 11
peptides in the 600-2000Da range matched the sequence (shown in
bold red), covering 33% of the mature protein sequence.
The peptide masses produced from the peptide mass fingerprint of the mastocytoma
derived tryptase were all within 0.05Da of the peptide masses predicted by trypsin
digestion of the cloned sequence (fig. 3.4) enhancing confidence in the assignment.
The cloned cDNA nucleotide and Aa sequences were submitted to the GenBank
database as equine tryptase (accession number AJ515902).
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Fig. 3.4 : Error between expected tryptic peptide masses for equine
tryptase and the observed peptide masses. All observed peptide masses
have low errors when compared to their predicted masses (dotted lines
represent +0.05 and -0.05).
The cDNA nucleotide sequence for equine tryptase shared greatest identity (81%)
with human tryptase-P and 78% identity with sheep tryptase-2. The corresponding
Aa sequence shared 77% identity with human tryptase-P and 73% with sheep
tryptase-2. Alignment analysis of these proteinase Aa sequences by Clustal W
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Eq PIVENSVCDRKYHTGVSTGDNIRIVQADMLCAGNRRHDSCQGDSGGPLVCKVKGTWLQAG 240
Hu PIMENHICDAKYHLGAYTGDDVRIVRDDMLCAGNTRRDSCQGDSGGPLVCKV GTWLQAG 240
Sh PIVENSVCDWKYHSGLSTDYSVPIVQEDNLCAGDGGRDSCQGDSGGPLVCKV GTWLQAG 238
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Fig. 3.5: Alignment analysis of Aa residues for equine tryptase (Eq), human
tryptase |3 (Hu) and sheep tryptase 2 (Sh). * denotes that the residues or nucleotides
in that column are identical in all sequences in the alignment, : denotes that
conserved substitutions have been observed, . denotes that semi-conserved
substitutions are observed. The signal / activation peptide is underlined, serine
proteinase catalytic triad residues are in red, residues governing primary substrate
specificity are in blue, putative glycosylation sites are in green, A-B interface
residues are in bold type and A-D interfaces are in bold italics. These A-B / A-D
interfaces are the monomeric interfaces of the tetrameric active protease
configuration as shown in fig. 3.6.
A-D interface Fig. 3.6 : Schematic diagram showing
the monomeric interfaces A-B and A-D
of the active tryptase tetramer.
A-B interlace
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The cloned equine tryptase sequence contains residues highly conserved within
trypsin-like proteinases, including the activation site region IVGG (residues 31-34)
preceded by a 30 Aa leader sequence, WVLTAAHC active site histidine region
(residues 68-75), a DIALL active site aspartic acid region (residues 120-124), M-
CAG (residues 208-212) downstream of the active site serine and GDSGGP active site
serine region (residues 221-226). Potential N-linked carbohydrate binding regions
were present at positions 132 and 233. Residues at monomer interfaces, illustrated
schematically in fig. 3.6, were identified by alignment with human tryptase-(3, where
these contact residues have previously been identified (Pereira et al., 1998).
Further sequence observations are made using the archetypal chymotrypsinogen
numbering system, which is based upon the alignment of serine proteinase amino
acid sequences with chymotrypsinogen. Thus, Serl95 is the catalytic residue of all
serine proteinases. Equine tryptase, like all trypsin-like proteinases, contains an
aspartate at residue 189 which confers substrate specificity for cleavage C-terminal
to arginine or lysine at the P] residue (nomenclature of Shechter and Berger [1967])
except when followed by proline (Steitz et al., 1969). Unusually for a trypsin-like
proteinase, equine tryptase contains an alanine, rather than a glycine, at residue 216.
As this residue forms part of the substrate binding pocket wall (fig. 3.7), this
substitution may subtly alter substrate specificity. Enzyme kinetics of equine tryptase
for arginine and lysine substrates were therefore investigated (section 3.4.2). Other
conserved trypsin-like proteinase features present are the cysteine residues at 191 and
220, the disulphide bond between which acts to support the substrate binding pocket.
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\ /• Fig. 3.7 : Schematic representation of
.O the substrate binding pocket of equine
O tryptase. Asp 189 confers a negative
\Q charge on the substrate binding pocket
/ rucvyi® attracting side chains with a positive
°N 8DHS11® charge e.g. Arg or Lys. The presence of
O an alanine rather than glycine at residue
/ 216 is highly unusual in trypsin-like
proteases.
3.4.2. Enzyme Kinetics of Equine Tryptase
The Michaelis-Menten plot of rates of equine tryptase activity with varying
concentrations of the p-nitroanilide substrates GPK and GPR is shown in fig. 3.8. Km,






Fig. 3.8: Michaelis-Menten plot of equine tryptase activity
rates with varying substrate concentrations of GPK and GPR.
The number in parentheses following the substrate name
denotes the replicate number.
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GPR(l) GPR(2) GPR(av) GPK(l) GPK(2) GPK(av)
Km
(mM) 0.802 1.042 0.922 3.370 2.328 2.849
yr max
(AUmirf1 ) 0.070 0.072 0.071 0.041 0.032 0.036
kcat
(s-1) 23.3 23.7 23.5 13.5 10.6 12.0
kcat /
(M"1 s"1) 2.90xl04 2.28xl04 2.59xl04 4.0 lxl 03 4.55xl03 4.28x103
Table 3.4: Substrate profiles for equine tryptase with the substrates GPR and GPK.
Numbers in parentheses following the substrate name denotes the replicate number,
(av) indicates the average value for that substrate.
The mean kcat /Km ratio for GPR was six times greater than that of GPK, indicating
preferential selectivity of equine tryptase for arginine substrates over lysine
substrates.
3.4.3. Putative Eq.MCP-1 Sequence
The cDNA nucleotide sequence of cloned putative eq.MCP-1 was 744 base pairs
long and is shown in fig. 3.9 from start to stop codons. This translated into a 247 Aa
protein, composed of a 20Aa leader sequence and a 227 Aa catalytic protein, with a












Fig. 3.9 : cDNA sequence from start to stop codon for the cloned putative eq.MCP-1
protease
However, the first 20 residues of the N-terminal Aa sequence for putative eq.MCP-1
deduced from the cDNA nucleotide sequence differed by two Aas from the
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proteinase isolated from equine mastocytoma tissue and assigned the name eq.MCP-
1 (Pemberton et al., 2001) (table 3.5). The cloned cDNA and Aa sequences were
submitted to GenBank as putative equine mast cell proteinase-1 (AJ548473).
Proteinase N-terminal Aa sequence
Mastocytoma eq.MCP-1 IIGGHEARPHSRPYMAFVQF
Cloned putative eq.MCP-1 IIGGHEAKPHSRPYMALVQF
Table 3.5: N-terminal Aa sequence of mastocytoma derived eq.MCP-1 and cloned
putative eq.MCP-1. Differing Aa residues are shown in red in the cloned sequence.
Peptide mass fingerprinting of eq.MCP-1 isolated from equine mastocytoma tissue
was performed on two occasions. Fourteen peptide masses matched between these
two fingerprint analyses, however neither analysis resulted in a positive match with
any known protein sequence from the GenBank database, including the above
putative eq.MCP-1 sequence. In fact, only three of these 14 matching peptides
corresponded with predicted peptides from the cloned putative eq.MCP-1 sequence
(fig. 3.10) suggesting that in fact a similar, but novel, proteinase had been cloned.
IIGGHEAKPH SRPYMALVQF LFEEILHSCG GVLVRQDIVL TAAHCWGRLM NVTLGAHNIR
RQEKTQQVIT VRQAIHHPDY NPKSFSNDIM LLKLGRRAKL TAAVRPLSLP RGKTQVRPGE
VCSVAGWGQT, APKGRFPOTT, QF.VELTVOOD EVCESYFRNY FNSTTQLCVG DPKDKKSSFQ
GDSGGPLICE NGLQGIVSYG LDNGSIPQAF TKVSSFLPWI KKTMKRL
Fig. 3.10: Mature protein Aa sequence for cloned putative eq.MCP-1. Residues in
red are the predicted trypsin digested peptides of cloned putative eq.MCP-1 that
match peptides from peptide mass fingerprinting of eq.MCP-1 isolated from
equine mastocytoma tissue.
The putative eq.MCP-1 cDNA nucleotide sequence shared greatest identity (75%)
with the cytotoxic T lymphocyte associated serine esterases human granzyme B and
H. The closest related mast cell proteinases were the sheep chymase mast cell
proteinase-3 (SMCP-3, 71% identity) and the dual specific (exhibiting both trypsin-
like and chymotrypsin-like specificity) sheep mast cell proteinase-1 (SMCP-1, 70%
identity). The translated Aa sequence shared 65% identity with human granzyme B,
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63% with human granzyme H, 57% with SMCP-3 and 56% with SMCP-1. The
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Fig. 3.11: Aa alignment analysis of putative eq.MCP-1 (Eq), human granzyme B
(HG) and sheep mast cell protease 3 (S3). * denotes that the residues or nucleotides
in that column are identical in all sequences in the alignment, : denotes that
conserved substitutions have been observed, . denotes that semi-conserved
substitutions are observed. The signal / activation peptide is underlined, serine
proteinase catalytic triad residues are in red, residues governing primary substrate
specificity are in blue, putative glycosylation sites are shown in green, residues in
bold are the predicted trypsin digested peptides of cloned putative eq.MCP-1 that
match peptides from peptide mass finger printing of eq.MCP-1 isolated from equine
mastocytoma tissue.
Further classifications are made using the chymotrypsinogen numbering system. The
active site H, D, S residues are located at positions 35, 79 and 174, respectively. The
uncharged glutamine residue at position 226 is expected to confer chymase substrate
specificity with preference for uncharged, aromatic substrates (Zamolodchikova et
al., 2003). Other conserved features specific to non-trypsin-like proteinases present
within the putative eq.MCP-1 sequence include the Cysl36-Cys201 disulphide bond
and the conserved N-terminal sequence (IIGG residues 16-19 and PHSRPYMA
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residues 24-31). Importantly, the putative eq.MCP-1 Aa sequence displays the main
structural characteristic of graspases; the absence of the active site double cysteine
bond between residues 191 and 220. The latter is highly conserved among other
serine proteinases (Zamolodchikova et al., 2003).
3.4.4. Expression of Proteinases in Equine Tissues
Both equine tryptase and putative eq.MCP-1 were expressed in all tissues analysed;
bronchus, bronchiole, liver, skin and colon (fig. 3.12). Some genomic DNA
contamination was evident in some samples. Southern blot analyses of gels with
DIG-labelled oligos were positive.
Fig. 3.12: PCR products of tryptase (a) and eq.MCP-1 (b) expression in equine
tissues run out on a 1.6% agarose gel with 0.1% ethidium bromide at 160V for
30min. The top row of PCR products are protease fragments (209bp tryptase, 226bp
eq.MCP-1), the bottom row of products are P-actin fragments (500bp). Samples are
ordered: bronchiole, bronchus, liver, colon, skin for each horse in turn. Kb =
Kilobase pair markers (25-1000bp).
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3.5. Discussion
3.5.1. Cloning and Sequencing of Equine Tryptase
This is the first reported cDNA nucleotide sequence for equine tryptase. The cloned
equine tryptase Aa sequence was the same length (245 Aa mature protein) and shared
>70% identity with other mammalian tryptases. The N-terminus corresponded
exactly with that determined by N-terminal Aa sequencing of the first 20 residues of
equine tryptase isolated from equine mastocytoma tissue. Furthermore, results of
peptide mass fingerprinting ofmastocytoma derived tryptase corresponded well with
the cloned Aa sequence. We are therefore confident that equine tryptase was cloned
and sequenced.
Many features of the cloned equine tryptase sequence were characteristic of trypsin-
like proteinases, including the aspartate 189 residue governing substrate specificity,
the cysteine residues at 191 and 220 and the highly conserved tryptase sequence
regions of the activation site region and active site residues (Furie et al., 1982). The
30 Aa leader sequence is followed immediately by the 245 Aa catalytic proteinase
sequence without an intermediate activation peptide which is also typical of serine
proteinases, and tryptase in particular (Miller et al., 1989). Mast cell granules contain
active tryptase without this 30 Aa leader peptide and therefore roles for directing the
proteinase into the granules or in formation of the active tetramer from the individual
monomers have been suggested for the leader sequence (Miller et al., 1989;
Caughey, 1991).
In addition to the importance of residue 189 conferring substrate specificity, the
backbone conformation around residue 216 is critical in determining serine
proteinase specificity (Perona et al., 1995). The presence of an alanine residue at 216
in equine tryptase is highly unusual among tryptases. The only other reported
tryptase which does not have a glycine residue at position 216 is human tryptase-a,
which has an aspartate substitution (Miller et al., 1989). Residues 216 and 226 form
part of the walls of the substrate binding pocket and are usually both glycines in
trypsin-like proteinases. The aspartate 189 residue, these glycine residues and the
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double cysteine bond between residues 191 and 220 are believed to give a rigid
conformational shape to the substrate binding pocket with the small glycine residues
allowing access of bulky arginine and lysine side chains to the negatively charged
aspartate at the bottom of the pocket. Alanine contains a methyl (CH3) side chain,
which is larger than the glycine side chain (H), and will therefore project further into
the substrate pocket. This substitution may therefore influence substrate binding
pocket conformation and consequently substrate specificity in a subtle way. Indeed,
kinetic profiles of equine tryptase with arginine and lysine substrates (GPR and
GPK) revealed a six-fold preferential selectivity for the arginine substrate. In
contrast, trypsin and other tryptases generally show equivalent enzyme kinetics with
these same two substrates (Huang et al., 1997) which are identical except for
arginine or lysine at the Pi residue, indicating that this preferential selectivity must
be associated with these Pi residues. Increased specificity for arginine substrates is
somewhat counter-intuitive as arginine bears a bulkier side chain than lysine.
However, this is consistent with the genetically engineered substitution of alanine for
glycine at residue 216 in trypsin, which also resulted in increased selectivity for
arginine substrates (Craik et al., 1987). Other naturally occurring substitutions in this
area include that of an aspartate for glycine at residue 216 in human tryptase-a which
increases tetramer stability compared with human tryptase-P (Selwood et al., 2002)
but alters substrate specificity such that it is unable to cleave fibrinogen (Huang et
al., 1999). However, as human tryptase-a is the predominant tryptase found in
peripheral blood (Schwartz et al., 1995), this may be a biologically advantageous
mutation. The biological significance of the alanine 216 substitution in equine
tryptase is unknown but may be important with regard to cleavage of fibrinogen-p
chains. Human tryptase cleaves the human fibrinogen-P chain at the Pi residue
lysine-21 (Thomas et al., 1998). Currently, only a 19 residue fragment of the Aa
sequence encoding equine fibrinogen-P chain has been determined and therefore it is
unknown if this lysine-21 Pi residue also exists in the equine fibrinogen-P sequence.
However, if this lysine residue is present, the alanine 216 substitution could have a
significant biological effect restricting fibrinogenolysis in vivo.
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Tryptase is enzymatically active as a heparin-stabilised tetramer of 120-140 kDa
consisting of four tryptase monomer subunits of 31-34kDa in a ring-like structure
with a central pore (Pereira et ah, 1998). Each monomer contacts neighbouring
monomers at two sites (demonstrated as A-B and A-D interfaces in fig. 3.6) and has
an active site directed towards the oval central pore (Pereira et al., 1998). This
protected location restricts access to the active site and explains the inherent
resistance of tryptase to endogenous proteinase inhibitors. Instead of regulation via
inhibitors, tryptase activity is thought to be restricted in vivo by loss of stabilisation
by heparin, or other acidic polysaccharides, from the tetramer such that it dissociates
into inactive monomers (Schwartz and Bradford, 1986; Addington and Johnson,
1996). Examples of this are lactoferrin and myeloperoxidase, neutrophil granule
proteins which scavenge heparin from tryptase, leading to loss of activity (He et ah,
2003). Therefore, interestingly, the inflammatory neutrophil influx into the airway
lumen in equine heaves may perform an important role in regulating tryptase activity.
3.5.2. Cloning and Sequencing of Putative Eq.MCP-1
The deduced Aa sequence for putative eq.MCP-1 shared greatest identity (65%) with
the lymphocyte derived proteinases, human granzymes B and H, whereas the closest
related mast cell specific proteinases shared <60% identity. The N-terminal Aa
sequence of eq.MCP-1 extracted from mastocytoma tissue also shared greatest
identity with the chymase human granzyme H (Pemberton et ah, 2001). However,
the N-terminal Aa sequence of this mastocytoma derived eq.MCP-1 differed from
that of cloned putative eq.MCP-1 by 2 Aas. The peptide masses predicted by trypsin
digestion of the cloned Aa sequence also corresponded poorly with the peptide mass
fingerprint of mastocytoma derived eq.MCP-1. Furthermore, a search of all known
sequence databases did not result in a positive match for the mastocytoma eq.MCP-1
peptide mass fingerprint. It therefore appears likely that a similar, but novel,
proteinase was cloned and sequenced rather than eq.MCP-1. Mast cells of many
mammalian species express multiple closely-related chymases (McAleese et ah,
1998; Miller and Pemberton, 2002) and therefore the cloned sequence may
correspond to another equine mast cell chymase. As a mixed cell population was
67
used for RNA extraction, it is also possible that the cellular origin of the cloned
proteinase is the lymphocyte which as discussed above, may also express
chymotrypsin-like proteinases. In situ hybridisation would be necessary to confirm
the cellular location of this novel proteinase. An alternative explanation for this
apparently novel proteinase may be that the deduced eq.MCP-1 sequence does not
actually represent a gene product as it could only be constructed from two separate,
albeit overlapping, sequences.
It is helpful to consider a recent re-classification of the chymotrypsin family of serine
proteinases, which has divided members into the 'trypsin-like' group and the
'graspase' group based upon the presence or absence, respectively, of the disulphide
bond between cysteine residues 191 and 220 (Zamolodchikova et al., 2003).
Accordingly, by lacking this bond, putative eq.MCP-1 is considered to be a graspase.
The cysteine 191-220 disulphide bond is believed to support the architecture of the
substrate binding pocket and consequently is thought to be highly important for
proteinase activity. Although the loss of this bond from trypsin and chymotrypsin
dramatically decreases their enzymic activity and the specificity of trypsin
(Varallyay et al., 1997), graspases are active proteinases and display a wider range of
specificities than trypsin-like enzymes. However, the residue which contributes most
influence over substrate specificity in graspases is residue 226, not 189. The putative
eq.MCP-1 sequence also contains other highly conserved graspase features such as
the Cysl36-Cys201 disulphide bond and the residues 16-19 and 24-31 in the N-
terminus.
Graspases are further divided according to the nature of residue 226 into
chymozymes (uncharged residue), duozymes (aspartate or glutamine) or aspartases
(arginine) (Zamolodchikova et al., 2003). Therefore the presence of an uncharged
glutamine residue at position 226 in putative eq.MCP-1 classifies this proteinase as a
chymozyme, displaying expected chymotrypsin-like specificity for hydrophobic
substrates. Similarly, mastocytoma derived eq.MCP-1 was found to cleave the
thioester chymotrypsin substrate FLF-SBzl but not the tryptase substrate S2366
(Pemberton et al., 2001). However substrate specificity of this mastocytoma derived
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eq.MCP-1 was found to be very restricted, hydrolyzing only one of four peptide
substrates readily cleaved by other chymases (Pemberton et al., 2001). The
chymozyme human granzyme H, which has the highest identity with putative
eq.MCP-1, also shows highly restricted specificity, cleaving only FLF-SBzl
(Edwards et al., 1999). Of the other proteinases that shared high identity with
putative eq.MCP-1, only SMCP-3 is an apparent chymozyme by this classification,
whilst human granzyme B is an aspartase and SMCP-1 is a duozyme.
Chymotryspin-like mast cell proteinases had previously been classified into a- and (3-
chymases according to their ability to convert angiotensin I to angiotensin II
(Chandrasekharan et al., 1996). Homologous mammalian a-chymases, which can
catalyse this conversion, have been identified in man and dog, whereas P-chymases,
which do not necessarily possess angiotensin forming ability, are expressed by
rodent and ruminant mast cells (Miller and Pemberton, 2002). Eq.MCP-1 isolated
from mastocytoma tissue was only able to hydrolyse angiotensin I very slowly and
therefore is most likely to be a P-chymase (Pemberton et al., 2001). The distinction
between a- and P- chymases is believed to be due to the residues in the extended
substrate binding site determining specificity but the precise molecular basis for this
has not been deduced (Chandrasekharan et al., 1996).
3.5.3. Proteinase Expression in Equine Tissues
Mast cell proteinase expression in equine tissues has not previously been reported.
All tissues analysed (bronchus, bronchiole, colon, liver and skin) were found to
express equine tryptase and putative eq.MCP-1. Quantitative analysis was not
undertaken and therefore relative tissue expression can not be assessed. Pemberton et
al. (2001) likewise identified equine tryptase and eq.MCP-1 positive mast cells in
equine skin, duodenum and lung with immunohistochemistry. However, due to the
uncertain identity of putative eq.MCP-1, immunohistochemically positive cells using
antibodies directed against eq.MCP-1 isolated from mastocytoma tissue may
represent a different population of cells than those expressing putative eq.MCP-1. A
polyclonal antibody was used to identify eq.MCP-1 positive cells and therefore it
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may also have recognised other similar mast cell chymase proteins. Sheep tryptase,
which shares 73% identity with equine tryptase, is also widely expressed in ovine
tissues (Pemberton et al., 2000). In contrast, SMCP-1, which shares 56% identity
with putative eq.MCP-1, is less abundantly expressed in normal ovine tissues
(Pemberton et al., 2000).
3.6. Conclusion
Equine tryptase was cloned and sequenced and found to be widely expressed in
equine tissues. Uniquely among trypsin-like proteinases, equine tryptase has an
alanine substitution at residue 216 which confers increased specificity for arginine
residues. The biological significance of this substitution in vivo remains to be
elucidated; however it may restrict fibrinogenolysis. Molecular probes subsequently
designed from this sequence were used to investigate mRNA transcripts in the lungs
of control and heaves affected horses (Chapter 5). Whilst attempts were made to
clone eq.MCP-1, peptide mass fingerprinting of mastocytoma derived eq.MCP-1
indicated that a similar, but novel, chymase had been sequenced. As this cloned
proteinase shared strongest identity with lymphocyte derived human granzyme B, a
mast cell origin for the cloned chymase could not definitively be determined. This
novel chymase was also widely expressed in equine tissues.
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Chapter 4: Mast Cell Proteinase Concentration and
Expression in BALF from Control and Heaves
Susceptible Horses
4.1. Summary
ELISAs were developed and optimised in order to determine concentrations of
equine tryptase and eq.MCP-1 in BALF from controls (n=22), heaves horses during
clinical exacerbation (n=21), heaves horses in remission (n=13) and horses with
other pulmonary disease (n=7). Chromogenic assays were performed to determine
BALF tryptase activity. BALF histamine concentrations were measured using a
commercial ELISA. Immunolabelling of BALF cytospins was performed to
investigate proteinase expression of BALF mast cells in control (n=8) and heaves
(n=5) horses.
Clinical heaves horses had significantly increased BALF tryptase concentrations
compared to controls and heaves horses in remission. Horses with other pulmonary
diseases also had significantly elevated BALF tryptase concentrations compared to
controls. BALF from clinical heaves horses also had greater tryptase activity
compared to remission horses. Very low eq.MCP-1 concentrations were measured in
BALF from all horses. BALF histamine concentrations were not significantly
different among groups, which was considered, at least in part, to be the result of
histamine degradation in archived samples. BALF mast cells were predominantly
tryptase positive with only occasional eq.MCP-1 positive cells observed. There was
no significant difference in proteinase content of BALF mast cells between control
and heaves horses.
This study demonstrates mast cell degranulation and tryptase release into the
pulmonary airspace following challenge of heaves susceptible horses suggesting that




Mast cell mediators are regarded as playing a key role in the airway inflammation
and remodelling which occurs in response to inhaled allergens and irritants in human
asthma (Holgate, 2000), despite mast cells constituting only a small proportion of the
total BALF cell population in human asthmatics, as they do in heaves horses.
Consequently, BALF tryptase and histamine concentrations have been measured as
indicators of mast cell degranulation and are significantly elevated in symptomatic
asthmatics compared to control subjects (Casale et al., 1987a; Wenzel et al., 1988;
Chan-Yeung et al., 1989; Broide et al., 1990; Broide et al., 1991; Jarjour et al., 1991;
Bousquet et al., 1991).
Much prior research investigating equine heaves has focused upon the neutrophil due
to the influx of large numbers of neutrophils into the airway lumen during
exacerbation of disease. However, there is now a growing body of evidence to
suggest that mast cells may play an important role in the pathogenesis of equine
heaves. This includes elevated BALF IgE to common fungal allergens (Halliwell et
al., 1993; Schmallenbach et al., 1998), increased PELF histamine concentrations 5h
following challenge of heaves susceptible horses (McGorum et al., 1993c) and
increased numbers of bronchiolar mast cells in horses with chronic bronchiolitis
(Winder and von Fellenberg, 1988).
The aim of this study was therefore to: (a) determine mast cell proteinase
concentrations and activity and histamine concentrations in BALF from control and
heaves susceptible horses during disease exacerbation and remission, and (b)
investigate proteinase expression ofBALF mast cells in control and heaves horses.
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4.3. Materials and Methods
4.3.1. Subjects and Collection of BALF for Determination of BALF
Mast Cell Proteinase and Histamine Concentrations
Samples utilised comprised those collected from clinical cases at the Royal (Dick)
School of Veterinary Studies (RD[S]VS) during routine clinical investigation
procedures and archived samples which had been collected during 2 previous studies.






Other pulmonary diseases 7
Total 63
Table 4.1: Status of horses from which BALF samples
were collected for determination of BALF mast cell
proteinase and histamine concentrations.
BALF samples were obtained from three groups of subjects as follows:
4.3.1.1. Horses Undergoing Bronchoalveolar Lavage (BAL) at R(D)SVS
BALF samples (n=24) were collected from horses referred to R(D)SVS for
investigation of respiratory disease or poor performance. Following sedation with
30pg/kg romifidine (Sedivet, Boehringer Ingelheim Ltd.) and 15pg/kg butorphanol
(Torbugesic, Willow Francis Veterinary) and restraint with a nose twitch, the
endoscope (Olympus CF Type 200HL, 1.7m working length, Olympus Optical Co.
Ltd.) was introduced via the nares and rima glottidis into the trachea and then
advanced until wedged in the right accessory lobe. Following instillation of 300ml
0.9% saline (Ivex) (room temperature) and then approximately 30ml air, BALF was
retrieved manually using gentle suction with 60ml syringes. Attempts were made to
reduce dwell time of lavage fluid to minimise exchange of molecules between the
airspace and pulmonary circulation (Marcy et al., 1987). BALF supernatant was
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harvested by centrifugation (400g, lOmin) and stored at -70°C until further
processing (<6mths).
Three further samples were obtained from control horses that were lavaged
immediately post mortem following euthanasia for non-pulmonary reasons. A BAL
catheter (240cm length, 10mm external diameter; Irish Equine Centre) was passed
blindly into the lungs per nasum until wedged. Thereafter, BAL was performed as
described above.
The disease status of these horses was defined by the history (including husbandry
practices) and BALF cytology. A history of clinical signs suggestive of heaves
following exposure to hay / straw and a differential neutrophil count >5% with
normal neutrophil morphology was taken as indicative of clinical heaves (hereafter
termed 'heaves') (Dixon et al., 1995b). Horses with no history of coughing or nasal
discharge and normal BALF cytology were classified as controls. Horses with
normal BALF cytology following prior diagnosis and treatment of heaves were
classified as heaves horses in remission (hereafter termed 'remission'). Cases which
did not fit into one of these 3 groups and had a mixed inflammatory pattern on BALF
cytology were given the status of other pulmonary disease, hereafter termed 'other
disease'.
The 24 samples collected from the R(D)SVS hospital referred cases were comprised
of 6 controls, 5 heaves, 6 remission and 7 other disease (viral disease n=4,
eosinophilic pulmonary disease n=2, inflammatory airway disease n=l). The median
and range of ages and sex distribution for these groups is shown in table 4.2. This
sample population is hereafter termed R(D)SVS hospital.
Group No. horses Median (range)
age (years)
Sex
Control 6 7(4-18) 1 F, 5 MN
Heaves 5 12 (4-20) 2 F, 2 MN, 1 M
Remission 6 12 (10-30) 2 F, 4 MN
Other pulmonary disease 7 7(6-12) 7 MN
Table 4.2: Age and sex distribution of horses in R(D)SVS hospital
population. Key: F female, MN gelding, S stallion.
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4.3.1.2. Archived Samples from Natural Hay /Straw Challenge ofControl or Heaves
Susceptible Horses at R(D)SVS
In a former study, horses previously classified by natural hay / straw challenge as
controls (n=3) or heaves susceptible (n=5) horses, were exposed for 5h to a challenge
environment consisting of a small (3.7m x 3.7m), poorly ventilated stable with the
doors and air vents closed, a deep litter straw bed and fed dusty hay with visible
mould growth. The median (range) total and respirable dust concentrations in this
challenge environment were 1.5 (0.5-1.9) and 0.2 (0.1-0.3) mg/m3 respectively. This
hay / straw challenge has previously been shown to induce heaves in susceptible
horses only (McGorum et al., 1993d). BALF samples and supernatant were collected
as described above at 6h and / or 24h following initiation of challenge and stored at -
70°C for 2-4 years prior to further processing.
There were 4 samples from the 3 control horses (all mares) with a median (range)
age of 4y (4-6y). Nine samples were from the 5 heaves susceptible ponies (3 mares, 2
geldings) with a median age 14y (7-24y). This sample population is hereafter termed
R(D)SVS archive.
4.3.1.3. Archived Samples from Natural Hay /Straw Challenge ofControl or Heaves
Susceptible Horses at the Animal Health Trust (AHT), Newmarket
Horses categorised, as described above, into control (n=6) or heaves susceptible
(n=7) horses underwent a 24h natural hay / straw challenge to induce disease in
susceptible animals in a model similar to that described above. Stable dimensions
were 3.6m x 5.6m with an airspace volume of 72m3. Total and respirable dust
concentrations were not performed for this challenge model however mould species
analysis was available. Hay and straw used in this challenge contained 286 x 10 /ml
particulates (<60pm diameter) and 200cfu/g Thermophilic actinomycetes and 69cfu/g
Aspergillusfumigatus in the hay and straw, respectively. BAL was performed 7 days
prior to challenge (baseline) and immediately following cessation of challenge with
an instillation volume of 200ml 0.9% saline, pre-warmed to 37°C. Supernatant was
harvested (800g, lOmin, 4°C) and frozen at -70°C for <1 year.
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There was 1 mare and 12 geldings with the median (range) control age of 7y (5-15
years) and median heaves susceptible age of 15y (8-23 years). This sample
population is hereafter termed AHT archive.
4.3.2. Processing of BALF
4.3.2.1. Preparation ofCytospins and Differential Cell Counts (DCC)
Cytospins were prepared in duplicate from R(D)SVS hospital samples by
cytocentrifugation of lOOpl BALF at 300g, for 3min (Shandon Cytospin 3).
Cytospins were air dried and then stained with Leishmans stain (Fisher Scientific).
DCC of 500 cells were performed on each cytospin and mean counts calculated for
each horse from duplicate slides. Cytospins and DCC had previously been performed
in an identical manner for R(D)SVS archive samples. DCC were obtained from the
AHT (Shandon Cytospin 3, minimum 200 cells, stained with haematoxylin and
eosin) for AHT archive samples.
4.3.2.2. Concentration ofBALF Samples
As preliminary trials showed that unconcentrated BALF proteinase concentrations
were very low, frozen BALF supernatant was thawed on ice and concentrated using a
lOkDa centrifugal filter device (Centricon, Millipore) at 5000g for 90min. This
technique has been used previously in studies measuring tryptase in human BALF
and nasal lavage fluid (Castells and Schwartz, 1988; Wenzel et al., 1988; Broide et
al., 1990; Sedgwick et al., 1991; Jarjour et al., 1991). The mass of supernatant was
measured pre- and post-centrifugation to enable calculation of the concentration
factor. Proteinases, having a molecular weight greater than lOkDa, were retained in
the upper reservoir, whilst histamine passed through into the filtrate. The mean
(range) concentration factor was 2.74 (1.31-7.73).
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4.3.2.3. Determination ofTryptase and Eq.MCP-1 Concentration by ELISA
For all ELISAs, primary coating antibodies (lpg/ml) in carbonate buffer (pH 9.6)
were applied (50pl/well) to plastic 96 well plates (Immulon 96W, Dynatech M 129B,
Thermo Life Sciences) (hereafter termed ELISA plates) and incubated overnight at
4°C. All further dilutions used ELISA buffer (4% bovine serum albumin [Sigma] /
PBS / 0.05% Tween 20 [Sigma]) unless otherwise stated. All incubation steps were
for lh at 37°C unless otherwise stated, and were followed by washing which
consisted of six washes with 0.9% saline containing 0.05% Tween 20, followed by
rigorous tapping of the plate onto absorbent paper to dry wells. Analyses were
performed in duplicate and all steps used a final volume of 50pl/well. Following
incubation with the secondary antibody, all ELISAs were developed using
streptavidin-horse radish peroxidase conjugate (S-HRP) (Amersham Biosciences,
and latterly Sigma) for 30 min (Amersham Biosciences, 1:5000) or 60 min (Sigma,
1:1000) followed by TMB substrate (Insight Biotechnology) which caused a blue
colouration of positive samples. Following adequate colour development, the
reaction was stopped with 0.18M H2SO4. Absorbance of samples was read in a
microplate reader (Bio-Rad Model 550, Bio-Rad Laboratories) at 450nm. The
standard curve was generated using a linear curve fit and sample concentrations
calculated using Microplate Manager 4.0 software (Bio-Rad Laboratories) and
corrected for concentration factor.
4.3.2.4. Development ofProteinase ELISAs
To test antibody specificity for equine tryptase, ELISA plates were coated with
lgg/ml equine tryptase (previously extracted from equine mastocytoma tissue as
described by Pemberton et al. [2001]) overnight at 4°C and then incubated with
1/1000 or 1/5000 mouse monoclonal anti-human tryptase-biotin (clone AA5,
Promega) or lpg/ml or 0.2pg/ml polyclonal rabbit anti-equine tryptase followed by
biotinylated goat anti-rabbit IgG at 1/400 or 1/2000.
Following successful recognition of equine tryptase by both these antibodies, a
sandwich ELISA was developed. ELISA plates were coated with 1 pg/ml polyclonal
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rabbit anti-equine tryptase and then a dilution series of equine tryptase (l-100ng/ml)
in ELISA buffer applied. Mouse monoclonal anti-human tryptase-biotin at 1/1000 or
1/3000 dilution was then used as the secondary antibody. This ELISA failed to detect
tryptase and therefore an alternative sandwich ELISA was investigated using mouse
monoclonal anti-human tryptase (clone AA1, Novocastra) as the coating antibody at
1/100, 1/500 or 1/1000 dilution and polyclonal rabbit anti-equine tryptase as the
secondary antibody (0.5pg/ml) followed by biotinylated goat anti-rabbit IgG at
1/2000 dilution.
Following lack of recognition of tryptase by mouse monoclonal anti-human tryptase
(clone AA1), biotinylated rabbit polyclonal anti-equine tryptase was tested for
specificity against equine tryptase using 0.2, 0.5 and lpg/ml dilutions on wells
coated with l-100ng/ml tryptase. Rabbit polyclonal anti-eq.MCP-1 and biotinylated
rabbit polyclonal anti-eq.MCP-1 were likewise investigated for specificity against
eq.MCP-1 coated wells. As these antibodies successfully recognised their respective
target proteinases, sandwich ELISAs using rabbit polyclonal anti-equine tryptase /
anti-eq.MCP-1 as the coating antibody and biotinylated rabbit polyclonal anti-equine
tryptase / anti-eq.MCP-1 as the secondary antibody were tested. A range of tryptase /
eq.MCP-1 concentrations were used on the ELISAs to find the upper limit of
linearity of the standard curves.
4.3.2.5. Final Proteinase ELISA
ELISA plates were coated with lpg/ml polyclonal rabbit anti-equine tryptase /
eq.MCP-1. Standards (0.25-10ng/ml tryptase / 0.25-20ng/ml eq.MCP-1 in ELISA
buffer), blanks and samples were applied. Wells containing ELISA buffer alone were
used as blanks. Biotinylated rabbit polyclonal anti-equine tryptase / eq.MCP-1
(lpg/ml) were applied as secondary antibodies.
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4.3.3. Validation of Mast cell Proteinase ELISAs
4.3.3.1. Control ELISA Experiment
ELISAs were performed with a positive control of proteinase at mid standard curve
concentration (5ng/ml tryptase, lOng/ml eq.MCP-1) plus a series of negative controls
each omitting one component of the ELISA to ensure that none of the reagents used
were responsible for non-specific colour development.
4.3.3.2. Spiked BALFELISA
To validate the proteinase concentrations determined using the ELISA,
unconcentrated BALF and BALF spiked with 1000, 500, 100, 50 and 25ng/ml
tryptase and 1000, 500 and lOOng/ml eq.MCP-1 were applied to the ELISA. Serial
dilutions of spiked BALF were assessed to ensure that at least one reading fell within
the standard curve.
4.3.3.3. Reduction ofBackground Colouration in Tryptase ELISA
When serial dilutions of unconcentrated or spiked BALF were analysed by the
tryptase ELISA, an unacceptably high level of background colouration was observed.
In an attempt to determine the nature of this background colouration, a series of
experiments was undertaken.
Firstly, a blocking step of incubating plates with ELISA buffer for 30min was
employed, before addition of the secondary antibody, to reduce any non-specific
binding.
As BALF mucus was considered a possible source of interference in the ELISA,
0.5mg/ml dithiothreitol (DTT, Sigma) was added to serial dilutions of
unconcentrated BALF and of BALF spiked with lOOng/ml tryptase, to reduce
disulphide bonds quantitatively and maintain monothiols in the reduced state. As
BALF from heaves affected horses contains more mucus than that from control
horses (Dixon et al., 1995b), BALF from both groups of horses was used. Samples
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with DTT were read against a standard curve with DTT added, because DTT may
reduce the slope of the ELISA curve {Mark Buckley, personal communication).
In a further attempt to minimise the potential effect of insoluble mucus on the
ELISA, BALF samples from control and heaves horses (previously concentrated by
Centricon YM10 filters) were subject to high speed centrifugation at 20,000g, for
lOmin, 4°C and filtration through a 0.45pm filter (Millex-HV Durapore filters,
Millipore Corporation) prior to testing on the ELISA.
4.3.3.4. Heparin-Agarose Tryptase ELISA
To ascertain that the tryptase ELISA was measuring tryptase specifically, an ELISA
using concentrated BALF supernatant with and without addition of heparin-agarose,
which binds tryptase, was investigated. A suspension of heparin-agarose beads in
saline (pH 6.0) was added to BALF in a 1:1 dilution, mixed briefly and then
sedimented by centrifugation at lOOOrpm, lmin. BALF diluted 2:1 with saline was
used as a negative control, this being equivalent to the net volume of liquid added to
samples with the agarose beads. Positive controls consisted of 150pl saline spiked
with lOpl of lOOOng/ml tryptase (resultant concentration of 66.7ng/ml) and saline
spiked with tryptase diluted 1:1 with heparin agarose.
4.3.3.5. Intra- and Inter-assay Coefficients of Variation (CV) for ELISA
To determine intra-assay variability, measurement of proteinase concentration was
repeated 8 times within the same plate. Inter-assay variability was determined by
running the same sample on different ELISA plates on 5 separate occasions. For
tryptase CV experiments, one sample from a control horse and one sample from a
heaves horse were chosen. For eq.MCP-1, only one sample was used as preliminary
studies had shown all samples to have very low concentrations of this proteinase.
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4.3.4. Determination of BALF Histamine Concentration
BALF histamine concentrations were determined using a commercial competitive
histamine ELISA (Immunotech) based on competition between histamine and its
enzyme conjugate, histamine-alkaline phosphatase, for monoclonal anti-histamine
antibody. To compete with this enzyme conjugate, histamine in the sample must be
derivatised in the same manner as the histamine in the conjugate prior to analysis and
this was achieved by an acylation step.
The kit was equilibrated to room temperature prior to use and all steps were
performed using gloves to prevent contamination with extraneous histamine. All
samples and standards were assayed in duplicate. The manufacturers state an intra-
assay coefficient of variation of 7-10%, an inter-assay coefficient of variation of 8-
13% and sensitivity down to 0.05ng/ml histamine.
Acylation was performed by thorough mixing of 25pi acylation buffer, 25pi
acylation reagent and lOOpl standards, control or samples. Acylated samples (50pl)
were applied to the antibody coated microwells followed by 200pl enzymatic
conjugate. Plates were incubated for 2h at 4°C, 350rpm (Stewart Scientific Bibby,
Stewart Scientific) and then washed with 0.9% saline, 0.05% Tween 20 three times
and dried by vigorously tapping the plate onto absorbent paper. Substrate solution
(para-nitrophenylphosphate in diethanolamine-HCl solution, pH 9.8, 200pl) was
added to wells and the plate incubated for 30min, 350rpm, room temperature. The
reaction was then stopped by addition of IN NaOH and the optical density of wells
read by microplate reader at 405nm. Sample histamine concentrations were then
interpolated from the standard curve.
4.3.5. Measurement of Tryptase Activity
As the ELISA will measure both active (tetrameric) and inactive (monomeric)
tryptase, concentrations determined by ELISA give no measure of the proteolytic
activity of BALF. Therefore BALF supernatant samples used for proteinase
quantitation were also subjected to chromogenic assay for tryptase activity. Eq.MCP-
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1 activity was not assessed, as preliminary trials showed that BALF samples
contained very low concentrations of eq.MCP-1.
Samples were assayed at room temperature in ELISA plates using 50pl BALF
sample, 45pl activity buffer (1M glycerol, 0.1M NaCl, 0.1M Tris-HCl and lOOpg/ml
heparin, pH 8.0) and 5pl chromogenic substrate S2366 (2.5mM). The substrate
S2366 has previously been reported to be the most sensitive known substrate for
equine tryptase (Pemberton et al, 2001). A standard curve of tryptase concentrations
typical of that found in equine BALF (5-60ng/ml) using activity buffer as diluent was
assayed alongside samples to ensure that tryptase activity could be measured at these
physiological concentrations. PBS was used as a negative control. Sample
absorbance at 405nm was read by a microplate reader at t=0, 5, 10, 15, 20min and
24h. The increase in absorbance by 20min was minimal and therefore results were
calculated from the 24h absorbance. Each sample was used as its own blank by
subtracting absorbance at t=0 from final absorbance read at 24h and the rate
calculated by the following equation:
Activity rate (absorbance units / h) = absorbance t=24h - absorbance t=0
24
4.3.6. Western Blotting of BALF Samples
4.3.6.1. Western Blotsfor Probing ofMast Cell Proteinases
Equine BALF supernatant (lOpl), concentrated as previously described (4.3.2.2), or
cell pellets with or without the addition of 0.1 pg tryptase or eq.MCP-1 were heated
with 11 pi of reducing buffer for 5min. Samples were run on two SDS separating gels
as described in section 2.3.1.3. Tryptase and eq.MCP-1 (0.1 pg) were also run as
positive controls. One gel was stained with Coomassie blue for 15min and then
destained as described in section 2.3.1.3 until bands could be visualised. The other
gel was used for immunoblotting as described in section 2.4.1.
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4.3.6.2. Western Blot to Determine Limit of Sensitivity of Mast Cell Proteinase
Detection
In order to determine the limit of sensitivity of mast cell proteinase detection by
Western blotting, a BALF cell pellet sample shown by ELISA to have a tryptase
concentration of >200ng/ml was spiked with equine tryptase (O-lOOOng) and
subjected to SDS-PAGE. Western blotting and probing with lpg/ml rabbit anti-
equine tryptase were then performed as previously described.
4.3.7. Subjects and Collection of BALF for Immunolabelling
BALF samples (n=19) were collected as described previously (4.3.1.1) from controls
(n=8), heaves horses (n=5) and horses with other pulmonary diseases (n=6) which
had been referred to R(D)SVS for investigation of respiratory disease. Eight
cytospins were made per BALF sample using a Shandon Cytospin 3 (lOOpl BALF,
300g, 3 min). Two cytospins were stained with Leishmans stain for DCC and the
remaining slides fixed by immersion in acetone for lOmin for later immunolabelling.
Preliminary investigations with acetone, 4% paraformaldehyde and Carnoy's fixative
determined that acetone was the most suitable fixative (data not shown).
4.3.8. Immunolabelling of BALF Cytospins
4.3.8.1. Trial Immunohistochemical Staining
Initial attempts at immunolabelling consisted of immunohistochemical staining with
rabbit anti-equine tryptase / anti-eq.MCP-1 and normal rabbit IgG as a negative
control. Briefly, slides were rehydrated in PBS, immersed in 97% methanol, 3%
hydrogen peroxide to quench endogenous peroxidase activity, and then placed in
Sequenza slide holders (Shandon). Non-specific binding was blocked with PBS,
0.5M NaCl, 0.5% Tween 80 for 30min. All further reagents were made up in this
blocking buffer. Primary antibodies rabbit anti-equine tryptase / anti-eq.MCP-1 /
normal rabbit IgG were applied at lpg/ml for lh. Slides were washed with PBS and
the secondary antibody, biotinylated goat anti-rabbit IgG (Vector Laboratories)
applied at 1/400 dilution for 30min. Following washing, avidin-horseradish
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peroxidase conjugate (ABC reagent, Vector Laboratories) was added for 30min, then
slides were washed and colour developed with 3,3'-diaminobenzidine (DAB kit,
Vector Laboratories) for 2min. Slides were then washed, immersed in Mayer's
haematoxylin (Sigma) for 5min, Scott's tap water for 2 min and then dehydrated
through graded alcohols and xylene.
As staining was poor with this protocol, mouse monoclonal anti-human tryptase-
biotin (clone AA5) and antigen retrieval by incubation in O.lmg/ml trypsin in PBS at
37°C for 30min were also investigated, without success. Immunofluorescent
labelling was therefore attempted.
4.3.8.2. Initial Immunofluorescent Labelling Protocol
Initially, cytospins were rehydrated in PBS and incubated with blocking buffer (PBS,
0.5M NaCl, 0.5% Tween 80, 10% normal donkey serum [Sigma]), for lh to prevent
non-specific binding. Rabbit anti-equine tryptase / anti-eq.MCP-1 / normal rabbit
IgG were applied, lpg/ml, for lh and then slides washed and donkey anti-rabbit IgG
conjugated to the green fluorochrome Alexafluor 488 (Invitrogen) was applied, at
4pg/ml, for 30min in the dark. Slides were washed with PBS and then coverslips
mounted with Mowiol.
4.3.8.3. Final Tryptase Immunofluorescent Labelling Protocol
As some positive labelling of neutrophils and macrophages was observed with anti-
equine tryptase labelling, the following dual immunofluorescence protocol was
adopted for tryptase labelling.
After rehydration and blocking of slides as above, primary antibodies were applied
overnight at 4°C as follows: lpg/ml rabbit anti-equine tryptase + 2pg/ml sheep anti-
equine neutrophil elastase-Cy3 (red fluorochrome; kindly donated by M. Dagleish) /
lpg/ml rabbit anti-equine tryptase + 2pg/ml normal sheep IgG-Cy3 (kindly donated
by M. Dagleish) / 1 pg/ml normal rabbit IgG + 2pg/ml sheep anti-equine neutrophil
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elastase-Cy3. Slides were washed with PBS and then donkey anti-rabbit IgG-
Alexafluor 488 applied as previously described (4.3.8.2).
4.3.8.4. Counting Protocolfor Dual Immunofluorescence Cytospins
The number of tryptase or eq.MCP-1 positive mast cells per 500 (total) cells was
counted under 488nm excitation at x400 magnification (Leica Laborlux S
conventional compound microscope, Leica Microsystems). When positive cells were
observed with anti-equine tryptase, cells were also viewed under 568nm excitation to
assess anti-equine neutrophil elastase labelling, thus allowing differentiation between
mast cells and neutrophils / macrophages.
4.3.8.5. Western Blot to Investigate Possible Cross Reactivity with Rabbit Anti-
Equine Tfyptase
Equine tryptase, elastase, trypsin and eq.MCP-1 (1 pig / lane) were subject to SDS-
polyacrylamide gel electrophoresis, western blotting and probing with 1 pg/ml rabbit
anti-equine tryptase as described in section 2.3.1.3 and 2.4.1.
4.3.8.6. Isolation and Immunofluorescent Labelling ofPeripheral Blood Neutrophils
In order to further investigate the positive tryptase labelling ofBALF neutrophils and
macrophages, peripheral blood neutrophils were isolated and subject to dual
immunofluorescent labelling. Neutrophils were isolated from peripheral blood using
a discontinuous Percoll (Amersham Bioscience) gradient and centrifugation which
separates cells according to their density. Briefly, blood was collected immediately
post mortem from a horse euthanased for orthopaedic disease and citrated by
addition of 1ml 3.8% sodium citrate / 10ml blood. Erythrocytes were allowed to
sediment freely under gravity for 30min at room temperature at which point
leukocyte rich plasma was removed and centrifuged at 380g for 6min. Pelleted cells
were resuspended in 2ml platelet poor plasma (PPP) (previously made by
centrifugation of plasma at 240g for 20min) and underlain by 2ml of 42% Percoll
gradient (42% of 90% Percoll [90% Percoll, 10% sterile 0.9% saline] / 58% PPP)
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followed by 2ml of 52% Percoll gradient (52% of 90% Percoll / 48% PPP). The
resultant discontinuous gradient was centrifuged at 265g for 12min at room
temperature allowing neutrophils to be harvested from the 52% / 42% interface.
Neutrophils were washed in PPP and used to make cytospins (300g, 3min) which
showed 98% purity of isolation. Neutrophils were washed twice in Hanks buffered
salt solution without calcium and magnesium (Sigma), once in Hanks buffered salt
solution with calcium and magnesium (Sigma) and were finally resuspended in the
latter solution. Cytospins of purified peripheral blood neutrophils were prepared and
immunolabelled as described in section 4.3.8.3.
4.3.8.7. Western Blot ofPeripheral Blood Neutrophils
Isolated peripheral blood neutrophils were also subjected to SDS-polyacrylamide gel
electrophoresis (2xl05 cells / lane), western blotting and probing with rabbit anti-
equine tryptase as described in sections 2.3.1.3. and 2.4.1. Equine neutrophil elastase
was used as a positive control probe. Equine tryptase (lpg / lane) was also blotted
and used as a positive control for the rabbit anti-equine tryptase probe.
4.3.9. Statistical Analyses
Statistical analyses were performed using Minitab 14 (Minitab). Normality of data
was assessed using Anderson-Darling normality tests. Significance was taken at
p<0.05 throughout. Outliers were defined as values differing from the middle 50% of
data by a factor of 3 or more in either direction (Minitab).
4.3.9.1. ELISA CV
ELISA intra- and inter-assay CV were determined by expressing the standard
deviation as a percentage of the mean for each group of values.
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4.3.9.2. Data Transformation and Statistical Tests
All other data were analysed, where possible, using t-tests or analysis of variance
(ANOVA) to allow possible confounding factors to be taken into account (section
4.3.9.3). The assumptions of ANOVA are that; (i) the data represents random
sampling, (ii) data points are independent, (iii) groups have equal variance and (iv)
the residuals follow a normal distribution (Crawley, 2002). If these assumptions were
not met, attempts were made to normalize the data using square root or log
transformation as appropriate (Crawley, 2002). If transformation did not result in the
data meeting the assumptions for ANOVA, non-parametric statistics were performed
using Kruskal Wallis tests for inter-group comparisons and Mann Whitney tests for
two unpaired group comparisons. Only BALF absolute MC counts were normally
distributed and therefore all other data were transformed as described. BALF tryptase
concentration and activity rates were square root transformed. BALF absolute
neutrophil count and immunolabelled BALF neutrophil data were log transformed.
BALF eq.MCP-1 and histamine concentrations, and immunolabelled BALF MC data
could not be transformed and were therefore subjected to non-parametric statistical
analyses.
The relationship between two non-parametric data variables was examined by
calculating the Spearman Rank Correlation Coefficient whereas the Pearson Product
Moment Correlation Coefficient was calculated for parametric data variables.
Regression analysis was performed to examine the relationship between two
variables when the y variable depended upon the x variable and y was normally
distributed.
4.3.9.3. Confounding Factors
As BALF proteinase and histamine data were drawn from 3 different populations, a
number of confounding factors were likely to be present such as place, duration and
type of challenge (natural vs. experimental) etc. These factors were examined using
sequential univariate ANOVA models to examine their effect on the data. However,
as some factors confounded each other (e.g. place of challenge and duration of
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challenge), it was necessary to concentrate on the most important potential
confounders which were deemed to be place of challenge, natural vs. experimental
exposure and sampling time post challenge. Variables of interest were added into
sequential multivariate ANOVA to examine data after taking significant confounders
into account.
4.4. Results
4.4.1. Development of Mast Cell Proteinase ELISAs
4.4.1.1. Tryptase ELISA
Both mouse monoclonal anti-human tryptase-biotin (clone AA5) and polyclonal
rabbit anti-equine tryptase successfully recognised equine tryptase. The mouse
monoclonal antibody developed strong colour reaction at 1/1000 dilution but only a
weak reaction at 1/5000 dilution. Polyclonal rabbit anti-equine tryptase developed a
strong colour reaction at both 1 and 0.2pg/ml. However, no colour developed in the
sandwich ELISA using polyclonal rabbit anti-equine tryptase as the coating antibody
and mouse monoclonal anti-human tryptase-biotin (clone AA5) as the secondary
antibody after incubation for lh at room temperature or overnight at 38°C, indicating
possible competition of antibodies for the same epitope.
Mouse monoclonal anti-human tryptase (clone AA1) appeared to have no specificity
for equine tryptase. The sandwich ELISA using this monoclonal antibody as the
coating antibody and polyclonal rabbit anti-equine tryptase as the secondary antibody
showed only a weak colour change with 1/100, 1/500 and 1/1000 dilutions of
primary antibody.
Biotinylated rabbit polyclonal anti-equine tryptase showed optimal colour
development at lpg/ml with a linear curve up to lOng/ml tryptase with a mean and
standard deviation standard curve correlation coefficient of 0.97 ± 0.01 (n=23).
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4.4.1.2. Eq.MCP-1 ELISA
Rabbit polyclonal anti-eq.MCP-1 and biotinylated rabbit polyclonal anti-eq.MCP-1
both reacted positively with eq.MCP-1 coated wells. The sandwich ELISA using
these antibodies showed linear development of colour along the standard curve up to
20ng/ml and a mean and standard deviation standard curve correlation coefficient of
0.99 ±0.01 (n=5).
Unconcentrated BALF samples appeared to have very low eq.MCP-1 concentrations
as eq.MCP-1 was undetectable in 5 samples analysed by ELISA. There was no
background colour to the eq.MCP-1 ELISA.
4.4.2. Validation of Proteinase ELISAs
4.4.2.1. Control ELISA Experiment
Very little non-specific background colour was attributable to reagents used in either
the tryptase or the eq.MCP-1 ELISAs (table 4.3).
Sample Tryptase OD Eq.MCP-1 OD
Positive control 0.177 0.363
No coating antibody 0.042 0.043
No tryptase 0.041 0.040
No secondary antibody 0.035 0.041
No S-HRP 0.039 0.040
No reagents 0.022 0.024
Table 4.3: Optical density (OD) of samples in control
ELISA experiment. S-HRP streptavidin horse radish
peroxidase.
4.4.2.2. Spiked BALF
The mean (range) spiked BALF tryptase concentration read by the ELISA was 83%
(53-118%) of the calculated value for low spiked tryptase concentrations and 195%
(74-362%) for high spiked concentrations. Actual spiked concentrations and ELISA
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readings for the low tryptase spiked concentration are shown in table 4.4 and high
tryptase spiked concentrations are shown in table 4.5.
Unconcentrated Tryptase Spiked ELISA BALF % Actual




4.9 5 9.9 8.8 89
1.7 10 11.7 6.2 53
1.7 8 9.7 5.5 57
1.7 6 7.7 5.5 71
1.7 4 5.7 4.4 77
1.7 2 3.7 2.9 78
1.7 1 2.7 2.5 93
1.7 0.5 2.2 2.5 114
1.7 0.25 1.95 2.3 118
Mean 83
Table 4.4: Calculated concentrations and ELISA readings of BALF spiked with low
concentrations of tryptase.
[ Spike] Dilution Factor [Tryptase] % Actual Value
(ng/ml) (ng/ml)
1000 0 > scale N/A
10 > scale N/A
100 942.1 94
1000 2184.0 218




100 0 > scale N/A
10 74.2 74
100 149.8 150
1000 < scale N/A









Table 4.5: ELISA readings of high concentration tryptase
spiked BALF. N/A = not applicable, > scale = ELISA
reading above the top of the standard curve, < scale = ELISA
reading below the bottom of the standard curve.
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The mean (range) spiked BALF eq.MCP-1 concentration read by the ELISA was
184.4% (93.3-431.8) of the spiked concentration as shown in table 4.6. As
unconcentrated BALF samples appeared to contain very little eq.MCP-1, further
manipulation of this ELISA was not performed.
[ Spike] Dilution Factor [Eq.MCP-1] % Actual Value
(ng/ml) (ng/ml)
1000 0 > scale N/A
10 > scale N/A
100 1399.4 140
1000 1609.7 161
500 0 > scale N/A
10 > scale N/A
100 892.2 178
1000 2159.2 432
100 0 > scale N/A
10 101.9 102
100 93.3 93
1000 < scale N/A
Mean 184
Table 4.6: ELISA readings of eq.MCP-1 spiked BALF. N/A =
not applicable, > scale = ELISA reading above the top of the
standard curve, < scale = ELISA reading below the bottom of
the standard curve.
4.4.2.3. Background Colouration in Tryptase ELISA
Blocking with ELISA buffer prior to addition of the secondary antibody did not
improve ELISA determination of tryptase concentrations of unconcentrated BALF
serial dilutions (table 4.7).
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Sample 1 Sample 2









0 2.3 3.1 1.7 1.6
1.3 2.4 2.8 2.3 2.6
2.0 3.1 5.4 3.2 3.6
4.0 4.8 5.7 5.6 8.2
6.7 N/A N/A 6.2 6.7
10.0 N/A N/A 10.0 9.0
20.0 N/A N/A 12.0 8.0
100.0 N/A N/A < scale 16.8
Table 4.7: ELISA determined tryptase concentrations of serial
dilutions of unconcentrated BALF with and without a blocking step
of ELISA buffer prior to addition of secondary antibody. N/A = not
applicable, < scale = ELISA reading below the bottom of the
standard curve.
Addition of 0.5mg/ml DTT also did not reduce the background colouration obtained
in the ELISA using unconcentrated BALF from control or heaves affected horses
(table 4.8). At higher, spiked tryptase concentrations, DTT appeared to adversely
affect the ELISA causing underestimation of tryptase readings (table 4.9).
Unconcen trated Unconcentrated
Control BALF Heaves BALF











0 3.3 2.9 3.4 2.8
1.3 3.5 2.8 3.7 2.9
2 4.9 4.7 5.4 4.0
4 6.2 7.1 7.0 6.3
10 9.9 11.4 10.6 9.3
20 10.4 10.8 13.3 6.7
50 28.0 17.1 29.9 < scale
100 < scale 32.4 < scale < scale
Table 4.8: ELISA determined tryptase concentrations in raw BALF from control and
heaves affected horses with and without treatment with 0.5mg/ml dithiothreitol
(DTT). < scale = ELISA reading below the bottom of the standard curve.
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Spiked Spiked
Control BALF Heaves BALF
No DTT 0.5mg/ml No DTT 0.5mg/ml
DTT DTT
[Spike] Dilution [tryptase] [tryptase] [tryptase] [tryptase]
(ng/ml) Factor (ng/ml) (ng/ml) (ng/ml) (ng/ml)
100 0 > scale 9.9 > scale 6.9
10 92.9 19.6 > scale 21.4
100 141.0 34.2 116.9 40.5
1000 < scale < scale < scale < scale
50 0 > scale 7.8 > scale > scale
10 51.2 11.0 63.2 12.0
20 44.4 14.8 59.4 13.7
100 61.1 36.0 98.6 61.3
Table 4.9: ELISA determined tryptase concentrations in spiked BALF from control
and heaves affected horses with and without treatment with 0.5mg/ml dithiothreitol
(DTT). > scale = ELISA reading above the top of the standard curve, < scale =
ELISA reading below the bottom of the standard curve.
High speed centrifugation at 20,000g for lOmin and filtration of BALF to remove
mucus strands also did not produce consistent improvement in ELISA tryptase
readings (table 4.10).
Control BALF Heaves BALF















0 9.9 7.6 7.8 > scale > scale > scale
10 14.2 8.9 4.6 > scale > scale > scale
50 < scale < scale < scale 384.6 533.5 304.8
100 < scale < scale < scale 454.4 652.4 431.4
Table 4.10: ELISA determined tryptase concentrations in control and heaves BALF
with no treatment (N), centrifugation at 20,000g, lOmin (C), or centrifugation at
20,000g, lOmin plus filtration through a 0.45pm filter (C & F). > scale = ELISA
reading above the top of the standard curve, < scale = ELISA reading below the
bottom of the standard curve.
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Performance of the tryptase ELISA was not consistently improved by any of the
methods investigated. ELISA determination of tryptase concentrations was most
consistent with BALF of lower proteinase concentrations and when minimal
dilutions were used for higher tryptase concentrations. Therefore, when dilution of
samples was necessary, the minimal dilution to achieve a reading within the range of
the standard curve was used.
4.4.2.4. Heparin-Agarose Tryptase ELISA
Incubation with a heparin-agarose saline slurry reduced the tryptase concentration by
68% in the BALF sample and by 44% in the tryptase-spiked saline sample (table
4.11). The negative control saline diluted BALF (diluted with saline equivalent to
that added with heparin-agarose slurry) showed a tryptase reduction of 25%, very
close to the predicted 33% expected from the dilution factor. In this case, the positive
control tryptase-spiked saline contained 66.7ng/ml and therefore the ELISA slightly
underestimated the tryptase concentration (51.7ng/ml).
BALF Spiked Saline
(66.7ng/ml)
Treatment [tryptase] Reduction in [tryptase] Reduction in
(ng/ml) tryptase (%>) (ng/ml) tryptase (%<>)
- 16.0 N/A 51.7 N/A
Heparin Agarose 5.1 68 28.8 44
Saline dilution 11.7 27 N/A N/A
Table 4.11: ELISA determined tryptase concentrations of BALF and
tryptase-spiked saline with and without addition of heparin-agarose to
remove tryptase from solution. N/A = not applicable.
4.4.2.5. Coefficients of Variation
Intra-plate and inter-plate CVs for the tryptase ELISA were 20.4% and 22.1% for
control horse samples and 10.8% and 24.1% for heaves horse samples, respectively.
Intra-plate and inter-plate CV for the eq.MCP-1 ELISA were 14.9% and 23.6%,
respectively.
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4.4.3. BALF Tryptase Concentrations
The ELISA method described above was used to compare tryptase concentrations in
BALF from control, heaves, remission and other disease horses. Following square
root transformation, the residuals of the tryptase data set assumed a normal
distribution apart from 4 samples (3 from the heaves group and 1 from the other
disease group) with very high tryptase values (>70ng/ml). Log transformation did not
result in these residuals assuming a normal distribution. The order of mean tryptase
values for control, remission, other disease and heaves groups of horses were
unaffected by omission of these 4 values (3.1, 5.1, 20.4, 22.5ng/ml and 3.1, 5.1, 7.1,
8.3ng/ml, respectively before and after exclusion). This is demonstrated by the graph
of raw data tryptase concentrations (fig. 4.1) being qualitatively the same as the
graph of normalised tryptase values (fig. 4.2). These four data points were therefore
excluded from statistical analyses. Furthermore, despite exclusion of these values,
one-way ANOVA of normalised BALF tryptase concentrations revealed a highly
significant difference among groups (pO.OOl) (fig. 4.2).
Control Heaves Other Remission
Fig. 4.1: BALF tryptase concentrations (ng/ml) in control
(n=22), heaves (n=21), other disease (n=7) and remission
(n=13) horses. ° denotes statistical outlier, T ° denotes
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Control Heaves Other Remission
Fig. 4.2: Normalised (square root) BALF tryptase
concentrations (ng/ml) in control (n=22), heaves (n=18),
other disease (n=6) and remission (n=13) horses.
ANOVA revealed a highly significant difference in
BALF tryptase concentration among groups (p<0.001). °
denotes outlier.
Since the sample population was derived from several experiments, the effect of
potential confounding factors (fig. 4.3) on the data was initially examined separately


























Fig. 4.3 : Normalised BALF tryptase concentrations (ng/ml) of
control (n=22), heaves (n=18), other disease (other) (n=6) and
remission (n=13) horses showing confounding factors of place and
type of challenge. Samples were obtained from three studies; AHT
archive (AHT) (n=26), R(D)SVS archive (n=13) and R(D)SVS
hospital (n=20). Horses received either natural (n=20) or
experimental (n=39) challenge.
These univariate ANOVA revealed that BALF tryptase concentrations were
significantly different with respect to time of sampling (F2,58=14.7, p<0.001) (fig.
4.4) and place of challenge (F2,58=15.2, p<0.001) (fig. 4.5). The three challenges
differed in duration: R(D)SVS archive study, 5h; AHT archive study, 24h; R(D)SVS
hospital, chronic challenge. Duration of challenge was found to have a highly
significant effect on BALF tryptase concentrations (F3,58=12.3, p<0.001) (fig. 4.6).
Type of challenge (natural vs. experimental) did not cause a significant difference in




Time of sampling post challenge (h)
Fig. 4.4 : Normalised BALF tryptase concentrations
(ng/ml) of horses sampled immediately (0) (n=13), lh
(n=40) or 19h (n=6) following end of challenge. One-way
ANOVA revealed a highly significant difference among
groups (p<0.001). ° denotes outlier.
AHT archive R(D)SVS archive
Place of Challenge
R(D)SVS hospital
Fig. 4.5 : Normalised BALF tryptase concentration
(ng/ml) in AHT archive study (n=26), R(D)SVS archive
study (n= 13) and R(D)SVS hospital (n=20). One-way
ANOVA revealed a highly significant difference among
groups (p<0.001). ° denotes outlier.
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1 1 1 1
0 5h 24h chronic
Duration of Challenge
Fig. 4.6 : Normalised BALF tryptase concentration
(ng/ml) following no challenge (0) (n=13), 5h (n=13),
24h (n=13) or chronic (n=20) challenge. One-way
ANOVA revealed a highly significant difference among
groups (p<0.001). ° denotes outlier.
Natural Experimental
Type of Challenge
Fig. 4.7 : Normalised BALF tryptase concentration
(ng/ml) following natural (n=20) or experimental (n=39)
hay / straw challenge. One-way ANOVA revealed no
significant difference between groups (p=0.07). 0
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Sequential multivariate ANOYA taking these significant confounding factors into
account showed that there was no significant difference in BALF tryptase
concentrations between control and challenged control horses (Fi,i8=2.5, p=0.13).
Data for control and challenged control horses were therefore pooled. Additional
multivariate ANOVA, again taking significant confounders into account, revealed
there was a highly significant difference in BALF tryptase concentration among
disease groups (F3;52=8.1, p<0.001). Multivariate ANOVAs for specific group
comparisons showed that despite confounding factors, there was still a significant
difference in BALF tryptase concentrations between control and heaves horses
(Fi,35=26. 1, p<0.001), heaves and remission horses (Fi(26=5.4, p=0.03) and control
vs. other disease horses (Fi)23=11.4, p=0.002) (fig. 4.8). There was no significant
difference in tryptase concentrations between control and remission horses (Fi,3o=3.2,
















Control Heaves Other Remission
Fig 4.8 : Normalised BALF tryptase concentration
(ng/ml) of residuals in control (n=22), heaves (n=18),
other disease (n=6) and remission (n=13) horses
following removal of the effect of time of sampling
post challenge and place of challenge. * denotes
significant difference to control (p<0.01), ® denotes
significant difference to remission horses (p<0.05).
BALF absolute neutrophil count residuals assumed a normal distribution following
log transformation. Univariate ANOVA revealed that there was no significant
difference in the absolute BALF neutrophil count of heaves susceptible horses post
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challenge among the three different places of challenges (F2,is = 0.27, p=0.76) (fig.


















AHT archive R(D)SVS hospital
Place of Challenge
R(D)SVS archive
Fig: 4.9: LoglO post challenge BALF absolute
neutrophil counts of heaves susceptible horses in AHT
archive (n=7), R(D)SVS hospital (n=5) and R(D)SVS
archive (n=9). There was no significant difference in
neutrophil count among groups.
Univariate ANOVA also revealed that type of challenge (natural vs. experimental)
and time of sampling post challenge had no significant effect on BALF absolute
neutrophil response (Fi,i9=0.49, p=0.49; Fi,i9=2.09, p=0.16 respectively). Duration of
challenge had no significant effect on post challenge BALF absolute neutrophil count
(F2, 18 = 0.27, p=0.76). In contrast, a highly significant effect of duration of challenge
on tryptase concentration in heaves susceptible horses (F2,i5=8.6, p=0.003) (fig. 4.10)





Fig: 4.10: Square root BALF tryptase concentration (ng/ml)
in heaves susceptible horses post 5h (R[D]SVS archive)
(n=8), 24h (AFIT archive) (n=7) or chronic (R[D]SVS
hospital) (n=3) challenge. There was a significant difference
in tryptase concentration with duration of challenge
(p=0.003).
Although individual group correlations were not significant, there was a highly
significant correlation between BALF tryptase concentration and BALF absolute
neutrophil count within the complete dataset (Pearson i^0.53, p<0.001, n=55,
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-2.0 -1.5 -1.0 -0.5 0.0 0.5
log10 absolute neutrophil count
Fig. 4.11: Scatterplot showing positive
correlation of BALF absolute neutrophil count
(xl05/ml) and BALF tryptase concentration
(n=55), Pearson r=0.53, p<0.001.
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Absolute mast cell counts were only available for 33 samples. There was no
significant relationship between BALF tryptase concentration and absolute mast cell
count (t=0.71, p=0.49, R2=1.8%).
One set of archived material (AHT archive) consisting of baseline and post 24h
challenge samples represented paired data. Paired t-tests revealed a significant
increase in BALF tryptase concentration in both control (t=-6.55, p=0.001) (fig.








Fig. 4.12: Normalised BALF tryptase concentration
in AHT archive control horses (n=6) at baseline and
immediately post 24h challenge, * denotes











Fig. 4.13: Normalised BALF tryptase concentration
in AHT archive heaves susceptible horses (n=7) at
baseline and immediately post 24h challenge, *
denotes significant difference between baseline and
post challenge values (p=0.02).
Two sample t-tests revealed no significant difference in BALF tryptase concentration
between this subset of control and heaves susceptible horses at baseline (t=-1.1,
p=0.3) (fig. 4.14).
rnntrol heaves
Fig. 4.14: Normalised BALF tryptase concentrations
(ng/ml) of AHT archive control (n=6) and heaves
susceptible (n=7) horses at baseline.
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A strong trend was evident towards a significant difference between control and
heaves horses post challenge (t=-2.2, p=0.057) (fig. 4.15), however, there was no



















Fig. 4.15: Normalised BALF tryptase concentrations
(ng/ml) of AHT archive control (n=6) and heaves
susceptible (n=7) horses post 24h hay / straw
challenge. There was no significant difference between
control and heaves horses (p=0.057).
4.4.4. BALF Eq.MCP-1 Concentrations
Very low (<3ng/ml) (n=28, 44%) or undetectable (<0.25ng/ml) (n=35, 56%)
concentrations of eq.MCP-1 were measured in BALF samples. Due to the high
proportion of samples with undetectable eq.MCP-1, this data could not be
successfully transformed and therefore Kruskal Wallis analysis was performed.
There was no significant difference in eq.MCP-1 among groups of horses (p=0.47)
(fig. 4.16) and therefore no further statistical analysis was performed.
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Control Heaves Other Remission
Fig. 4.16: BALF eq.MCP-1 concentration (ng/ml) in
control (n=22), heaves (n=21), other disease (n=7) and
remission (n=13) horses. Kruskal-Wallis analysis
revealed no significant difference in eq.MCP-1
concentration among groups, ° denotes outlier.
4.4.5. BALF Histamine Concentrations
Histamine was undetectable (<0.05ng/ml) in 42 (67%) samples and ranged from 0.1-
7.5ng/ml in the remaining 21 (33%) samples. Again, transformations were
unsuccessful in making the residuals of this data set assume a normal distribution due
to the majority of samples having undetectable values for BALF histamine
concentration. Kruskal Wallis analysis was therefore performed and revealed no
significant difference in histamine among groups of horses (p=0.26) (fig. 4.17).
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Control Heaves Other Remission
Fig. 4.17: BALF histamine concentration (ng/ml) in
control (n=22), heaves (n=21), other disease (n=7) and
remission (n=13) horses. There was no significant
difference in histamine concentration among groups
(p=0.26), ° denotes outlier.
As histamine is very labile and since BALF samples may have been processed
differently at the three places of challenge, samples were divided into place of origin.
Subsequent Kruskal Wallis analysis revealed that BALF histamine concentrations
were significantly different among places of challenge (p<0.001) (fig. 4.18).
AHT archive R(D)SVS Hospital
Place of Challenge
R(D)SVS archive
Fig. 4.18: Histamine concentration (ng/ml) of BALF
samples from AHT archive (n=26), R(D)SVS archive
(n=13) and R(D)SVS hospital (n=24) groups. Kruskal
Wallis analysis revealed a highly significant difference
among groups (p<0.001). ° denotes outlier.
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Because variable degrees of histamine degradation prior to sample analysis could
have accounted for some of the inter-group difference in histamine concentrations,
data were divided into samples with minimal storage and only one freeze-thaw cycle
(R[D]SVS hospital) and archived samples (AHT and R[D]SVS archived studies).
These archived samples had been stored for >lyr and possibly subjected to multiple
freeze-thaw episodes. Mann Whitney analysis showed that archived samples had














Fig, 4.19: Histamine concentration (ng/ml) of BALF
samples from R(D)SVS hospital group (hospital, n=24)
and from archived AHT and R(D)SVS studies (archived,
n=39). Archived samples had significantly less histamine
(p<0.001), ° denotes outlier.
Due to this apparent effect of storage on histamine concentration, the R(D)SVS
hospital subset of data was analysed separately by Kruskal Wallis test. Due to the
wide range in histamine concentrations, there was no significant difference in BALF
histamine concentrations with disease status (p=0.8) (fig. 4.20).
Hospital Archived
108
Control Heaves Other Remission
Fig. 4.20: BALF histamine concentrations (ng/ml) in the
R(D)SVS hospital subset of control (n=6), heaves (n=5),
other disease (n=7) and remission (n=6) horses. There
was no significant difference in histamine concentration
among groups (p=0.8).
Within this R(D)SVS hospital dataset, there was a suggestion of a trend for a




Fig. 4.21: Scatterplot showing weak positive correlation of
BALF tryptase and histamine concentrations in the
R(D)SVS hospital dataset (n=21), Spearman r=0.36,
p=0.10.
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Regression analysis to explore the relationship of BALF histamine with absolute
mast cell count for this data subset could not be performed as the histamine data
could not be normalised due to the high proportion of zero values.
4.4.6. Tryptase Activity
4.4.6.1. Standards
Tryptase activity rates were measurable in the standards representing physiological
BALF concentrations. Regression analysis of these standards showed that activity














Fig. 4.22: Activity rate (units/h) of tryptase
standards as a function of tryptase concentration.
4.4.6.2. BALF Samples
BALF tryptase activity residuals were normalised by square root transformation.
This excluded data from 4 horses which had apparent negative BALF tryptase
activity rates. Univariate ANOVA showed that there was a strong trend for a






















Fig. 4.23: BALF tryptase activity rates in control (n=20),
heaves (n=17), other disease (n=7) and remission (n=ll)
horses. One-way ANOVA revealed a strong trend for an
inter-group variation in BALF tryptase activity (p=0.051).
° denotes outlier.
Control Heaves Other Remission
Multivariate ANOVA allowing for the effects of time of sampling and place of
challenge showed that BALF tryptase activity was significantly greater in heaves
horses than remission horses (F 1,23=4.9, p=0.04) (fig. 4.24).
Control Heaves Other Remission
Fig. 4.24: BALF tryptase activity rates of
residuals in control (n=20), heaves (n=17), other
disease (n=7) and remission (n=ll) horses
following removal of the effect of time of
sampling and place of challenge. * denotes
significantly different groups (p<0.05).
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Interestingly however, paired t-tests did not reveal a significant increase in BALF
tryptase activity in the AHT archive subset of heaves susceptible horses following
challenge (t=-0.8, p=0.50). Nor was there a significant difference in tryptase activity
as a function of duration of challenge of heaves susceptible horses (Fij6=1-0,
p=0.33).
Regression analysis showed there was a very weak relationship between BALF
tryptase concentration and BALF tryptase activity rate (t=1.55, p=0.13, R2=4.6%)
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Square root BALF [tryptase] (ng/ml)
Fig. 4.25: Scatterplot demonstrating the weak positive
relationship (t=1.55, p=0.13, R~=4.6%) between BALF
tryptase concentration and BALF tryptase activity rate.
The grey line is a regression line for the whole dataset.
Furthermore, there was no relationship between BALF absolute mast cell count and
tryptase activity rate (t=0.35, p=0.73, R2=0.5%).
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4.4.7. Western Blotting of BALF Samples
4.4.7.1. Western Blotsfor Probing ofMast Cell Proteinases
Spiked BALF samples and the positive control proteinase samples developed
positive bands of approximately 32kDa for tryptase and eq.MCP-1 (Tigs. 4.26, 4.27)
whereas unspiked samples failed to develop positive bands.
kDa MW Tsn sn cp Tcp T+ Fi"' 426: Western blot of BALF
200 supernatant and cell pellets, +/-
addition of 0.1 pg tryptase, probed with
66 rabbit anti-equine tryptase. Positive
45 bands of approximately 32kDa
Ml developed with tryptase spiked samples
and the positive control (0.1 pg) only.
MW = molecular weight markers, Tsn
= tryptase spiked supernatant, sn =
supernatant, cp = cell pellet, Tcp =
tryptase spiked cell pellet, T+ =
positive control. kDa = size of
molecular weight markers in kilo
Daltons.
kDa MW sn cp Msn Mcp M4
Fig. 4.27: Western blot of BALF supernatant
and cell pellets, +/- addition of 0.1 pg
eq.MCP-1, probed with rabbit anti-eq.MCP-
1. Positive bands of approximately 32kDa
developed with eq.MCP-1 spiked samples
and the positive control (0.1 pg) only. MW =
21 molecular weight markers, sn = supernatant,
cp = celi pellet, Msn = eq.MCP-1 spiked
supernatant, Mcp = eq.MCP-1 spiked ceil
pellet, M+ = positive control. kDa = size of







4.4. 7.2. Western Blot to Determine Limit of Sensitivity of Mast Cell Proteinase
Detection
The western blot probed with rabbit anti-equine tryptase in order to determine the
limit of sensitivity for detection of mast cell proteinases did not develop any positive
1 It
staining with the cell pellet sample containing >200ng/mi tryptase. Cell pellet
samples spiked with lOOOng and 500ng tryptase (100 and 50pg/ml) tryptase
developed strong positive bands. Faint positive bands could be visualised with spiked
tryptase samples down to lOng tryptase (1 pg/ml) (fig. 4.28).
kDa MW 1 2 3 4 5 6 7 8 9 Fig" 428: Western blot of BALF
200 cell pellet spiked with 0-lOOOng
'Ij tiyptase probed with rabbit anti-
66 equine tryptase. Strong positive
bands developed for 1000 and
500ng tryptase and faint bands for
100, 50 and lOng. A distinct band
could not be discerned with
tryptase spikes < IOng. 1 = BALF
ceil pellet, 2-9 = BALF cell peliet
spiked with 1000, 500, 100. 50, 10,
5, 1, 0.5ng tryptasc respectively.
kDa = size of molecular weight





4.4.8. BALF Cytospin Immunoiabeiling
4.4.8.1. Trial Immunohistochemical Staining
No positive staining was seen with immunohistochemical staining using rabbit anti-
equine tryptasc / anti-eq.MCP-1 or mouse monoclonal anti-human tryptase-biotin
(clone AA5). Antigen retrieval with O.lmg/ml trypsin incubation did not improve
staining.
4.4.8.2. Initial Immunofluorescent Labelling Protocol
Good labelling ofmast cells was seen under 488nm excitation with rabbit anti-equine
tryptase / anti-eq.MCP-1 (fig. 4.29a). However, some positively labelled cells were
noted to have multi-lobed nuclei. Using autofluorescence of their nuclei, these cells
with multi-lobed nuclei were determined to be neutrophils (fig. 4.29b). Occasional
tryptase positive macrophages were also observed with this technique. The majority
of positively labelled phagocytes had a granular appearance of labelling (fig. 4.29b)
although a surface halo type appearance was seen less commonly (fig. 4.31a).
t 14
Fig. 4.29a Fig. 4.29b
Fig 4.29: BALF mast cell (a) and neutrophil (b) showing positive
labelling with rabbit anti-equine tryptase under 4X8nm excitation.
Note the autofluorescenee of the nucleus allowing cellular
identification.
4.4.8.3. Western Blot to Investigate Possible Cross Reactivity with Rabbit Anti-
Equine Tryptase
Probing of the western blot of equine tryptase, trypsin, equine elastase and eq.MCP-1
with rabbit anti-cquinc tryptasc resulted in a positive reaction with equine tryptase
only, demonstrating that rabbit anti-equine tryptase was specific for equine tryptase
and does not show cross reactivity with the other proteinases tested (fig. 4.30).





Fig. 4.30: Western blot of equine
tryptase (T), trypsin (Tn), equine
clastasc (E) and cq.MCP-i (M)
(Ipg/lane) probed with rabbit anti-
equine tryptase. A positive reaction
was only observed with tryptase.
kDa = size of molecular weight





4.4.8.4. Immunofluorescence ofPeripheral Blood Neutrophils
Some immunofluorcsccnt labelling of peripheral blood neutrophils was observed
with rabbit anti-equine tryptase, although the majority of neutrophils were not
labelled. Labelling of peripheral blood neutrophils was of a surface halo nature only,
and thus could be readily differentiated from mast cells.
4.4.8.5. Western Blot ofPeripheral BloodNeutrophils
Probing of the western blot of equine peripheral blood neutrophils with rabbit anti-
equine tryptase resulted in the development of a very faint band with a molecular
weight much higher than that of tryptase at approximately 67kDa, which was
considered most likely to be non-specific reaction with albumin.
4.4.8.6. Final Immunofluorescent Labelling Protocol
Good labelling was achieved with the dual immunofluorescent protocol for tryptase
(fig. 4.31) and the single labelling method for eq.MCP-1.




Fig. 4.31: Immunofluorescence of BALL cytospins: (a) positive
labelling of a mast cell (MC) with rabbit anti-equine tryptase (green) and
dual staining of neutrophils (NEUT) with rabbit anti-equine tryplase and
sheep anti-equine neutrophil elastase (red) showing halo appearance of
labelling, (b) tryptase negative control showing positive staining of
neutrophils with sheep anti-equine neutrophil elastase, (c) elastase
negative control showing positive staining of neutrophils with rabbit
anti-equine tryptase, (d) eq.MCP-1 positive staining mast ceil. Size
markers all 10pm.
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Data for the number of tryptase positive BALF mast cells could not be transformed
to assume a normal distribution by either square root or log manipulation and was
therefore analysed by Kruskal Wallis test. As the proportion of tryptase positive cells
consisted of proportional data with values at both extremes of the scale, this was also
analysed by Kruskal Wallis test. There was no significant inter-group difference in
the number or proportion of tryptase positive mast cells (p=0.89 and p=0.51
respectively).
Statistical analysis of eq.MCP-1 data was not performed as eq.MCP-1 positive cells
were so rarely observed. Eq.MCP-1 positive BALF cells were only observed in 6/19
(32%) horses compared to 18/19 (95%) horses with tryptase positive cells. The
horses with observed eq.MCP-1 positive cells were distributed across the 3 status
groups.
The number of elastase positive cells was log transformed such that the data met the
assumptions for ANOVA. There was a significant inter-group difference in the
number of elastase positive BALF cells (F2,16=0.74, p=0.02). A two-sample t-test
showed significantly increased elastase positive BALF cells in heaves horses
compared to controls (t=-3.6, p=0.006).
4.5. Discussion
4.5.1. Development and Validation of ELISAs
Polyclonal rabbit anti-equine tryptase and mouse monoclonal anti-human tryptase-
biotin (clone AA5) both recognised equine tryptase. However, when used in a
sandwich ELISA together, no reaction developed, probably because the two
antibodies shared a common epitope. As this mouse monoclonal antibody was only
available biotinylated, the ELISA could not be performed using the monoclonal
antibody as the coating antibody, which may have allowed the polyclonal antibody to
bind to a different epitope. An alternative non-biotinylated mouse monoclonal anti-
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human tryptase antibody was used; however this was from a different clone (AA1
rather than AA5) and appeared to have no specificity for equine tryptase.
Control experiments showed that there was very little non-specific background
colour attributable to the other reagents used in both the tryptase and eq.MCP-1
ELISAs. Heparin-agarose treatment to remove tryptase resulted in an approximately
equal reduction in tryptase concentration, as determined by the ELISA, from both
spiked saline and BALF samples, confirming that the ELISA was specific for
tryptase.
Determination of tryptase concentrations by the ELISA appeared to be more reliable
at lower tryptase concentrations which did not require diluting to reach the standard
curve. This, and the relatively high background colour that could not be improved by
addition of a blocking step or by attempts to remove mucus using DTT treatment or
centrifugation and filtration, will have led to some inherent inaccuracy in tryptase
measurement, particularly in BALF samples with higher tryptase concentrations.
BALF, being a biological sample, contains many molecules that could potentially
interfere with the ELISA. It was suspected that mucus in particular might interfere
because BALF from heaves horses (which also has increased tryptase
concentrations) contains more mucus than that from controls (Dixon et al., 1995b).
DTT treatment of BALF samples markedly reduced the tryptase concentrations read
by the ELISA and it was suspected that the DTT may have inactivated the coating
antibody. Successful treatment of human sputum mucus with 0.01% DTT has been
reported without a deleterious effect on subsequent ELISA measurement of tryptase
(Pizzichini et al., 1996; Alvarez et al., 2000). However, sputum contains much more
mucus than BALF and many studies have successfully measured human BALF
tryptase by ELISA without DTT treatment (Wenzel et al., 1988; Sedgwick et al.,
1991; Broide et al., 1991; Jarjour et al., 1991; Bousquet et al., 1991). High speed
centrifugation and filtration should have decreased the mucus content of samples.
Therefore, as these procedures did not improve tryptase determination by the ELISA,
it suggests that other BALF components may have been responsible for the
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background colouration. This error in measurement due to background colouration is
likely to have contributed to the four very high outlier tryptase concentrations.
4.5.2. BALF Tryptase Concentrations
The graphs of raw, square root and residual BALF tryptase concentrations are all
qualitatively similar and demonstrate that BALF tryptase concentrations are higher in
heaves horses than controls or heaves horses in remission. This increase was still
highly significant (p<0.001) for heaves vs. controls and significant (p<0.05) for
heaves vs. remission horses following removal of the effects of time of sampling and
place of challenge. There was no significant difference in BALF tryptase
concentrations between controls or challenged controls or between controls and
heaves horses in remission. These results indicate that hay / straw challenge of
control and heaves susceptible individuals causes tryptase release into the airway
lumen in heaves susceptible horses only. It is therefore possible that tryptase could
contribute to the pathogenesis of heaves as discussed in detail in section 1.4.4.1.
This study is the first to report equine BALF tryptase concentrations. Mast cell
activation and tryptase release into BALF is well documented following challenge of
human asthmatics (Wenzel et al., 1988; Broide et al., 1990; Broide et al., 1991;
Jarjour et al., 1991; Bousquet et al., 1991) with concentrations reported being similar
to those found in this study (table 4.12). Comparison of values in horses to those in
asthmatic subjects is not straightforward however due to the multiple human asthma
phenotypes, including atopic and non-atopic asthma. Although BALF tryptase
concentrations increase in both these asthma phenotypes, the magnitude of increase
is greater in atopic asthmatics (Wenzel et al., 1988). Control horses have
considerably higher BALF tryptase concentrations than control human subjects
which may reflect the higher equine intraluminal mast cell population. Control
horses frequently have up to 10% mast cells in BALF (Dixon et al., 1995b)
compared to <1% in humans (Wenzel et al., 1988; Broide et al., 1991).
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Group Mean (± SD) BALF
ftryptase] (ng/ml)
Clinical heaves 8.3 (4.4)
Remission heaves 5.1 (4.8)
Control horses 3.1 (2.0)
Symptomatic human asthmatics 10.1 (8.2)1
13.2 (14.8)2
Asymptomatic human asthmatics 2.0(1.7)'
3.9 (3.9)2
Healthy humans 0.6 (0.4)1
Table 4.12: BALF tryptase concentrations (ng/ml) in
control and heaves susceptible horses and asthmatic and
1 9
healthy humans. (Wenzel et al., 1988), (Broide et al.,
1991).
A highly significant positive correlation (Pearson r=0.53, p<0.001) was found
between BALF tryptase concentration and severity of pulmonary inflammation as
measured by BALF absolute neutrophil count. BALF neutrophilic response to in vivo
challenge with hay dust suspension has previously been shown to be dose dependent
(Pirie et al., 2002a) and therefore the positive correlation between absolute
neutrophil count and BALF tryptase concentration may suggest that there is a
relationship between severity of inhalational dust challenge and BALF tryptase
concentration. However it is difficult to examine this relationship fully due to the
differences between the three challenges and the lack of a common specific measure
of severity of challenge. Level of dust mite exposure is significantly correlated with
sputum tryptase concentrations in asthmatics (Alvarez et al., 2000) and ideally dust
analysis or pulmonary function indices would have been used in this study to
compare response to challenge; however this information was not available for all
challenges.
There was no significant difference in tryptase concentrations between naturally and
experimentally challenged animals, suggesting that experimental challenge was a
reasonable model of the natural challenge environment. Duration and place of
challenge and time of sampling post challenge had significant effects on BALF
tryptase concentrations, demonstrating differences within the three challenge systems
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and highlighting the difficulty in comparing heaves studies performed using different
challenge models. It is unlikely that the difference in BALF tryptase concentrations
in the different challenge systems (AHT archive, R[D]SVS archive and R[D]SVS
hospital) can be attributed solely to duration of challenge, since there was a non¬
linear trend in tryptase concentrations with increasing duration of challenge. The
source and composition of hay dust in the challenge environment is likely to have
had an important influence on the response to challenge, since inhalation of the same
quantity of hay dust from three different sources of hay resulted in markedly
different responses in heaves susceptible horses (Pirie et al., 2002a). It is likely that
there was variation in organic dust composition among the three challenge systems
which were from three different geographical areas. Interestingly, BALF tryptase
concentration, but not BALF neutrophil count, was significantly affected by place of
challenge. BALF tryptase concentration may therefore be a more sensitive indicator
of pulmonary inflammation than neutrophil count. An in vivo dose response study
investigating BALF tryptase concentrations following increasing organic dust
challenge would need to be performed to clarify this relationship further.
Surprisingly, a significant correlation between BALF absolute mast cell count and
tryptase concentration was not evident. Indeed, the increased BALF tryptase noted in
heaves and other disease horses occurred despite a lack of increase in BALF mast
cell numbers. Previous studies have also reported no increase in BALF mast cell
ratios in heaves horses following hay / straw challenge (Dixon, Railton, &
McGorum, 1995b; McGorum, Dixon, & Halliwell, 1993d). This is also consistent
with the increased BALF tryptase concentrations reported in human asthmatics,
without concurrent increase in BALF mast cells (Wardlaw et al., 1986; Wenzel et al.,
1988; Chan-Yeung et al., 1989; Broide et al., 1991). This suggests that an increase in
the number of BALF mast cells is not required to produce increased levels of BALF
tryptase or alternatively, that mast cells outwith the BALF compartment, in particular
those in an intra-epithelial location, may also be a source of BALF tryptase.
Consistent with this possibility, increased numbers ofpartially and fully degranulated
intra-epithelial mast cells have been identified in the bronchioles of human
asthmatics compared to control subjects (Beasley et al., 1989; Djukanovic et al.,
121
1990; Pesci et al., 1993; Laitinen et al., 1993; Di Stefano et al., 1993; Carroll et ah,
2002a). This hypothesis is explored further in chapter 5.
Despite there being no significant difference in BALF tryptase concentrations
between controls and challenged controls in the whole data set, paired data from the
AHT archive study showed a significant increase in tryptase concentration in both
the control and heaves susceptible horses following experimental challenge.
Interestingly, these control horses also had a strong trend towards increased BALF
absolute neutrophil count post challenge (p=0.059). It is well documented that
control horses may develop a moderate BALF neutrophilia following severe
challenge (Derksen et al., 1985; Tremblay et al., 1993; Pirie et al., 2002a), although
much lower than that seen in heaves susceptible horses. However, unlike heaves
susceptible individuals, airway dysfunction and mucus hypersecretion do not occur
(Pirie et al., 2002a). It is possible that the control subgroup used in the AHT archive
study received a sufficient challenge to cause an increase in BALF neutrophil count
and tryptase concentration whereas the other control horses did not. However, the
AHT subgroup of horses also had lower BALF tryptase concentrations following hay
/ straw exposure than the other groups, suggesting that they may have received a less
severe challenge. As stated previously, as the source and composition of dust is an
important determinant of the challenge response, this may explain the different
response seen in the AHT group of horses. The tryptase concentrations of the
R(D)SVS archive and R(D)SVS hospital populations share greater similarity,
suggesting that the R(D)SVS experimental challenge may have mimicked natural
hay / straw challenge more closely than the AHT model.
Horses with other pulmonary diseases also had significantly increased BALF
tryptase concentrations compared to controls suggesting that elevated BALF tryptase
concentrations are not specific for heaves and may occur with other diseases with a
pulmonary inflammatory response. This group was comprised predominantly of
horses with putative (unconfirmed) viral respiratory infections (4/7 samples), which
have previously been reported to result in increased BALF tryptase concentrations in
other species (Lorente et al., 2001; Jolly et al., 2004). Indeed some studies have
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suggested that tryptase can activate respiratory viruses such as influenza (Chen et al.,
2000; Lorente et al., 2001; Sato et al., 2003). One sample in this group was collected
from a horse with inflammatory airway disease (IAD), which shares some clinical
and pathological features of heaves (Hoffman et al., 1998; Couetiel et al., 2001).
Furthermore, increased BALF mast cells have been reported in some cases of IAD
(Hoffman et al., 1998) and it therefore seems probable that tryptase release may also
occur with this disease.
4.5.3. BALF Eq.MCP-1 Concentrations
Very little eq.MCP-1 was present in the BALF from any of the groups of horses;
with over half of the samples having no detectable eq.MCP-1. BALF chymase
concentrations have not previously been reported in horses or other species. It would
appear that basal BALF eq.MCP-1 concentrations are low and that, in contrast to
tryptase, eq.MCP-1 is not released following challenge of heaves susceptible
individuals. As samples were harvested from both acute and chronically challenged
horses at different timepoints, it seems unlikely that elevated eq.MCP-1 BALF
concentrations were missed due to insufficient sampling. This is further supported by
the paucity of eq.MCP-1 labelled cells present in BALF and in airway epithelium
from control and heaves horses (sections 4.4.8 and 5.5.1). Collectively, these
findings suggest that eq.MCP-1 may be of little importance in the pulmonary
airspace of healthy horses and horses with the types of pulmonary inflammation
studied. In other species, chymases appear to be important in expulsion of nematodes
(Knight et al., 2002) and this can not be excluded in the equine lung as no horses
with lungworm were sampled.
4.5.4. BALF Histamine Concentrations
Histamine was undetectable in two thirds of BALF samples and displayed a wide
range of concentrations (0.1-7.5ng/ml) in the remaining samples. A likely
explanation for this observation appears to be degradation of labile histamine in
some samples. This was evident in some of the R(D)SVS hospital samples and to a
greater extent in archived samples which had been stored for longer periods of time
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and which may have undergone prior freeze-thawing. Although samples were
acylated as a stabilising step prior to testing on the commercial immunoassay as
recommended, it appears that prior histamine degradation had occurred in some
samples. This explanation seems likely given that samples from the R(D)SVS
hospital population, which had been stored for a shorter period and had not
undergone repeated freeze-thawing prior to analysis, had significantly greater
histamine concentrations than the archived samples. McGorum et al. (1993c) found
only minor changes in histamine concentration of BALF supernatant samples during
prolonged (but unspecified duration) storage at -20°C, however storage of whole
BALF samples on ice for up to lh prior to collection of supernatant resulted in a
progressive decline in histamine concentration with a half life of 15-50min. If
samples are not stored on ice, the half life of histamine is reported to be as short as
lmin (Keyzer et al., 1984). Although supernatant was separated from all BALF
samples within 15min of collection, histaminase activity would still be present in the
supernatant and degradation may have occurred during centrifugal concentration of
BALF supernatant samples which was performed prior to acylation over 90min at
4°C. Furthermore, archived samples may have also previously been thawed for
unknown periods of time at unknown temperatures. Although studies have reported
human (Rankin et al., 1987) and equine (Hare et al., 1994) BALF histamine
concentrations to be stable for over 2 months at -70°C, the duration of recommended
storage may have been exceeded as archived samples were stored for more than a
year. Interestingly, if diluted plasma samples are frozen prior to histamine analysis,
there is a dramatic decrease in histamine such that it is recommended that diluted
samples should be alkylated (to stabilise histamine) prior to freezing if they cannot
be analysed immediately (Laroche et al., 1995). This loss of histamine by freezing
diluted samples may also have occurred with the BALF samples.
Histamine appears to be less useful than tryptase as a marker of mast cell
degranulation due to its labile nature. Furthermore, tryptase concentrations have been
found to correlate more closely with clinical symptoms (Castells and Schwartz,
1988) and antigen challenge dose (Sedgwick et al., 1991) of hay fever sufferers than
histamine concentrations.
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It has been well documented that BALF histamine concentrations in asymptomatic
and symptomatic human asthmatics are significantly greater than non-asthmatic
controls (Casale et al., 1987b; Wenzel et al., 1988; Casolaro et al., 1989; Chan-
Yeung et al., 1989; Broide et al., 1991; Jarjour et al., 1991). Although mean and
median BALF histamine concentrations were greatest in heaves horses in the hospital
data subset of this study, no statistical difference in histamine concentrations was
observed among groups due to the wide range in data, which included nine samples
with undetectable (and possibly degraded) histamine. Therefore, the high proportion
of histamine negative samples may have reduced the power to detect a difference
between control and heaves horses.
To the author's knowledge, the only prior study measuring equine BALF histamine
concentrations is that of McGorum et al. (1993c) which detected increased PELF
histamine concentrations in heaves susceptible horses 5h following hay / straw
challenge, however BALF concentrations were not significantly increased. Due to
the variable dilution of retrieved PELF by lavage fluid, PELF concentrations of a
given constituent may be more accurate than BALF concentrations; however urea
and albumin standardisation methods (the two most frequently used) may lead to
either under or over-estimation of concentrations (Rennard et al., 1986; Marcy et al.,
1987). Furthermore, if a standard lavage volume is instilled (as occurred with the
R[D]SVS hospital population), it is reasonable to assume that released histamine is
homogenously diluted such that recovered BALF yields a representative aliquot
reflecting histamine concentration in total BALF. Samples necessary to calculate
PELF constituent concentrations (i.e. paired BALF and serum samples) were not
collected for the archived samples and could not be collected for hospital samples
and therefore it was not possible to calculate PELF histamine concentrations in this
study.
BALF histamine concentrations for the hospital subgroup of horses reported in this
study are similar to those previously reported in horses by McGorum et al. (1993c)
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or in human asthmatics (Wenzel et al., 1988; Chan-Yeung et al., 1989; Broide et al.,
1991; Jarjour et al., 1991) (table 4.13).
Group Mean, median (horses only) (± SD)
BALF [histamine] (ng/ml)
Clinical heaves 2.5, 1.9(2.9)'
1.1 (0.02-6.4)2 *
Remission heaves 1.5,0.2 (3.0)'
Control horses 0.6,0.1 (1.4)'
1.4 (0.1-2.4)2 *




Asymptomatic human asthmatics 0.7 (1.1)3
0.2 (0.2)4
2.3 (2.3)5
Healthy humans 0.2 (0.2)3
0.2 (0.1)4
0.04 (0.006)6
Table 4.13: BALF histamine concentrations (ng/ml) in control and heaves
susceptible horses and asthmatic and healthy humans, 'current study
(R[D]SVS hospital population only), 2McGorum, Dixon and Halliwell
(1993c), 3Wenzel, Fowler and Schwartz (1988), 4Broide et al. (1991),
5Chan-Yeung et al. (1989), 6Jarjour et al. (1991). * Median and range only
reported by authors.
Histamine concentrations have been reported to increase in human blood and plasma
if not stored on ice due to an inherent 'leakiness' of basophils which is more apparent
at higher temperatures (Laroche et al., 1995). Leakage of histamine from mast cells
should not have occurred in this study because BALF was stored on ice until
separation of supernatant within 15min of collection. Bacteria have also been shown
to cause histamine release from human BALF mast cells (Clementsen et al., 1991).
Although microbiological culture was not performed on BALF samples, it is unlikely
that significant bacterial contamination occurred due to the speed of harvesting
supernatant from cells.
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Only a weak correlation was evident between BALF histamine and tryptase
concentrations. Although it might be expected that constituents of the same cell
would be highly correlated, there is evidence to suggest that differential
degranulation of mast cell mediators can occur (Dvorak et al., 1996; Theoharides,
2002). However, data available to enable investigation of a potential relationship
between these two variables was limited to the R(D)SVS hospital data subset due to
the high number of (presumed) degraded samples in the other data subsets.
Histamine and tryptase concentrations are positively correlated in human asthmatics
(Wenzel et al., 1988; Broide et al., 1991) and a stronger relationship is likely to have
been found if histamine concentrations were available for more samples. BALF
histamine concentrations have also been shown to closely correlate with lung
function indices in asthmatics (Flint et al., 1985a; Casale et al., 1987a; Wardlaw et
al., 1988; Broide et al., 1991; Jarjour et al., 1991), however these comparisons could
not be performed in this study as lung function was not measured in horses referred
to R(D)SVS hospital and since archived samples, for which lung function data was
available, had undetectable histamine concentrations.
4.5.5. Tryptase Activity
A significant difference in BALF tryptase-like activity was found among groups.
When potential confounding factors had first been taken into consideration, BALF
from heaves horses still contained significantly greater tryptase-like activity than that
from remission horses. Similarly, Clarke et al. (1995) showed that antigen challenge
of allergic sheep increased BALF tryptase activity and could be blocked by the
tryptase inhibitor APC 366. Interestingly however, despite both control and heaves
susceptible horses from the AHT archive group having a significant increase in
BALF tryptase concentration post challenge, neither group showed a significant
increase in apparent tryptase activity. The AHT subgroup of horses had the lowest
tryptase concentrations post challenge, which may not have been sufficient to
measure an increase in BALF tryptase activity.
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Although the mean and median tryptase activity rate of control BALF samples
(0.0035, 0.0026 absorbance units/h [AU/h], respectively) was lower than those of the
heaves affected group (0.0049, 0.0042 AU/h, respectively), the range of activity rates
from the control group (-0.0004 to 0.0112 AU/h) was very wide, such that it is not
surprising that there was no significant difference between controls and heaves
affected horses.
Tryptase activity was measurable at concentrations found in equine BALF. Tryptase
activity rates of BALF samples showed only a weak relationship with tryptase
concentrations determined by the ELISA and there could be several explanations for
this finding. For example, the presence of additional trypsin-like proteinases in the
BALF may have contributed to the activity rate and therefore the apparent active
tryptase concentration. Additionally, tryptase present in samples was subject to an
unknown degree of dissociation into inactive monomers, by the action of heparin
scavengers such as neutrophil lactoferrin, which would add to the scatter of results.
Lavens et al. (1993) measured tryptase activity from human lung mast cells over a
72h period using benzoyl-DL-arginine-p-nitroaniline (BAPNA) and found good
correlation between tryptase activity and tryptase concentration. That study however
assessed tryptase immediately following mast cell stimulated release by
degranulating agents and also did not assess tryptase activity in complex biological
samples. BAPNA was not used in this study due to its very poor cleavage by equine
tryptase (Pemberton et al., 2001).
4.5.6. Western Blot of BALF Samples
Tryptase could be detected on probing of western blots with rabbit anti-equine
tryptase down to lpg/ml. As even BALF supernatant and cell pellet samples with
high concentrations of tryptase contained less than lpg/ml tryptase, it is not
surprising that these samples did not develop visible positive bands. Probing of
western blots was therefore not sufficiently sensitive to demonstrate mast cell
proteinase content of equine BALF samples.
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4.5.7. BALF Cytospin Immunolabelling
4.5.7.1. Positive Tryptase Labelling ofNon-Mast Cells
The positive labelling of BALF neutrophils and occasional macrophages with rabbit
anti-equine tryptase may have been due to recognition of phagocytosed degranulated
tryptase, or even whole mast cells, by these phagocytic cells. As it has now been
demonstrated that equine BALF contains tryptase, it seems probable that some of this
would be engulfed or otherwise scavenged by phagocytic cells as has been described
with neutrophil elastase (Schmekel et al., 1990), in a control mechanism to limit
proteolysis in the airway. Tryptase positive macrophages have previously been
reported in human BALF and lung tissue and their presence attributed to
phagocytosis of tryptase (Walls et al., 1990; Berger et al., 1999; Beil and Pammer,
2001).
Occasional peripheral blood neutrophils also labelled positively with rabbit anti-
equine tryptase but it seems unlikely that tryptase would be phagocytosed in the
bloodstream. Compared to the granular nature of labelling of the majority of BALF
neutrophils, immunolabelling was restricted predominantly to the surface of
peripheral blood neutrophils. It would seem extremely unlikely that BALF
neutrophils and macrophages contain endogenous tryptase since significant
expression of tryptase has only ever been described in mast cells. Although basophils
contain tryptase, it is only at approximately 0.4% of the concentration observed in
mast cells, which is too low to stain positively with immunohistochemistry (Castells
et al., 1987). Recently, human airway epithelial cells have been reported to contain a
serine proteinase termed tryptase epsilon, however this proteinase has only 38-44%
sequence homology with other human tryptases and therefore is likely to be different
in structure and substrate specificity to mast cell tryptase (Wong et al., 2001). It is
feasible that due to the surface nature of labelling observed in peripheral blood
neutrophils, a trans-membrane tryptase is also present on these cells and that rabbit
anti-equine tryptase showed low specificity to this molecule. However, the faint band
on probing the western blot of peripheral blood neutrophils was of higher molecular
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weight than tryptase or trans-membrane tryptase and was considered to be most
likely due to non-specific reaction with albumin.
Alternatively, non-specific binding may have occurred with the positive labelling
resulting from cross-reactivity of the polyclonal rabbit anti-equine tryptase with a
constituent of the other cells. Unfortunately monoclonal equine tryptase antibodies,
which would have been more specific, were not available for use. Cross-reactivity
with equine neutrophil elastase was excluded by western blot analysis and
furthermore, dual immunofluorescence demonstrated that elastase and tryptase
labelling did not co-localise. However cross-reactivity of the polyclonal rabbit anti-
equine tryptase with another neutrophil or macrophage protein is possible.
In summary, labelling of BALF phagocytes was considered most likely to be due to
positive labelling of phagocytosed tryptase granules due to the granular nature of
labelling and the lack of positive phagocyte labelling in other tissues tested (colon
and lung, section 2.5.3.3). Furthermore, no non-phagocytic cells stained positively
with the anti-equine tryptase in BALF. In contrast, it was considered that labelling of
peripheral blood neutrophils was most likely a result of non-specific cross-reaction to
a surface protein due to the surface nature of labelling. However, the cause of
positive phagocyte labelling could not be resolved fully.
4.5.7.2. Immunofluorescence ofMast Cells
Tryptase positive mast cells were the predominant mast cell phenotype in equine
BALF, with only occasional chymase positive cells, as documented in humans (Flint
et al., 1985b; Wenzel et al., 1988).
There was no significant difference in the number or proportion of tryptase positive
BALF mast cells between control and heaves horses and this can be interpreted in
several ways. It most likely suggests that there is no recruitment of tryptase positive
BALF mast cells to the airway lumen supporting the hypothesis that intra-epithelial
mast cells are an important source of BALF tryptase. It also appears that BALF mast
cells of heaves susceptible horses do not 'switch on' tryptase expression following
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challenge, as the proportion of tryptase positive mast cells is not increased in heaves
horses. These results may also suggest that BALF mast cells do not fully degranulate
whilst releasing tryptase into the BALF as this would have decreased the number of
immunolabelled cells. However, it is also possible that additional influx ofmast cells
and full degranulation of mast cells already present occur in parallel such that whilst
there is turnover of the mast cell population, the number of mast cells present in the
airways appears to remain stable.
As so few eq.MCP-1 positive BALF mast cells were seen in all horses, it is not
surprising that there was no significant difference in the number of immuno-positive
cells between control and heaves affected horses.
Heaves affected horses had significantly increased numbers of elastase positive cells,
reflecting the neutrophil influx into the airspace characteristic of clinical heaves.
4.6. Conclusion
This study has provided evidence for mast cell degranulation in heaves susceptible,
but not control, horses following natural hay / straw exposure. Furthermore, BALF
tryptase concentrations were significantly correlated with the severity of pulmonary
inflammation suggesting that mast cells may play a pivotal role in the pathogenesis
of the pulmonary inflammatory response in heaves. However, the role that tryptase,
or indeed any of the many other mast cell mediators, may play in the pathogenesis of
heaves remains to be elucidated. The source of BALF tryptase may be mast cells in
the airway lumina, within the airway epithelium, or less likely within the
parenchyma: this is explored further in Chapter 5. In contrast, BALF contained very
little eq.MCP-1 suggesting that eq.MCP-1 is of little importance in the airway of
healthy and heaves susceptible horses. Consistent with these findings, BALF mast
cells were predominantly tryptase positive and only rarely eq.MCP-1 positive.
Histamine appears to be a less stable, and therefore potentially a less useful indicator
ofmast cell degranulation in the horse.
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Chapter 5 : Proteinase Expression in the Equine
Lung in Response to Inhaled Dust Challenge
5.1. Summary
Mast cell proteinase expression in the equine lung was investigated at the protein and
mRNA level in control and heaves susceptible horses, before and after inhaled dust
challenge.
To investigate pulmonary mast cell distribution and phenotype, donated bronchial
and bronchiolar samples from 6 control and 7 heaves horses in early resolution phase
following dust challenge were stained with toluidine blue, anti-equine tryptase and
anti-eq.MCP-1. Mast cells were enumerated in the epithelium, connective tissue,
smooth muscle and alveoli and compared between control and heaves populations.
The vast majority of mast cells were tryptase positive, with eq.MCP-1 positive cells
rarely observed. There was a trend towards increased numbers of mast cells in the
epithelium of heaves horses that became statistically significant following the
exclusion of one control horse outlier.
To investigate pulmonary mast cell tryptase mRNA transcript expression in control
and heaves horses, RNA was extracted from BALF cell pellets from control (n=3)
and heaves susceptible (n=6) horses pre and post 48h hay / straw challenge and from
the bronchial and bronchiolar samples described above. Quantitative real-time RT-
PCR revealed no significant upregulation in BALF cell pellet tryptase mRNA
expression in control or heaves susceptible horses following challenge. In contrast,
bronchiolar tryptase transcripts were significantly down-regulated seven-fold in
heaves horses in early resolution phase compared to control horses. Bronchial
tryptase transcripts were not significantly different between control and heaves
horses, consistent with the premise that heaves is predominantly a disease of the
small airways.
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This study supports the involvement of bronchiolar mast cells, particularly those in
the epithelium, in the pulmonary inflammatory response in heaves horses. Therefore
airway luminal mast cells may be a senescent population of cells which contribute
little to the aforementioned (Chapter 4) increase in BALF tryptase noted in heaves
horses post challenge.
5.2. Introduction
In Chapter 4 it was demonstrated that heaves horses have significantly increased
BALF tryptase concentrations during clinical exacerbation compared with control
horses or heaves horses in remission. Elevated BALF tryptase concentrations may be
a result of degranulation of BALF mast cells and / or airway tissue mast cells. As
challenge of heaves susceptible horses does not result in mast cell influx into the
BALF compartment (Derksen et ah, 1985; McGorum et al., 1993d; Dixon et ah,
1995b), it was hypothesised that recruitment and degranulation of airway epithelial
mast cells may significantly contribute to this increase in BALF tryptase
concentration. The observation of increased mast cells in the bronchial mucosa of
occupational asthmatics would support this hypothesis (Di Stefano et ah, 1993).
Furthermore, allergen challenge in sensitised asthmatics induces mast cell infiltration
into the airway mucosa with subsequent degranulation (Casale et ah, 1987b; Pesci et
ah, 1993; Montefort et ah, 1994).
The numbers of mast cells within airway smooth muscle are also elevated in human
asthmatics compared to controls (Ammit et ah, 1997), where they are believed to
contribute to bronchospasm through their action as both a direct agonist and mitogen
for myocytes (Johnson et ah, 1997; Berger et ah, 2001a). Furthermore, mast cell
mediators have been shown to augment cholinergic tone in the equine airway and
have been suggested as important mediators of the mechanism for development of
airway obstruction in heaves (Olszewski et ah, 1999).
Although mast cell distribution in the lungs of control horses and horses with chronic
lung disease (of unknown aetiology) has been investigated (Nicholls, 1978; Mair et
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al., 1988; Winder and von Fellenberg, 1990), mast cell proteinase content and
distribution in control and confirmed cases of heaves have not been studied. It was
hypothesised that mast cell recruitment to the epithelium and smooth muscle may
occur in heaves susceptible horses following challenge, thus contributing to
increased BALF tryptase concentrations and airway obstruction respectively.
We were also interested in investigating tryptase mRNA expression in both luminal
and tissue mast cells from control and heaves susceptible horses in response to
challenge. Although quantitative studies of cytokine regulation in BALF cell pellets
have been performed with attention focused on T lymphocyte populations (Giguere
et al., 2002; Beadle et al., 2002; Ainsworth et al., 2003a; Ainsworth et al., 2003b),
there have been no studies investigating possible upregulation of proteinases or
cytokine transcripts in equine airway luminal mast cells, using cell specific markers,
during challenge of heaves susceptible horses. Equally, no studies have evaluated the
equine pulmonary tissue mast cell response to challenge. Even though mast cell
regulation has been explored in asthmatics and allergic rhinitis patients, these studies
have focused on mast cell cytokine, rather than proteinase, regulation (Kay et al.,
1995; Jaffe et al., 1995; Pawanker et al., 2000).
The aims of this study were therefore: (a) to investigate the number, distribution and
proteinase content of mast cells in the equine lung and (b) to probe tryptase mRNA
transcript regulation in BALF cell pellets and lung tissue in control and heaves
horses using quantitative real-time RT-PCR.
5.3. Materials and Methods
5.3.1. Collection of Tissues for Mast Cell Staining
Bronchial and bronchiolar tissue samples from control (n=6) and heaves susceptible
horses (n=7) were donated from a study performed at Michigan State University. The
controls comprised 3 mares and 3 geldings with a median (range) age of 18y (12-
21y). The heaves susceptible horses comprised 2 mares and 5 geldings with a median
(range) age of 21y (11 -34y). Florses were subjected to a high dust challenge
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environment (3.6m x 3.6m, poorly ventilated stable bedded with straw and fed poorly
saved hay) for 5d, followed by 7d in a low dust environment where hay and straw
were replaced with shavings and pelleted food. Bronchoalveolar lavage with
cytological analysis of retrieved fluid was performed on day 7 of the low dust
regimen. Heaves horses demonstrated a significant BALF neutrophilia in response to
challenge compared with control horses indicating that they had ongoing pulmonary
inflammation and were only in an early phase of resolution.
Horses were euthanased on day 8 of low dust regimen. Immediately post mortem,
small (approximately 1cm x 1cm) pieces of tissue were excised from a peripheral
area of lung and from a third generation bronchus and immersed in Carnoys fixative
for subsequent mast cell staining. The peripheral lung tissue was examined grossly
on cross section to ensure that several small bronchioles (<0.2cm) were present.
After 24h in Carnoys fixative, tissues were transferred to 70% ethanol until
processed further. Carnoys fixative is reported to be the preferred fixative for
identification of mast cells as formalin fixation leads to underestimation of mucosal
mast cells (Nicholls, 1978; Irani et al., 1986; Craig et al., 1986; Shanahan et al.,
1987; Winder and von Fellenberg, 1990; Kube et al., 1998; Kuther et al., 1998).
Indeed, preliminary trials with 4% paraformaldehyde fixed tissues revealed very poor
staining of mucosal mast cells, with toluidine blue in particular, which was not
improved following employment of antigen retrieval techniques discussed in Chapter
2 (data not shown). Furthermore, a subsequent pilot study of toluidine blue staining
in the lung following fixation with Carnoys fixative, 4% paraformaldehyde, zinc
fixative and isoformal acetic acid confirmed Carnoys fixative to be the optimal
fixative for histochemical enumeration ofmast cells (data not shown).
5.3.2. Processing of Lung Samples
Samples were submitted to the Division of Veterinary Pathology at R(D)SVS for
paraffin embedding, cutting of 4pm sections and mounting onto glass slides.
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5.3.3. Mast Cell Staining
All staining was performed in duplicate.
5.3.3.1. Toluidine Blue Staining
Sections were de-waxed with xylene, rehydrated though graded alcohols and water
and then immersed in 0.5% toluidine blue (Merck) in 0.5M HC1, pH 0.5, overnight.
Sections were then briefly washed with tap water and counter-stained by immersion
in 1% eosin (Surgipath) in 70% ethanol for 5s. Following a brief wash with tap
water, slides were allowed to air-dry and coverslips applied with DPX mountant
(Surgipath).
5.3.3.2. Proteinase Immunohistochemistry
Slides were de-waxed with xylene, rehydrated through graded alcohols and
immersed in 97% methanol / 3% hydrogen peroxide for 20min to quench
endogenous peroxidase activity. Slides were then transferred to Sequenza slide
carriers (Shandon) and non-specific binding blocked with PBS / 0.5M NaCl / 0.5%
Tween 80 (Sigma) / 10% normal horse serum for 30min. All further dilutions were
made using this blocking buffer unless otherwise stated. Sections were incubated
with lpg/ml rabbit anti-equine tryptase / anti-eq.MCP-1 / normal rabbit IgG, for
60min, washed with PBS and then incubated with biotinylated goat anti-rabbit IgG
(Vector Laboratories) at 1/400 dilution, for 30min. Following washing, slides were
treated with avidin-horseradish peroxidase conjugate (ABC kit, Vector Laboratories)
for 30min and then colour developed using 3,3'-diaminobenzidine (DAB kit, Vector
Laboratories). Sections were then counterstained with Mayer's haematoxylin
(Sigma), washed in Scott's tap water, dehydrated and mounted.
5.3.4. Mast Cell Counting
Slides were read at x250 magnification with a Leica microscope (Leica Laborlux S
conventional compound microscope, Leica Microsystems). The number of positive
cells in 20 views (10 per duplicate slide) of alveolar, bronchiolar and bronchial tissue
was recorded. Bronchial and bronchiolar mast cells were identified as being intra-
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epithelial, smooth muscle or connective tissue in location. Connective tissue was
defined as mucosal (excluding epithelium) and submucosal tissue.
An image of each counted area was acquired with a Sony DXC-390P 3CCD colour
video camera (Scion Corporation) to allow post-processing. The RGB video signal
from the camera was digitised using Scion Image (Scion Corporation) installed on a
G4 Macintosh computer (Apple Computer) fitted with a CG-7 frame grabber (Scion
Corporation). Stereological measurements according to Gunderson and Jensen
(1987) were performed using custom software developed for Object-Image (Vischer
et al., 1994). Object-Image is a public domain software package, based upon NIH
image (Rasband and Bright, 1995), and is available via the internet at
http://simon.bio.uva.nl/object-image.html. This allowed the area of alveolar, smooth
muscle, connective tissue and epithelial tissue to be calculated excluding any air,
such that the frequency of mast cell counts per mm2 of tissue could be determined.
Briefly, a grid was placed over the tissue image and each cross-point of gridlines was
attributed one of the four tissue descriptions or air. The number of cross-points per
tissue type was then expressed as a percentage of the total number of image cross-
points to find the proportion of each tissue type examined. The image area was
calculated and then the proportion of each tissue type used to calculate the area of
that particular tissue observed per image. Mast cell counts and areas of tissues
examined for the 20 fields of view were added together to give one mast cell count
per location per bronchial or bronchiolar tissue per horse.
5.3.5. Collection of Samples for RNA Extraction
5.3.5.1. BALF Cell Pellets
Archived BALF cell pellets stored at -70°C in Qiagen RLT Buffer (RNeasy Mini
Kit, Qiagen) were used to examine airway luminal mast cell tryptase transcript
regulation in response to hay / straw challenge. BALF had previously been collected
from control (n=3) and heaves susceptible (n=6) horses at baseline (-7d) and
immediately post 48h hay / straw challenge as previously described (4.3.1.1). The
control horses comprised 2 mares and one gelding with a median (range) age of 4y
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(4-6y). The heaves susceptible horses comprised 4 mares and 2 geldings with a
median (range) age of 14.5y (7-28y). Challenge conditions were as described in
section 4.3.1.2, however airborne dust concentrations were not measured for this
challenge. BALF cells were pelleted by centrifugation (400g, lOmin), resuspended in
RLT Buffer and stored at -70°C.
5.3.5.2. Lung Tissue Samples
Tissue samples were collected as described, and from the same horses as detailed in
section 5.3.1. Harvested samples were stored in RNA later (Ambion) at 4°C
overnight and then transferred to -20°C until processing. Inexplicably, samples from
one control horse appeared to disintegrate in RNA later and therefore could not be
used for RNA extraction.
5.3.6. RNA Extraction
Total RNA was extracted from lung tissue initially using TRI-reagent and
chloroform and latterly with the RNeasy mini kit (Qiagen). BALF cell pellet total
RNA was also extracted using this kit.
5.3.6.1. RNA Extraction Using TRI-reagent and Chloroform
RNA extraction and DNase treatment was performed as described in section 3.3.2.
5.3.6.2. RNA Extraction Using RNeasy Kit
Total RNA was extracted as per the manufacturer's instructions. Briefly,
approximately 20mg lung tissue was homogenised with 600pl RLT buffer, the tissue
lysate centrifuged 13,000g, for 3min and the supernatant harvested. BALF cell
pellets in RLT buffer joined the protocol at this point.
Following addition of 600pl 70% ethanol, RNA was loaded onto the silica
membrane of the RNeasy spin column by centrifugation at 13,000g, for 15s. RNA
was washed with buffer RW1 and on-column DNA digestion performed by
incubation with 80pl DNase I (RNase-Free DNase Set, Qiagen) for 15min, at room
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temperature. DNA-free RNA was washed with buffers RW1 and RPE, eluted in 30pl
RNase free water and the concentration and purity measured by spectrophotometry.
5.3.7. Reverse Transcription of RNA
DNA free mRNA was reverse transcribed using random hexamer primers and avian
myeloblastosis virus (AMV) reverse transcriptase (Reverse Transcription System,
Promega). The following reaction was set up on ice; 4pl 25mM MgC^, 2pl lOx
reverse transcription buffer (lOOmM Tris HC1, pH 8.8), 2pl lOmM dNTPs, 0.5pl
(20u) RNase inhibitor, 0.5pl (15u) AMV-RT, lpl (0.5pg) random hexamers and lpg
RNA. The reaction mixture was incubated for lOmin at room temperature, 50 min at
42°C and finally for 5min at 99°C to stop the reaction. The mixture was cooled on
ice, diluted to lOOpl with RNase free water and the cDNA concentration measured
by spectrophotometry.
5.3.8. Quantitative RT-PCR
Primers were designed from the known cDNA sequences for equine tryptase
(GenBank accession number AJ515902) and the house-keeping gene equine P-actin
(GenBank accession number P60708) to give products of 19 lbp and 500bp
respectively as indicated in table 5.1. Quantitative real-time RT-PCR was performed
by amplifying 250ng cDNA (in a volume of 8pl) with lOpl SYBR Green Master Mix
(Quantitect SYBR Green PCR Kit, Qiagen) and lpl each of forward and reverse
primers (6pM, final reaction concentration 0.3pM) in an Opticon DNA Engine (MJ
Research). The reaction was incubated at 95°C for 15min, to activate the HotStarTaq
DNA polymerase contained in the SYBR Green Master Mix and then subjected to 50
cycles of 94°C for 40s, 55°C for 40s and 72°C for 60s. Each sample was amplified in
duplicate with both tryptase and p-actin primers. Negative controls of water were
also included in every run. Melting curve analysis of PCR products was performed
every 1°C from 50-94°C at the end of every run to ensure that a single product had
been amplified.
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Gene Forward primer 5' —> 3' Reverse primer 5' —» 3'
Equine tryptase ACT GTG TTG GAC CGG ACA TT GAC ATG GCT GGA GAT GTT GA
Equine ft-actin TGG GCC AGA AGG ACT CAT AC CTT GAT GTC ACG CAC GAT TT
Table 5.1: Sequence of primers used in quantitative real-time PCR assays.
The crossing threshold (Ct) at which measurable fluorescence was produced was
used to calculate the relative expression (RE) of tryptase transcripts to P-actin
transcripts using the equation:
_ 2Cx P~act'n
2Ct tryptase
Tryptase PCR products were also subject to Southern blotting and DIG-labelled oligo
probing (section 3.3.13) to ascertain correct product amplification.
5.4. Statistical Analyses
Statistical analyses followed the format discussed in section 4.3.9. Where multiple
statistical results are listed together, only the lowest non-significant value or the
highest significant value is given.
5.4.1. Bronchial and Bronchiolar Mast Cell Counts
Examination of the data for the frequency ofmast cells in tissues showed that neither
square root nor log manipulation adequately transformed the data such that ANOVA
could be performed. Confounding factors were not an issue with this data set as
samples originated from one population and were treated identically. Therefore,
analyses comparing the frequency of bronchial or bronchiolar mast cells in each
tissue location between control and heaves horses were performed using Mann
Whitney tests. Mast cell counts for bronchial and bronchiolar tissues were also
combined to produce a 'total airway score', which was subject to the same inter-
group comparison. If only one population (heaves or control) contained mast cells in
a particular tissue location, Mann Whitney tests could not be performed. Therefore
analysis was considered as the presence or absence of mast cells in the tissue and
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performed using Fisher exact tests as expected counts consisted of groups of <5
(Crawley, 2002).
Data for the areas of tissue examined were also analysed by Mann Whitney tests to
evaluate whether equal areas were assessed in control and heaves horses.
5.4.2. Tryptase Transcript Expression
The correction of tryptase transcript RE values for control and heaves horse BALF
cell pellets for BALF mast cell number was considered. However, this normalisation
was not necessary as two-tailed Wilcoxon Sign Rank tests showed no significant
difference in BALF absolute mast cell count within control and heaves populations
following challenge (p=1.0 and p=1.0, respectively).
Initial examination of the data showed that it could not be adequately transformed by
either square root or log transformation. Mann Whitney tests were therefore used for
inter-group comparisons and two-tailed Wilcoxon Sign Rank tests for intra-group
comparisons.
In an attempt to verify that (3-actin expression was constant in both control and
heaves horses during challenge, crossing threshold values for P-actin transcripts were
also compared within populations by two-tailed Wilcoxon Sign Rank tests and
between populations by Mann Whitney tests.
5.5. Results
5.5.1. Bronchial and Bronchiolar Mast Cell Counts
5.5.1.1. Area ofTissues Examined
There was no significant difference between control and heaves populations in the
area of epithelium, connective tissue and smooth muscle examined in tryptase
stained bronchial sections (p>0.35). Likewise there was no significant difference
between control and heaves populations in the area of epithelium, connective tissue,
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smooth muscle and alveolar tissue in bronchiolar sections (p>0.28). Comparable
areas of tissue examined were therefore analysed in control and heaves horses.
5.5.1.2. Toluidine Blue Staining
Positive cells were stained dark blue. Intra-epithelial mast cells could not be counted
accurately on toluidine stained sections due to positive staining of mucus secreting
cells which could not be accurately differentiated from mast cells (figs. 5.1, 5.2).
Fig. 5.1: Toluidine blue
positive cells in bronchial
tissue. Positive cells in the
epithelium (EP) of this section
look like mucus secreting cells.
No positive cells are present in
the smooth muscle (SM). CT =
connective tissue. Size marker
= 10pm.
Fig. 5.2: Toluidine blue
positive cells in bronchial
tissue. Positive staining cells in
the epithelium (EP) could not
be accurately identified as
mucus secreting cells or mast
cells. CT = connective tissue,
SM = smooth muscle. Size
marker = 10pm.
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The frequency of toluidine blue stained mast cells observed in bronchial and
bronchiolar tissue is shown in table 5.2.
BRONCHIAL BRONCHIOLAR
Control Heaves Contro Heaves
Horse CT SM CT SM CT SM ALV CT SM ALV
1 113.3 15.5 86.1 17.8 136.9 0 50.5 139.7 11.9 47.8
2 21.5 0 78.6 9.1 232.8 36.2 101.4 206.0 0 63.8
3 51.3 3.8 85.5 2.9 133.7 12.1 80.4 136.3 0 46.5
4 18.9 0 76.7 0 70.4 0 17.0 158.0 9.7 54.8
5 5.3 0 12.8 0 57.9 13.8 4.2 54.3 0 25.9
6 84 3.3 109.7 16.5 147.3 8.7 66.8 167.2 0 64.5
7 N/A N/A 33.8 5.6 N/A N/A N/A 37.7 19.5 8.0





















Table 5.2: Frequency (cells/mm2) of toluidine blue stained mast cells in connective
tissue (CT), smooth muscle (SM) and alveolar tissue (ALV) from bronchial and
bronchiolar sections from control (n=6) and heaves (n=7) horses. N/A = not applicable.
There was no significant difference between control and heaves populations in the
number of toluidine blue positive mast cells in connective tissue or smooth muscle of
bronchial (p>0.34) or bronchiolar (p>0.41) samples. There was also no significant
difference in the number of alveolar mast cells in control or heaves horses (p=0.52).
5.5.1.3. Tryptase Staining
Tryptase positive cells stained intensely brown throughout the entire cytoplasm (figs.
5.3, 5.4). There was no positive staining of control sections (fig. 5.5).
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KM
Fig. 5.3 : Bronchial tissue
section from a heaves horse
stained with rabbit anti-
equine tryptase. Tryptase
positive cells are present in
the epithelium (EP) (white
arrows) and connective tissue
(CT) (black arrows) but not
the smooth muscle (SM).
Size marker = 10pm.
Fig. 5.4: Tryptase positive
mast cells (black arrows) in
alveolar tissue from a control
horse stained with rabbit anti-
equine tryptase. Size marker
= 10pm.
■MB 10 pm 31-5-2004
Fig. 5.5 : Control bronchiolar
section stained with goat anti-
rabbit IgG. No positive
staining was observed in the
epithelium (EP), connective
tissue (CT) or smooth muscle
(SM). Size marker = 10pm.
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The frequencies of tryptase positive mast cells in bronchial and bronchiolar tissues
are shown in tables 5.3 and 5.4, respectively. The total number of mast cells
observed in the bronchi and bronchioles and the percentage of mast cells in each
tissue location are also included for tryptase positive cells as these were the only
abundant mast cell phenotype identified in all tissue locations.
Control Heaves
Horse EP CT SM EP CT SM
1 0 25 4.4 9.9 2.9 5
2 0 3 0 15 37.9 0
3 0 2.4 0 10.3 9.3 5.5
4 5.5 9.6 3.2 12 47.7 10
5 89.9 86.7 18.0 0 20.6 0
6 0 0 3.8 24.5 104.6 40
7 N/A N/A N/A 0 18.5 3.9
Median 0 6.3 3.5 10.3 20.6 5
Range 0- 0- 0- 0- 2.9- 0-
89.9 86.7 18.0 24.5 104.6 40
% 0 64 36 29 57 14
Total 11.1 25.1
Table 5.3: Frequency (cells/mm ) of tryptase positive mast cells within bronchial
epithelium (EP), connective tissue (CT) and smooth muscle (SM) in control and
heaves horses. % = median number ofmast cells in tissue location as a percentage of
total mast cells counted in all tissue areas. Total = total number of mast cells




Horse EP CT SM ALV EP CT SM ALV
1 0 31.9 0 29.8 4. 7 22.6 0 12.7
2 0 19.2 0 1.7 5.3 43.8 12.6 22.1
3 0 22.6 0 24.0 0 17.3 0 36.4
4 0 12.6 0 11.1 72.4 89.7 35.7 81.8
5 10.7 126.9 0 30.1 0 18.0 0 5.0
6 0 47.7 12.9 50.7 0 47.6 0 21.0
7 N/A N/A N/A N/A 5.0 L 7-9 0 13.5

















% 0 50 0 50 10 47 0 43
Total 54.2 53.7
Table 5.4: Frequency (cells/mm ) of tryptase positive mast cells within bronchiolar
epithelium (EP), connective tissue (CT), smooth muscle (SM) and alveolar tissue
(ALV) from control and heaves horses. % = mast cells in tissue location as a
percentage of total mast cells and Total = total number of mast cells (calculated as
the median of individual horse total mast cell counts). N/A = not applicable.
There was no significant inter-group difference in the number of tryptase positive
mast cells in connective tissue or smooth muscle in bronchial (p>0.28) or bronchiolar
(p>0.72) sections. Likewise, there was no significant difference in the number of
tryptase positive alveolar mast cells (p=0.94) between control and heaves horses.
There was considerable inter-horse variation in mast cell numbers. Indeed, one
control horse (control horse 5) was a statistical outlier with regard to the number of
both bronchiolar and bronchial tryptase positive intra-epithelial mast cells. This was
the only control horse in which bronchiolar tryptase positive intra-epithelial mast
cells were identified. Additionally, while bronchial intra-epithelial mast cells were
observed in one other horse (control horse 4), these were only in very low number.
There was no significant difference between control and heaves horses in the number
of intra-epithelial mast cells in bronchial (p=0.28) or bronchiolar (p=0.32) sections.
However, a trend for increased airway epithelial mast cells in heaves horses (p=0.09)
was evident in the total airway score. When the control outlier (control horse 5) was
excluded from these comparisons, there were strong trends for increased tryptase
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positive mast cells in bronchial (p=0.06) (fig. 5.6) and bronchiolar (Fisher exact test
p=0.07) (fig. 5.7) epithelium. Furthermore, there were significantly increased total
airway epithelial mast cells in heaves horses compared to controls (p=0.02) (fig. 5.8).
Control Heaves
Fig. 5.6: Frequency (cells/mm ) of tryptase positive
bronchial epithelial mast cells in controls excluding
horse 5 (n=5) and heaves (n=7) horses. There was a


















Fig. 5.7: Frequency (cells/mm ) of tryptase positive
bronchiolar epithelial mast cells in controls excluding
horse 5 (n=5) and heaves (n=7) horses. There was a
strong trend towards increased mast cells in heaves
horses (p=0.07). |° denotes outlier off axis scale.
147
Control Heaves
Fig. 5.8 : Number of tryptase positive airway epithelial
mast cells/mm2 in controls excluding horse 5 (n=5) and
heaves (n=7) horses. There were significantly increased
intra-epithelial tryptase positive mast cells in heaves
horses (p=0.02). * denotes significantly different to
control, ° denotes outlier.
5.5.1.4. Eq.MCP-1 Staining
Eq.MCP-1 positive cells stained deep brown throughout the entire cytoplasm. There
was no positive staining of control sections. The numbers of eq.MCP-1 positive mast
cells/mm2 of bronchial and bronchiolar tissues are shown in tables 5.5 and 5.6,
respectively. Very few eq.MCP-1 positive mast cells were observed in the airways of
either control or heaves horses. No eq.MCP-1 positive cells were observed in airway
smooth muscle in either control or heaves horses. Additionally, eq.MCP-1 positive




Horse EP CT SM EP CT SM
1 31.4 14.9 0 0 0 0
2 0 0 0 0 0 0
3 0 12.2 0 0 0 0
4 0 0 0 0 38.3 0
5 0 0 0 0 0 0
6 4.3 0 0 0 0 0
7 N/A N/A N/A 0 0 0
Median 0 0 0 0 0 0
Range 0-31.4 0-14.9 0-0 0-0 0-38.3 0-0
Table 5.5: Frequency (cells/mm ) of eq.MCP-1 positive mast cells in bronchial
epithelium (EP), connective tissue (CT) and smooth muscle (SM) from control and
heaves horses. N/A = not applicable.
Control Heaves
Horse EP CT SM ALV EP CT SM ALV
1 0 12.7 0 1.8 0 0 0 0
2 0 0 0 0 0 0 0 0
3 0 2.3 0 3.1 0 0 0 0
4 0 0 0 0 0 30.7 0 38.6
5 0 0 0 0 0 0 0 0
6 0 0 0 0 0 0 0 0
7 N/A N/A N/A N/A 0 0 0 0
Median 0 0 0 0 0 0 0 0
Range 0-0 0-12.7 0-0 0-3.1 0-0 0-30.7 0-0 0-38.6
Table 5.6: Frequency (cells/mm ) of eq.MCP-1 positive mast cells in bronchiolar
epithelium (EP), connective tissue (CT), smooth muscle (SM) and alveolar tissue
(ALV) from control and heaves horses. N/A = not applicable.
There was no significant difference between control and heaves horses in the number
of eq.MCP-1 positive mast cells in any tissue (p>0.50). The presence of eq.MCP-1
was not significantly associated with control or heaves status (Fisher exact test
p=0.27).
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5.5.2. Tryptase Transcripts in BALF Cell Pellets
There was no significant change in tryptase transcript regulation in either control











Fig. 5.9 : Relative expression (RE) of tryptase transcripts
compared to [3-actin in control horses (n=3) pre and post 48h hay /
straw challenge. There was no significant upregulation of tryptase
transcripts during challenge (p=0.4).
-heaves 1





Fig. 5.10: Relative expression (RE) of tryptase transcripts
compared to (3-actin in heaves susceptible horses (n=6) pre and
post 48h hay / straw challenge. There was no significant
upregulation of tryptase transcripts during challenge (p=0.8).
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P-actin transcripts were not significantly different in control (p=1.0) or heaves
(p=0.5) horses following challenge. Similarly, there was no significant difference in
P-actin transcripts between control and heaves horses at baseline (p=0.2) or at 48h
(p=0.2).
5.5.3. Tryptase Transcripts in Bronchial and Bronchiolar Tissue
There was no significant difference in bronchial tryptase transcripts between controls
and heaves horses in the early resolution phase (p=0.7) (fig. 5.12). However,
bronchiolar tryptase transcripts were down regulated seven-fold in early resolution
heaves horses compared to controls (p=0.02) (fig. 5.13).
control early resolution heaves
Fig. 5.12: Relative expression (RE) of tryptase
transcripts compared to P-actin in bronchial tissue from
control (n=6) and heaves horses (n=7) in the early
resolution phase following hay / straw challenge. There
was no significant difference in tryptase transcripts
between the two populations (p=0.7), ° denotes outlier.
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challenged control early resolution heaves
Fig. 5.13: Relative expression (RE) of tryptase
transcripts compared to P-actin in bronchiolar tissue
from control (n=6) and heaves horses (n=7) in the early
resolution phase following hay / straw challenge.
Tryptase transcripts in heaves horses were down-
regulated seven-fold compared to controls (p=0.02), *
denotes significantly different to challenged control.
There was no significant difference in p-actin transcripts between control and early
resolution heaves horses in bronchial (p=0.2) or bronchiolar tissues (p=0.4).
5.6. Discussion
5.6.1. Bronchial and Bronchiolar Mast Cell Populations
5.6.1.1. General Mast Cell Population Characteristics
Tryptase positive mast cells were abundant while eq.MCP-1 positive mast cells were
scarcely observed in the equine lung, as previously noted by Pemberton et al. (2001),
confirming that equine pulmonary mast cells are predominantly tryptase positive,
chymase negative in their proteinase content. This is not surprising since it is well
documented across species that the lung contains predominantly tryptase positive,
chymase negative mast cells (Bienenstock et al., 1985; Irani et al., 1986; Schwartz et
al., 1987; Wenzel et al., 1988; Chen et al., 1993; Lavens et al., 1993; Gibson et al.,
1993; Kuther et al., 1998; Jolly et al., 1999). Intra-epithelial mast cells, in particular,
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were almost exclusively of this phenotype, again as reported in other species
(Bienenstock et al., 1985; Irani et al., 1986). Interestingly, the two horses (both
controls) with eq.MCP-1 positive bronchial intra-epithelial mast cells were different
control horses from those with tryptase positive bronchial intra-epithelial mast cells.
This suggests that a population of chymase positive, tryptase negative mast cells may
exist in the equine lung, as has been reported in cattle and dogs (Kube et al., 1998;
Kuther et al., 1998; Jolly et al., 1999). Indeed, occasional single eq.MCP-1 labelled
mast cells were observed on dual tryptase and eq.MCP-1 labelled equine lung
sections (section 2.5.3.3).
There is some disparity between numbers of tryptase positive and toluidine blue
positive mast cells counted in the airways. As discussed, effectively all equine
pulmonary mast cells are tryptase positive and therefore tryptase and toluidine blue
positive mast cell numbers should be closely correlated. However, equine basophils
are also reported to stain with toluidine blue (Dirscherl et al., 1993) as are canine and
simian basophils (Patterson et al., 1974). It therefore seems likely that basophils may
contribute to the toluidine blue stained cell counts in this study. Although basophils
are traditionally thought to be confined to the peripheral bloodstream, they have
been observed in tissue locations, including human airway tissues (Okuda et al.,
1983; Koshino et al., 1995). Although Koshino et al. (1995) reported increased
numbers of basophils in asthmatic airways compared to controls, the number of
toluidine blue positive cells (presumed to include basophils) is not elevated in heaves
horses compared to controls. Due to this potential exaggeration of the toluidine blue
mast cell count by basophils, tryptase positive cell counts will represent mast cell
enumeration in the tissues more accurately. Consequently, tryptase positive mast cell
values have been used for comparison with other studies.
The majority of toluidine blue and tryptase positive mast cells in the equine lung
were located in the alveoli and connective tissue with a smaller population resident in
the epithelial layer. This finding is consistent with a previous equine study (Mair et
al., 1988) and concurs with studies in other species (Craig et al., 1986; Shanahan et
al., 1987; Chen et al., 1990; Kuther et al., 1998). Likewise, there was no significant
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difference in alveolar and connective tissue mast cell numbers between control and
heaves horses, similar to studies comparing control and asthmatic humans
(Djukanovic et al., 1990; Pesci et al., 1993; Laitinen et al., 1993; Ammit et al.,
1997).
In contrast to the alveoli and connective tissue, very few mast cells were observed in
the smooth muscle of either control or heaves horses, as has also been reported in
normal canine lung tissue (Kube et al., 1998). High numbers of smooth muscle mast
cells are reported in the human lung (Carroll et al., 2002a) with further recruitment in
asthmatics (Ammit et al., 1997; Carroll et al., 2002a) where tryptase is believed to
act as both a direct and indirect agonist and mitogen of smooth muscle (Chambers et
al., 2001; Berger et al., 2001a; Berger et al., 2001b; Brown et al., 2002; Cho et al.,
2003). These results suggest that mast cell hyperplasia is not a pre-requisite for the
pulmonary smooth muscle hyperplasia observed in heaves (Ramos-Barbon et al.,
2004). This was somewhat surprising as mast cell mediators have been shown to
augment cholinergic airway tone in the equine airway and have been suggested as an
important mechanism in the development of airway obstruction in heaves (Olszewski
et al., 1999). It is still possible however that mast cell mediators diffuse from
surrounding tissue to act on smooth muscle in heaves horses.
It is difficult to directly compare the observed frequency of tissue mast cells to other
studies evaluating mast cell populations in horses and other species due to
inconsistencies in study design. These include differences in tissue fixation, staining
and method of mast cell enumeration and consequently reported figures are highly
variable. As pulmonary mast cells are predominantly of the mucosal mast cell type,
studies using formalin fixation, which interferes with staining of these cells, are
likely to underestimate mast cell numbers. Electron microscopy studies report the
highest values, presumably due to this technique allowing recognition and
enumeration of degranulated or 'ghost' mast cells which are likely be missed by mast
cell staining techniques that rely on staining granule constituents.
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Winder and von Fellenberg (1990) and Mair et al. (1988) have previously reported
mast cell populations of the equine lung using similar methodology to this current
study (Carnoys fixed tissue and toluidine blue staining). Whilst mast cell numbers in
the current study are similar to those reported in the former paper, they are lower
than those described by Mair et al. (1988). However the latter study included intra¬
epithelial mast cells and may possibly have over-estimated mast cell numbers due to
the difficulty in distinguishing these intra-epithelial mast cells from mucus secreting
cells, as reported in this study and by other authors (Nicholls, 1978; Winder and von
Fellenberg, 1990).
There was an increased number of mast cells in bronchiolar compared to bronchial
tissues, a trend which has previously been reported in horses (Nicholls, 1978) and
other species (Guerzon et al., 1979; Lamb and Lumsden, 1982; Chen et al., 1990;
Carroll et al., 2002a). The majority of airway mast cells were located in the
connective tissue compartment, as previously reported in healthy horses (Mair et al.,
1988) and other species (Guerzon et al., 1979; Shanahan et al., 1987; Kube et al.,
1998; Jolly et al., 2000). Mair et al. (1988) reported that the majority of mast cells
associated with the airways of healthy horses resided subepithelially within the
lamina propria connective tissue, a pertinent location for recruitment to the
epithelium during challenge in heaves susceptible individuals. In the current study,
mast cells in the lamina propria were not counted as a distinct population but were
included in the connective tissue count and therefore we are unable to comment on
subepithelial mast cell populations.
Increased (total) numbers of bronchiolar mast cells are reported in horses suffering
from bronchiolitis compared to controls (Winder and von Fellenberg, 1990)
suggesting recruitment of mast cells to the bronchioles during an inflammatory
response. This was not observed in the current study however the aetiology(ies) of
bronchiolitis in the study by Winder et al. (1990) was not disclosed and therefore
may have included other causes of bronchiolitis in addition to heaves such as
neoplastic, fibrotic and interstitial diseases, which can lead to elevated mast cell
counts in humans (Walls et al., 1990).
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Specific staining characteristics and comparisons with other studies are further
discussed below. Many studies have been performed in individuals with defined type
I mast cell mediated allergies such as allergic rhinitis. Caution should be exercised in
comparing heaves with these allergic conditions as the role of allergy in heaves has
not been definitively confirmed. Furthermore, the pathophysiological consequences
of non-immunological mast cell activation may differ from allergy driven mast cell
activation. Therefore, studies confined to investigating mast cell involvement in type
I allergic diseases have only been used for comparison with this study when data in
other diseases is lacking.
5.6.1.2. Toluidine Blue Staining
As positive staining ofmucus secreting cells was observed with toluidine blue, it was
not possible to accurately evaluate epithelial mast cells with this stain. This may be a
peculiarity specific to the horse as only two other reports, also in the horse, have
noted this effect (Nicholls, 1978; Winder and von Fellenberg, 1990), which is
presumed to be a result of toluidine blue staining sulphated mucopolysaccharides
(Culling, 1963) which both equine mucus and mast cells contain (Nicholls, 1978).
5.6.1.3. Tryptase Staining
Using the total airway score, a trend for increased tryptase positive intra-epithelial
mast cells was present in heaves horses compared to controls; however, this data was
skewed by the outlier control horse 5. This outlier control had been owned by
Michigan State University for many years and had undergone rigorous testing to
ensure control status. However, other diseases which can elevate pulmonary mast
cell counts as previously discussed may have been present but undetected.
Unfortunately, due to unidentified problems, lung samples from this horse
disintegrated in RNA later and consequently could not be used for quantitative RT-
PCR which may have yielded further information. Subsequent examination of lung
tissue from this horse by a pathologist did not reveal any histopathological
abnormalities. When this outlier horse was excluded, there were significantly
increased total airway intra-epithelial mast cells in heaves horses compared to
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controls. Likewise, when control horse 5 was excluded, trends for increased intra¬
epithelial mast cells in heaves horses also became evident in bronchial and
bronchiolar data subsets. As the number of horses used in this study was low, it is
possible that some non-significant results are due to lack of statistical power
resulting from small sample sizes.
The intra-epithelial accumulation ofmast cells in heaves horses noted in this study is
in agreement with the ultrastructural study performed by Kaup et al. (1990b), which
showed many of these mast cells to be degranulated. Except for the outlier horse,
intra-epithelial mast cells were rarely observed in controls. Similarly, intra-epithelial
mast cells are reportedly rare in control human subjects but are increased in the lungs
of human asthmatics (Lozewicz et al., 1988; Laitinen and Laitinen, 1988; Crimi et
al., 1991; Di Stefano et al., 1993; Pesci et al., 1993; Gibson et al., 1993; Laitinen et
al., 1993). Increased intra-epithelial mast cells are also reported in the lungs of
chronic bronchitis patients (Pesci et al., 1994) providing evidence for epithelial mast
cell recruitment in non-allergic pulmonary disease.
The number of intra-epithelial mast cells in remission heaves horses could not be
evaluated as tissues were not available from these horses. Asymptomatic, pre-
seasonal allergic rhinitis sufferers have reduced numbers of intra-epithelial nasal
mast cells compared to when symptomatic, but greater numbers than control
subjects, suggestive of some degree of persistent immunological activation of the
airway mucosa (Viegas et al., 1987; Juliusson et al., 1995). Following challenge of
asymptomatic allergic rhinitis sufferers, mast cell migration into the nasal epithelium
has been observed (Kawabori et al., 1985; Viegas et al., 1987). Indeed, in a canine
antigen challenge model, airway intra-epithelial mast cells increased in the lung as
rapidly as one hour following challenge (Turner et al., 1988). Treatment with the
corticosteroid beclomethasone propionate inhibits the seasonal increase in nasal
mucosal mast cells in allergic rhinitis sufferers (Gomez et al., 1988) and reduces the
numbers of intra-epithelial mast cells in symptomatic allergic rhinitis patients
(Otsuka et al., 1986; Juliusson et al., 1995). These observations entice speculation
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that a similar mechanism may be involved in the clinical response of heaves affected
horses to corticosteroid administration.
Concurring with the current study, intra-epithelial mast cells in the airway have
repeatedly been shown to be almost exclusively tryptase positive in proteinase
content in humans (Bentley et al., 1992; Gibson et al., 1993; Aldenborg and
Enerback, 1994; Juliusson et al., 1995). This epithelial accumulation ofmast cells in
both allergic and non-allergic asthma and also diseases unrelated to allergy such as
chronic bronchitis, indicate that this recruitment can be a feature of airway
inflammation per se rather than being specific to allergy. Although only a low
proportion of total mast cells are in an intra-epithelial location, comprising just 0-2%
of epithelial cells (Lamb and Lumsden, 1982), it is suggested that this is a substantial
number of cells when the whole lung surface is considered (Guerzon et al., 1979).
Positive correlations have been observed between the number of intra-epithelial mast
cells in bronchial brushings and airway hyperreactivity and airway obstruction in
human asthmatics (Gibson et al., 1993). Furthermore, electron microscopic evidence
of many partially or even fully degranulated mast cells in the pulmonary airway
mucosa has been documented in numerous studies (Fox et al., 1981; Famb and
Lumsden, 1982; Claman et al., 1986; Laitinen and Laitinen, 1988; Chen et al., 1990;
Djukanovic et al., 1990; Heard et al., 1990; Di Stefano et al., 1993; Pesci et al.,
1993; Laitinen et al., 1993; Beil and Pammer, 2001; Carroll et al., 2002a). These
degranulating and degranulated mast cells appear to be activated, possibly in an
attempt to replenish their stores of granule contents (Claman et al., 1986). Some mast
cell degranulation is reported to occur in airways from control individuals (Fox et al.,
1981; Lamb and Lumsden, 1982) and a gradient of mast cell degranulation has been
identified in normal human bronchi which appears to increase in magnitude from the
deep submucosa to superficial mucosa and epithelium (Heard et al., 1990). However,
increased numbers of degranulating and degranulated intra-epithelial mast cells are
observed in asthmatics (Beasley et al., 1989; Djukanovic et al., 1990; Di Stefano et
al., 1993; Pesci et al., 1993; Carroll et al., 2002a). Similarly, airway epithelium from
heaves horses is reported to contain intra-epithelial accumulations of mast cells, the
majority of which were in varying stages of degranulation (Kaup et al., 1990b). Mast
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cell degranulation can not be reliably assessed on stained sections and as electron
microscopy was not performed as part of the current study, we are unable to
comment on levels ofmast cell degranulation in equine airway epithelium. However,
if total degranulation of mast cells occurs in the airway of heaves horses as has been
described in asthmatic airways, the number of intra-epithelial mast cells counted by
immunohistochemistry is likely to have been underestimated.
In the current study, the increase in intra-epithelial mast cells without increased total
bronchiolar mast cells suggests re-distribution of resident bronchiolar mast cells with
migration to the epithelium, rather than recruitment of new cells. This concurs with a
previous canine allergic model in which early pulmonary epithelial mast cell
recruitment was followed by decreased mast cell counts at lOh post challenge
(Turner et al., 1988). This was attributed to mast cell degranulation and the inability
to visualise these 'ghost cells', rather than movement of mast cells back out of the
epithelium as mast cells were not increased in the subepithelial area or airway lumen
(Turner et al., 1988). It is suspected, but not conclusively proven, in human allergic
airway disease that intra-epithelial mast cells interact with inhaled allergens and
degranulate into the airway contributing to elevated histamine and proteinase
concentrations in BALF. Considering the number of intra-epithelial mast cells is
increased in heaves horses, but the number of luminal mast cells is not, it seems
likely that these intra-epithelial mast cells also contribute significantly to the
increased BALF tryptase concentration measured in these horses (Chapter 4).
Gibson et al. (1993) found a positive correlation between the number ofmast cells in
the epithelium and in the BALF in asthmatics, although intra-epithelial mast cells
outnumbered luminal mast cells by a factor of ten. BAL may wash mast cells from
the epithelial surface and / or mast cells may be extruded through the epithelium into
the airway lumen, the latter potentially being a clearing process for senescent cells.
Another clearance mechanism could be mast cell apoptosis and engulfment by
phagocytic cells and certainly phagocytosed mast cells in macrophages have been
observed in electron microscopy studies of the human airway (Walls et al., 1990;
Beil and Pammer, 2001). Tryptase positive macrophages and neutrophils observed in
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immunolabelled equine BALF cytospins (Chapter 4) was also suggestive ofmast cell
phagocytosis occurring in the equine airway lumen.
5.6.1.4. Eq.MCP-1 Staining
Eq.MCP-1 positive cells were much less frequently observed in airway tissues than
tryptase positive cells concurring with reports in other species that pulmonary mast
cells are predominantly tryptase positive, chymase negative in proteinase content
(Schwartz et ah, 1981; Irani et al., 1986; Wenzel et al., 1988; Lavens et al, 1993;
Gibson et al., 1993). There was no significant inter-group difference in the number
of eq.MCP-1 positive cells in any tissue. Chymase positive mast cells are reported to
decrease in inflammatory conditions associated with mast cell activation and
degranulation (Walls et al., 1990). It therefore might be expected that fewer eq.MCP-
1 positive cells would be observed in heaves horses. However, in this study, the
presence of eq.MCP-1 stained cells was not significantly associated with control or
heaves status.
Other than rodents, which appear to have different mast cell phenotypes to most
other species, chymase positive mast cells are found in greatest proportions in
connective tissue compartments and are largely absent from epithelium (Jolly et al.,
2000) as observed in this study. Interestingly, a pilot study for immunohistochemical
staining techniques found that eq.MCP-1 positive cells were abundant in intestinal
mucosa and therefore may have more similarity to rodent chymases.
In human bronchi, numbers of chymase positive mast cells are reported to be highest
around submucosal glands (Matin et al., 1992) which, given the potent secretagogue
properties of chymase (Sommerhoff et al., 1989a), would seem a pertinent
microenvironment. In the current study, peri-glandular mast cells were not counted
as a distinct population and were incorporated into the connective tissue count.
Beil and Pammer (2001) demonstrated high numbers of dual tryptase and chymase
positive mast cells in human lung parenchyma and suggested that prior studies had
not used optimal tissue processing (reportedly 4.5% formalin, for 6h, followed by
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70% ethanol until processing). All tissues used in the current study were collected
immediately post mortem into Carnoys fixative. Preliminary trials had shown
preferential staining of Carnoys fixed tissue compared to very poor staining,
particularly of mucosal mast cells, with formalin fixed equine tissues as previously
reported (Nicholls, 1978; Winder and von Fellenberg, 1990). Species variation in
optimal mast cell fixation and staining techniques, as well as disparity in mast cell
proteinase content with anatomical site and disease status is well recognised
(Bienenstock et al., 1985; Shanahan et al., 1987; Walls et al., 1990; Kube et al.,
1998). These factors may well explain the inconsistencies between studies and the
lower proportion of chymase positive mast cells observed in the equine lung.
Furthermore, as eq.MCP-1 is a P-chymase, its distribution may not be comparable
with human chymase which is an a-chymase. It is also possible that tissues used by
Beil and Pammer (2001) had some upregulation of chymase as has been reported, for
example, in fibrotic lung disease and pulmonary hypertension (Walls et al., 1990;
Hamada et al., 1999) as fibrotic alveolar septae were reported to be commonly
observed.
Sture et al. (1995) also report higher numbers of chymase positive cells in the sheep
lung than the current study with a mean ± SD of 23.8 ± 4.3 and 51.3 ± 18.3 sheep
mast cell proteinase positive cells/mm2 in ovine bronchial and lung tissue
respectively. Sheep mast cell proteinases have since been further classified into a
number of subtypes (McAleese et al., 1998) and sheep mast cell proteinase-1 shown
to be a dual specific proteinase with both tryptase and chymase properties
(Pemberton et al., 1997). Therefore the distribution reported by Sture et al. (1995)
may not reflect that of a mono-specific chymase.
5.6.2. Quantitative RT-PCR and Tryptase Transcript Expression
5.6.2.1. BALF Cell Pellets
It was hypothesised that luminal mast cells from heaves susceptible horses might
upregulate tryptase mRNA expression following hay / straw challenge in order to
increase tryptase production. This would account for the observation that BALF
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tryptase concentrations are increased in heaves horses (Chapter 4) without a
concurrent increase in BALF mast cell number. However, the lack of upregulation of
tryptase transcripts in both control and heaves susceptible horses following 48h hay /
straw challenge suggests that these luminal mast cells may not be capable of
increasing tryptase expression following challenge. It is feasible, although considered
unlikely, that upregulation was missed by an inappropriate time-point. Therefore it
appears that luminal mast cells in heaves susceptible horses can contribute to the
increased BALF tryptase concentration only by degranulation and can not respond to
challenge by upregulation of tryptase expression. Increased histamine releasability of
airway luminal mast cells following in vitro allergen challenge is reported in heaves
horses and allergic dogs compared to controls (Patterson et al., 1974; Hare et al.,
1999). However, human airway luminal mast cells release significantly less
histamine than dispersed parenchymal mast cells in response to calcium ionophore
(Casolaro et al., 1989). Therefore it seems likely that whilst luminal mast cells
contribute to the increased BALF tryptase concentrations observed in heaves horses,
tissue mast cells are the more potent participants in response to challenge. This
hypothesis is further supported by the elevated numbers of intra-epithelial mast cells
observed in heaves horses compared to controls. The inability of luminal mast cells
to upregulate tryptase expression in response to challenge suggests that these cells,
and possibly all luminal cells, may be an older, senescent cell population. This is
further supported by other quantitative studies which have failed to detect
upregulation of cytokine expression in luminal cells from challenged asthmatics
(Berkman et al., 2001; Muhlebach et al., 2004).
5.6.2.2. Bronchial and Bronchiolar Tissues
Bronchial tissue did not show any change in tryptase transcript regulation supporting
the belief that heaves is predominantly a disease of the small airways with
comparatively little contribution from the larger conducting airways. Only one
specific time-point was investigated however, and therefore involvement of
bronchial tissue at other time-points can not be excluded.
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In contrast, bronchiolar tissue from heaves horses in early resolution phase showed a
significant, seven-fold decrease in tryptase transcript expression compared to control
horses. This suggests that bronchiolar mast cells had 'switched off tryptase mRNA
expression following cessation of challenge. The decreased BALF tryptase
concentrations of heaves horses in remission compared to clinical heaves horses
(Chapter 4) suggests that this down-regulation of tryptase expression is continued
through to the protein level. This down-regulation was observed despite the presence
of increased numbers of intra-epithelial mast cells in these horses (section 5.5.1.3).
These results suggest that bronchiolar mast cells, in contrast to luminal mast cells,
are capable of altering tryptase expression in response to the challenge environment.
This, and the increase in intra-epithelial tryptase positive mast cells in heaves horses
post challenge invites speculation that tryptase upregulation may occur in
bronchiolar mast cells during clinical exacerbation of heaves. Ideally samples would
also have been collected from heaves horses during acute exacerbation of heaves to
investigate this possibility.
Although there are no previous investigations ofmast cell mediator regulation in the
lung or in airway luminal cells, quantitative studies of cytokine expression can be
used as a comparison of the response of these two compartments. As previously
mentioned there are no studies confirming upregulation of proteinase or cytokine
expression by airway luminal mast cells. In contrast however, cytokine upregulation
has been demonstrated in mucosal mast cells in nasal biopsies from allergic rhinitis
patients and in lung mast cells in an asthma model, thus supporting the hypothesis of
tissue mast cell response to challenge (Jaffe et al., 1995; Pawanker et al., 2000).
Indeed, antigen-activated nasal mast cells secreted greater levels of IL-4 and IL-13
than antigen-activated nasal T lymphocytes (Pawanker et al., 2000).
It seems probable that mast cells most accessible to the airway, i.e. intra-epithelial
and alveolar mast cells, would respond to challenge by alteration of mRNA
expression. During challenge these cells may be activated and upregulate tryptase
mRNA transcripts with subsequent increased expression at the protein level. These
mast cells may then pass into the airway lumen themselves when no longer able to
163
upregulate mRNA expression but still able to degranulate stored tryptase. If indeed
intraluminal mast cells are a senescent population, tryptase release from these cells
may also be partly due to autolysis, a concept supported by the apparent reduced
viability of mast cells compared to other luminal cells in allergic dogs (Patterson et
al., 1974). Alternatively, mast cells could be primed and upregulated in the tissues
before migrating into the lumen with maximal reserves of tryptase available for
degranulation. However, the lack of mast cell recruitment to the airway lumen in
clinical heaves (McGorum et al., 1993d; Dixon et al., 1995b) and the presence of
degranulating and degranulated mast cells in the airway epithelium of healthy horses
(Mair et al., 1988) suggests that this latter explanation is unlikely.
5.6.2.3. /3-actin Expression
The valid use of house-keeping genes in quantitative mRNA assays to normalise
gene-of-interest data for variations in processing and signal quantitation relies upon
their constant cellular expression. House-keeping genes are defined by specific gene
promoter elements which determine that they are expressed constitutively in every
cell. However, this does not necessarily mean that their expression is not regulated
and it is virtually impossible to find the perfect house-keeping gene whose
expression is unaffected by cellular proliferation, activation or differentiation
(Thellin et al., 1999; Glare et al., 2002).
P-actin, a cytoskeletal protein, was used in this study due to its reported use as a
house-keeping gene in the equine airway (Giguere et al., 2002; Bowles et al., 2002)
and the ability to design specific primers from the published equine cDNA sequence.
Recently variable P-actin expression in asthmatic airways has been reported (Glare et
al., 2002) casting doubt on its validity as a house-keeping gene. P-actin expression
was therefore compared between control and heaves horses in all quantitative assays
performed. No significant difference in P-actin expression was found during
challenge of either control or heaves horses or between the two populations of horses
such that it appears to be a suitable house-keeping gene in this disease model.
Although this is only a very crude measure of house-keeping gene validity, other
methods of verification are very time-consuming and difficult to perform.
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5.7. Conclusion
During disease exacerbation, heaves susceptible horses have increased numbers of
tryptase immunoreactive intra-epithelial mast cells compared with control horses.
This suggests a role for these cells in contributing to the increased BALF tryptase
concentrations reported in heaves susceptible horses post challenge in Chapter 4.
Furthermore, challenge of heaves horses failed to elicit upregulation of tryptase
mRNA expression in airway luminal mast cells whereas down-regulation of tryptase
occurred in bronchiolar mast cells following removal of challenge. Collectively,
these results imply that tissue mast cells may be more important in the development
and resolution of the pulmonary inflammatory response in heaves than luminal mast
cells. The response of luminal mast cells to organic dust challenge is investigated
further in Chapter 6.
An increase in mast cells in the smooth muscle compartment was not observed in
heaves horses suggesting that they are not critical to the development of
bronchospasm in these horses. This finding contrasts with observations in human
asthmatics.
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Chapter 6: In Vitro Mast Cell and Tracheal Explant
Challenges
6.1. Summary
To investigate whether hay dust can induce mast cell degranulation, mixed cell
pellets recovered from BALF from control (n=6) and heaves susceptible (n=6) horses
in remission were challenged with hay dust suspension (HDS). Supernatant tryptase
content could not be measured due to interference with the ELISA by unidentified
components of the FIDS, and therefore an indication of mast cell degranulation was
determined by measurement of residual tryptase in lysed cell pellets. Equine airway
luminal mast cells from heaves susceptible horses showed significant degranulation
with 75 and 7.5mg/ml HDS challenge. A trend for dose dependent degranulation was
evident in both control and heaves susceptible horses following challenge with HDS,
which suggests involvement of a non-IgE mediated mast cell response to challenge.
As no attempt was made to isolate a pure mast cell population, other cell types or
their products, may have contributed to mast cell degranulation. The increased
number of intra-epithelial mast cells in heaves horses compared to controls may be
important in the in vivo mast cell response to HDS challenge, such that increased
BALF tryptase concentrations only occur in heaves horses.
A potential secretagogue role for equine mast cell proteinases was investigated using
air-liquid interface tracheal explant culture. Explants harvested from 3 control horses
were challenged with tryptase, eq.MCP-1 and eq.MCP-1 plus soy bean trypsin
inhibitor. Mucus quantitation, as measured by optical density (OD) of explant PBS
washings incubated with Periodic Acid Schiff (PAS) reagent and by real-time RT-
PCR of equine mucin gene MUC-5AC expression, was not increased following
incubation with either mast cell proteinase. Therefore, equine mast cell proteinases
may not act as secretagogues on mucus secreting cells. However, it was considered
more likely that the high concentrations of mast cell proteinases achieved in vivo by
166
mast cell degranulation local to mucus glands may not have been achievable using
explants due to poor tissue penetration or inactivation of proteinases.
6.2. Introduction
In Chapter 4 it was demonstrated that heaves susceptible horses have increased
BALF tryptase concentrations following inhalational hay / straw challenge.
However, the relative contribution of airway luminal and intra-epithelial mast cell
degranulation to this increase in tryptase concentration is unknown. Results from
Chapter 5 suggest that intra-epithelial mast cells may contribute substantially to
degranulation and that airway luminal mast cells may be less important in the
pulmonary inflammatory response in heaves horses. Challenge of airway luminal
mast cell populations recovered from BALF would therefore confirm their ability to
degranulate in response to hay dust.
Mast cell degranulation has traditionally been viewed to occur as a result of allergen
specific crosslinkage of IgE to high affinity receptors (FcsRI) on the mast cell
surface. However, more recently neuropeptides, complement, tryptase, endotoxin,
lectins, cytokines, adenosine and changes in osmolality have also been reported as
alternative means of mast cell activation and degranulation, with neuropeptide and
cytokine activation, in particular, thought to be of biological significance in the
asthmatic airway (Church et al., 1989; Bingham and Austen, 2000; Holgate, 2000;
Hart, 2001). Hay dust, like grain dust, contains a number of pro-inflammatory agents
including endotoxin, |3-D-glucan, serine and metalloproteinases and particulates
(Pirie et al., 2002b), all of which may be capable of direct mast cell activation. Grain
dust has been shown to stimulate histamine release from human lung fragments in a
dose-dependent manner, independent of complement, cell cytotoxicity and IgE
(Chan-Yeung et al., 1987). Indirect mast cell activation by grain dust has also been
demonstrated via induction of a histamine releasing factor from lymphocytes (Alam
et al., 1988). Although increased BALF IgE has been reported in heaves horses
compared to controls (Halliwell et al., 1993; Schmallenbach et al., 1998), a definitive
role for IgE, and indeed allergy, in the pathogenesis of equine heaves has not been
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established. Therefore, this chapter hopes to further elucidate the role of allergy in
equine heaves by considering the response of both control and heaves susceptible
horses to HDS.
This study has identified increased tryptase concentrations in BALF of horses with
heaves, consistent with a potential role for mast cells in pathophysiology of heaves.
However, further work is required to determine the consequences of these increased
tryptase concentrations on airway inflammation and function in heaves. Tryptase
release in the lung could have several potential pro-inflammatory consequences
including smooth muscle contraction and hyperplasia, increased vascular
permeability, neuropeptide regulation and recruitment of inflammatory cells as
described in section 1.4.4.1. Trypsin is reported to be a secretagogue for goblet cells
in rodent airway epithelium (Niles et al., 1986). Intra-epithelial tryptase positive
mast cells observed in heaves horses (Chapter 5) are therefore in an ideal
microenvironment to stimulate local mucus secretion during clinical disease. Mast
cell chymase is also an important secretagogue for serous cells. Indeed, it is the most
potent secretagogue for cultured serous cells identified to date, with respect to
threshold concentration and magnitude of response (Sommerhoff et al., 1989a).
Although chymase positive cells are not present in large numbers in the human
airway, their strategic location around submucosal glands is considered to have
physiological importance in the exaggerated mucus production of asthmatics (Matin
et al., 1992; Carroll et al., 2002b). A similar role in equine heaves may contribute to
the mucus hypersecretion associated with clinical exacerbation of disease. Potential
secretagogue roles for tryptase and eq.MCP-1 are therefore investigated in this
chapter by proteinase challenge of equine tracheal explants and measurement of
mucus production at gross and molecular levels.
The aims of this chapter were therefore to: (a) determine if HDS can induce
degranulation of equine airway luminal mast cells and if so, (b) do mast cells from
control and heaves susceptible horses differ in their responsiveness to HDS and (c)
investigate mast cell proteinases for potential mucus secretagogue activity using
tracheal explant air-liquid interface cultures.
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6.3. Materials and Methods
6.3.1. Pilot Studies
6.3.1.1. HDS Challenge ofMouse MucosalMast Cells
Mouse mucosal mast cells were used in a pilot study to investigate mast cell response
to HDS challenge. These cells were used because they were readily available due to
their use in a concurrent study and because, in contrast to mast cells in a mixed
airway luminal cell population, they allowed investigation of a direct mast cell
response to HDS due to the use of a pure mast cell population.
The cell culture medium TI3S was prepared by supplementation of Dulbecco's
Modified Eagle's medium (DMEM, Life Technologies) with 10% heat inactivated
foetal calf serum (Serotec), lOOU/ml penicillin, 100pg/ml streptomycin, 2.5pg/ml
fungizone, 2mM L-glutamine, ImM sodium pyruvate, lng/ml recombinant human
transforming growth factor-pi (Sigma), lng/ml recombinant mouse IL-3 (R&D
Systems), 5ng/ml recombinant mouse IL-9 (R&D Systems) and 50ng/ml
recombinant rat stem cell factor (Amgen). Mouse mucosal mast cells grown from
cultured bone marrow mast cell precursor cells (Brown et al., 2003) were donated
from another concurrent study. Cells were washed three times with TI3S to remove
constitutive proteinases and a total cell count performed in duplicate using an
improved Neubauer counting chamber (Fisher Scientific). Viability was assessed by
0.2% nigrosin (Sigma) exclusion. Cells were resuspended in TBS at 5xl06 cells/ml
and then lOOjul aliquots of cells (5xl05 cells) incubated in triplicate for 30min at
37°C with lOOpl challenge media. Challenge media were as follows:
(a) TBS (negative diluent control)







Calcium ionophore was used as a positive control at a concentration of 10"6M as this
has previously been shown to induce high levels of degranulation of murine mast
cells (Levi-Schaffer et al., 1987; Thompson et al., 1990; Coleman et al., 1993). The
o
HDS used contained O.lg/ml hay dust and 1.2 x 10 /ml particulates (<60pm
diameter). This HDS had previously been produced and then characterised in vivo as
effective in inducing a heaves response in susceptible horses (Pirie, 2002). TI3S was
used as the HDS diluent. The dilution factor of the cell suspension resulted in a final
HDS challenge concentration of 50mg hay dust/ml for neat HDS challenge. Serial
dilutions therefore resulted in final challenge hay dust concentrations of 5mg/ml,
0.5mg/ml, 5pg/ml and 0.5pg/ml for challenges (d) to (g) respectively.
Following challenge, 20pl of cells were removed for total cell count and viability
studies. The remaining cells were pelleted at 735g for 5min at 4°C and the
supernatant removed and stored at -70°C for later ELISA quantitation ofmouse mast
cell proteinase-2 (mMCP-2). The cell pellet was washed 3 times with 1ml PBS by
vortexing followed by centrifugation at 735g for 5min at 4°C. Cells were then lysed
by 3 freeze-thaw cycles in 450pl 0.5M NaCl in PBS using dry ice and a 37°C water
bath. Cell debris was pelleted by centrifugation at 13,000g for 5min at 4°C and the
lysed cell pellet supernatant removed and stored at -70°C.
6.3.1.2. Calcium Ionophore Challenge ofEquine Airway LuminalMast Cells
The optimal calcium ionophore concentration for induction of mast cell
degranulation varies among species (Wardlaw et al., 1986; Sommerhoff et al.,
1989b; Hare et al., 1998). Therefore a pilot study was performed to verify the
appropriate concentration for use as a positive control challenge of equine mast cells.
Furthermore, this pilot study allowed optimisation of the in vitro equine airway
luminal mast cell challenge protocol.
Luminal airway mast cells were recovered by BAL from horses (control n=3, clinical
heaves n=l) referred to R(D)SVS for clinical investigation of pulmonary disease as
described in section 4.3.1.1. BALF total cell count and viability were assessed as
above and differential cell counts of 500 cells performed on duplicate Leishman's
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stained cytospins. Cells were pelleted by centrifugation at 200g for lOmin at 4°C and
the supernatant decanted. Cells were then washed twice in PBS, resuspended in
Tyrode's buffer and total cell count and viability assessments repeated. Following
centrifugation at 200g for lOmin at 4°C, cells were resuspended in Tyrode's buffer at
6xl05 mast cells/ml. Aliquots of cells (lOOpl, 6xl04 mast cells) were challenged in
triplicate with 300pl challenge media at 37°C for 30min as follows:
(a) Tyrode's buffer
(b) 10"6M calcium ionophore
(c) 1CT5M calcium ionophore
(d) 10"4M calcium ionophore
These challenge concentrations were based upon those reported to induce mast cell
degranulation in other species. Tyrode's buffer was freshly prepared for each
challenge by dissolving 4g NaCl (137mM), O.lg KC1 (2.7mM), 0.5g NaHCCE
(12mM), 0.03g NaH2P04 (0.37M), O.Olg MgCl2 (O.lmM), 0.1 lg CaCl2 (2mM), 0.5g
glucose (0.1%) and 0.5g gelatine (0.1%) in 100ml distilled water by heating for
approximately lmin in a microwave (Panasonic 800W D). When the gelatine was
dissolved, 395ml distilled water was added followed by 5ml HEPES buffer (lOmM,
pH 7.3, Sigma). The pH was then adjusted as necessary to pH -7.3.
Following challenge, cells were pelleted by centrifugation at 735g for 5min at 4°C
and the supernatant removed and stored at -70°C until analysis. Cell pellets were
washed 3 times with 1ml PBS and lysed by 3 freeze-thaw cycles with 450pl 1M
NaCl in PBS. The lysed cell pellet supernatant was harvested by centrifugation at
13,000g for lOmin and stored at -70°C until further analysis.
6.3.1.3. Effect ofHDS on Determination ofTryptase by ELISA
As preliminary trials suggested that FIDS might interfere with determination of
equine tryptase by the ELISA, dilutions of O.lg/ml FIDS (neat - 1:10,000) in ELISA
buffer were mixed in equal volume with lOng/ml equine tryptase. Tryptase
concentrations of samples were then determined by ELISA as previously described
(4.3.2.3).
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6.3.1.4. /?-hexosaminidase Assay to Determine HDS Content ofSupernatant and Cell
Pellet
As HDS was shown to interfere with ELISA determination of equine tryptase
concentrations, the relative amount of HDS retained in the supernatant and cell pellet
following challenge was investigated. Dilutions of HDS (neat to 1:10,000) were
made with PBS, centrifuged at 735g for 5min and the supernatant removed. Washing
of the centrifuged pellet with 1ml PBS was performed 3 times and then lOOpl PBS
added. Neat HDS was used a positive control and PBS as a negative control. HDS
had previously been shown to contain significant P-hexosaminidase activity and
therefore supernatant and washed 'pellet' samples were assayed for P-
hexosaminidase activity. Samples (5pl) were applied in triplicate to an ELISA plate.
Substrate solution (1.3mg/ml p-nitrophenyl-N-acetyl-P-D-glucosamine in 0.1M
sodium citrate pH 4.5; 50pl) was added and the plate incubated for 40min at 37°C.
The reaction was then quenched by addition of 150pl 0.2M glycine solution (pH
10.7) and absorbance of samples read by a microplate reader at 405nm.
6.3.2. HDS Challenge of Equine Airway Luminal Mast Cells
6.3.2.1. Subjects and Collection ofBALF
BALF was collected from control (n=6) and heaves susceptible (n=6) horses in a
high state of clinical remission being used in a concurrent study at the AHT. Control
horses comprised 2 mares and 4 geldings with a median (range) age of 1 ly (6-16y).
Heaves susceptible horses comprised 2 mares and 4 geldings with a median (range)
age of 15y (9-2ly). Prior to sampling, all horses had been maintained at pasture and
fed haylage (Marksway Horsehage) for a minimum of 3 months.
BAL was performed following sedation with 30pg/kg romifidine and 15pg/kg
butorphanol using a 12mm x 1.8m flexible video colonoscope (model EC-3801L
Pentax UK Ltd) connected to an EPM 3000 processor unit (Pentax UK Ltd). A
lavage volume of 500ml 0.9% sterile saline at 37°C was instilled into the left
dorsocaudal lung lobe in two 250ml aliquots with manual aspiration of BALF
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following each instillation. BALF recovered from each instillation was pooled and
kept on ice until further processing (approximately lOmin). The remission status of
the heaves susceptible horses and the health of the control horses was confirmed by
BALF differential neutrophil counts of <4% (Dixon et ai, 1995b) on differential cell
counts of 500 cells on Leishmans stained cytospin preparations.
Cells recovered from BAL were pelleted and washed as previously described
(6.3.1.2) and then resuspended in Tyrode's buffer at 3xl05 mast cells/ml. A lower
mast cell concentration was used compared to the calcium ionophore study in order
to ensure that sufficient cells were available for all challenges. Total cell counts and
viability were only assessed for these cells prior to final resuspension as the calcium
ionophore pilot study had shown no significant decrease in viability with the above
processing.
6.3.2.2. HDS Challenge
Aliquots of airway luminal cells (lOOpl, 3x104 mast cells) were challenged in
triplicate with 300pl challenge media at 37°C for 30min as follows:
(a) Tyrode's buffer
(b) 10"5M calcium ionophore
(c) Neat HDS
(d) HDS 1:10 dilution
(e) HDS 1:100 dilution
(f) HDS 1:1000 dilution
(g) HDS 1:10,000 dilution
The HDS used in this experiment was produced at the AHT according to the method
described by Pirie (2002) from hay that had previously been shown to result in
marked neutrophilic airway inflammation upon natural challenge in these heaves
susceptible horses, but not in the controls. This HDS contained O.lg/ml hay dust, had
a particulate count (<60pm diameter) of 286 x 108/ml and when nebulised, induced
significantly greater neutrophil influx into the pulmonary airspace in heaves
susceptible horses compared to the control group (D. Marlin, personal
173
communication). The dilution factor of the cell suspension resulted in a final
challenge concentration of 75mg hay dust/ml for neat HDS challenge. Serial
dilutions therefore resulted in final challenge concentrations of 7.5mg/ml,
0.75mg/ml, 75pg/ml and 7.5pg/ml for challenges (d) to (g) respectively.
Following challenge (30min, 37°C), cells were pelleted by centrifugation at 735g for
5min at 4°C. The supernatant was discarded as preliminary trials had shown that the
component of HDS which interfered with ELISA determination of tryptase
concentration was predominantly retained in the supernatant (sections 6.5.1.3 and
6.5.1.4). Cell pellets were washed 3 times with 1ml PBS at 735g for 5min at 4°C and
lysed by 3 freeze-thaw cycles with 450pl 1M NaCl in PBS. The lysed cell pellet
supernatant was then harvested by centrifugation at 13,000g for lOmin at 4°C and
stored at -70°C until analysis.
6.3.3. Measurement of Mast Cell Degranulation
6.3.3.1. Mouse Mast Cell Proteinase-2 ELISA
Mouse mucosal mast cell degranulation was assessed using an mMCP-2 ELISA. All
steps used a volume of 50pl/well. ELISA plates (Immulon 96W, Dynatech M 129B,
Thermo Life Sciences) were coated with lpg/ml sheep anti-mMCP-2 in carbonate
buffer (pH 9.6) and incubated overnight at 4°C. Wells were washed as described in
section 4.3.2.1 and standards (purified mMCP-2 at 0.1-5ng/ml) and samples applied
in duplicate, diluted as appropriate in ELISA buffer (section 4.3.2.1). Following
incubation at 37°C for lh, plates were washed and incubated with rat anti-mMCP-2
at 0.5pg/ml for lh at 37°C. Plates were washed and then incubated with biotinylated
rabbit anti-rat IgG (Vector Laboratories) at 1:500 dilution for 30min at 37°C.
Following washing, plates were incubated with streptavidin horse radish peroxidase
conjugate (Sigma, 1:1000) for lh at 37°C. Finally, plates were washed and TMB
substrate (Insight Biotechnology Ltd) added. After sufficient colour had developed,
0.18M H2SO4 was added to stop the reaction. Plates were read at 450nm by a
microplate reader. The standard curve was generated using a linear curve fit and
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sample concentrations calculated using Microplate Manager 4.0 software (Bio-Rad
Laboratories).
6.3.3.2. Tryptase ELISA
Pilot study samples and lysed cell pellet supernatant samples from equine airway
mast cell challenges were analysed using the tryptase ELISA. Lysed cell pellet
supernatant samples were centrifuged at 20,000g for lOmin at 4°C to ensure that all
lysed cellular debris was pelleted. Tryptase concentrations of samples were then
determined by ELISA as detailed in section 4.3.2.3.
6.3.3.3. Cytotoxicity Assay
As the cell viability of equine airway luminal cells was not assessed post-challenge,
cytotoxicity assays (Cytotoxicity Detection Kit [LDH], Roche) were performed to
ensure that challenge media had not caused a cytotoxic rather than a degranulation
response. As cells were lysed at the end of challenge, the cell pellet supernatant
should contain high concentrations of the intracellular enzyme lactate dehydrogenase
(LDH). If however cytotoxicity had occurred during challenge with HDS, prior to
cell lysis, LDH would have been discarded with the supernatant and consequently
sample LDH would be low. The use of this assay assumes that HDS cytotoxicity
would affect all cell types equally within the population, as the assay would not be
sufficiently sensitive to detect isolated mast cell cytotoxicity in the mixed cell pellets.
Lysed cell pellet samples were analysed in duplicate by addition of lOOpl reaction
mixture (Diaphorase/NAD+ with iodotetrazolium chloride and sodium lactate) to
1 OOjLtl of sample in ELISA plate wells. Following incubation at room temperature for
30min, absorbance of samples at 490nm was read by a microplate reader using a
reference filter of 600nm.
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6.3.4. Proteinase Challenge of Tracheal Explants
6.3.4.1. Tracheal Explant Air-Liquid Interface Culture
To investigate the potential role for mast cell proteinases as secretagogues, a pilot
study was performed using air-liquid interface tracheal explant culture. Tracheal
tissue was collected immediately post mortem from 3 horses euthanased at
Cambridge University Veterinary School for reasons other than pulmonary disease.
The left side of the neck was clipped and washed with chlorhexidine solution
(Hibiscrub, Astrazeneca) and the skin reflected. The cranial 6 ribs were then
removed allowing isolation and dissection of the trachea from the thorax. Tracheal
tissue was immersed in DMEM supplemented with lOOpg/ml gentamicin, 50pg/ml
penicillin, 50pg/ml streptomycin and 50pg/ml natamycin for 4h at 37°C, with a
change ofmedium at 2h. The tracheal tissue was then washed with antimicrobial-free
DMEM for 20min, 6 times. The trachea was opened by incision of the tracheal
membrane and individual tracheal rings isolated by sharp dissection. Explants of
approximately 1cm length were harvested atraumatically using a single downward
incision though the tissue and a fresh scalpel blade for each tracheal ring. Explants
were lifted by the cartilage and placed on sterile filter paper squares on top of 1%
agarose plugs in 6 well plates (Corning Life Science) with 5ml DMEM / well. Tissue
viability was assessed by addition of 1 Opl of a white suspension of 1 pm latex beads
in PBS to the surface of the explant. Cilia of viable explants cleared this latex bead
suspension to the anatomically proximal edge of the explant within 15min (fig. 6.1).
Explants were allowed to equilibrate overnight at 37°C to restore constitutive mucus
production prior to challenge.
Fig. 6.1: Assessment of tracheal explant viability by clearance of lOpl of a
suspension of 1pm latex beads in PBS to the anatomically proximal edge of the
explant (black arrowhead) over 15min. Explants sit on sterile filter paper on top of
a 1% agarose plug in 5ml DMEM. a) Latex bead suspension immediately post
application, b) latex beads starting to clear proximally at approximately 5min post
application, c) latex beads cleared to anatomically proximal edge of explant after
15min.
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6.3.4.2. Challenge ofTracheal Explants
Following equilibration overnight, viability was again assessed by latex bead
clearance. DMEM was replaced by challenge media (5ml / well) for 24h at 37°C as
follows:







(h) 10"8M eq.MCP-1 + lOOpg/ml soy bean trypsin inhibitor (SBTI)
(i) lOOpg/ml SBTI
For challenge (h), eq.MCP-1 was incubated with the chymase inhibitor SBTI for
15min prior to addition of diluent (DMEM), to ensure inactivation of chymase prior
to dilution. These challenge concentrations have previously been used to challenge
serous cells in culture.
The viability of explants was re-assessed at the end of challenge. Explants were then
cut in half and placed in 0.5ml PBS and 2ml RNA later. PBS samples were processed
immediately whereas samples in RNA later were stored at 4°C overnight and then at
-20°C until RNA extraction (approximately 2 months).
Following the first explant challenge (hereafter EXP1) it was suspected that
proteinases may not be able to penetrate through the thick tracheal cartilage and
therefore in the latter two experiments (hereafter EXP2 and EXP3, respectively)
tracheal epithelium was stripped off the cartilage by sharp excision and used as the
explant. Submersion of explants in medium for the first hour of challenge was also
employed for EXP3 in an attempt to improve proteinase tissue penetration.
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6.3.5. Measurement of Tracheal Explant Mucus Production
6.3.5.1. PASAssay
A semi-quantitative measurement of explant mucus production was determined using
the optical density of explant PBS washings following addition of PAS. Explants
were vortexed in 0.5ml PBS for 10s to release any mucus from the epithelium. PAS
(50pl) was added to lOOpl of PBS washings and the OD measured at 595nm by
spectrophotometer. The epithelium was then stripped off the tracheal cartilage (if
present) and weighed. The absorbance of washings was then expressed as OD/mg
epithelium to correct for variation in explant size. This assay is reported to have a
detection limit of l-2pg/ml mucin (Thornton et al., 1989).
6.3.5.2. Quantitative Real-Time RT-PCR for EquineMUC-5AC Upregulation
Quantification of explant mRNA expression for MUC-5AC, a gel-forming mucin
that is known to be upregulated in heaves horses (Gerber et al., 2003) was performed
on negative control explants and those deemed most likely to show a positive
response, i.e. 10"8M tryptase and 10~8M eq.MCP-1 challenged explants. If a
significant result was obtained for these maximal challenges, RNA would be
extracted from the other explant challenges. Total RNA was extracted using the
Qiagen RNeasy kit (section 5.3.6.2), reverse transcribed (section 5.3.7) and subject to
quantitative RT-PCR for the mucin gene equine MUC-5AC and the house-keeping
gene P-actin using the protocol described in section 5.3.8. Equine P-actin primers
were those described in section 5.3.8 and previously published equine MUC-5AC
primers for an 80bp fragment were used to quantify mucus production (Gerber et al.,
2003). Primers are shown in table 6.1.
Gene Forward primer 5' —> 3' Reverse primer 5' —» 3'
Equine
MUC5AC
GAG GTC TTC GAG CCG TGC GGT CAA ACA CAC AGC CTT GGT
Equine
/3-actin
TGG GCC AGA AGG ACT CAT AC CTT GAT GTC ACG CAC GAT TT




6.4.1. In Vitro Mast Cell Challenge Pilot Studies
6.4.1.1. HDS ChallengedMouseMucosalMast Cells
The mMCP-2 content of the supernatant and lysed cell pellet supernatant was
calculated from the proteinase concentrations determined by the ELISA. The
percentage mast cell degranulation for each sample was then derived using the
following equation:
% degranulation = supernatant proteinase (ng) x 100
supernatant proteinase (ng) + cell pellet proteinase (ng)
Due to the restricted sample size of this pilot study, no statistical analyses were
performed on this data.
6.4.1.2. Calcium Ionophore Challenge
The percentage mast cell degranulation for each sample was calculated as described
for mouse mucosal mast cells using mean values of triplicate data. Data were not
normally distributed and therefore a Friedman test for repeated measures was
performed to compare degranulation among challenges followed by post hoc Dunn's
test if a significant result was obtained. Supernatant tryptase content was also
compared among challenges using the same analyses.
6.4.1.3. HDS Challenged EquineAirway LuminalMast Cells
As supernatants could not be used to assess tryptase release from HDS challenged
equine mast cells (sections 6.5.1.3, 6.5.1.4), assessment of degranulation could only
be made using cell pellets. Little variation occurred in tryptase determination of
triplicates and therefore a mean value for each set of triplicate values was calculated
to give one value per challenge per horse. As basal cell pellet tryptase content was
variable between horses, challenge data were expressed as the percentage of negative
control cell pellet tryptase remaining post challenge and was calculated using the
following equation:
% negative control cell pellet = challenged cell pellet tryptase (ng) x 100
tryptase remaining negative control cell pellet tryptase (ng)
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Data were not normally distributed and therefore Friedman tests with post hoc
Dunn's test were used to examine if challenges had a significant effect on the
percentage of cell pellet tryptase remaining within control and heaves susceptible
horse populations. Responses of control and heaves susceptible horses to each
challenge were compared using Mann Whitney tests.
6.4.2. Tracheal Explants
6.4.2.1. PASAssay
The residuals from an ANOVA of the PAS assay data assumed a normal distribution
following log transformation of the PAS assay data. Significant effects of challenge,
explant experiment and their interaction on mucus production could therefore be
analysed by two-way ANOVA.
6.4.2.2. MUC-5AC mRNA Expression
The crossing threshold (Ct) at which measurable fluorescence was produced was
used to calculate the relative expression (RE) of MUC-5AC transcripts to P-actin
transcripts using the equation:
_ 2Ct P_act'n
^Ct MUC-5AC
RE values were log transformed which resulted in the residuals from ANOVA
assuming a normal distribution. Significant effects of challenge, explant experiment
and their interaction on relative expression of MUC-5AC transcripts were again




6.5.1.1. HDS Challenge ofMouse Mucosal Mast Cells
Cultured mouse mucosal mast cells had an initial viability of 88.3%. Mann Whitney
tests revealed that total cell count and viability were not significantly different
following HDS challenge (data not shown) such that HDS had no detectable
cytotoxic effect on mouse mucosal mast cells. Increased degranulation, as indicated
by increased supernatant mMCP-2 levels, was observed following calcium ionophore
challenge, however HDS challenge did not increase degranulation above basal

















Fig. 6.2: Mouse mucosal mast cell mMCP-2 degranulation
following challenge with media (neg), 10"6M calcium
ionophore (pos), neat HDS or HDS dilutions.
6.5.1.2. Calcium lonophore Challenge ofEquine Airway LuminalMast Cells
Considerable inter-horse variation in basal levels of degranulation was evident,
however the response of each horse to calcium ionophore showed a similar trend.
There was a significant difference in degranulation among calcium ionophore
challenge concentrations (p=0.012) with 10"5M and 10~4M calcium ionophore
neg pos HDS 1:10 HDS 1:100 HDS 1:1000 HDS 1:10000 HDS
Challenge
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resulting in significantly increased degranulation compared to negative control























Fig. 6.3: Percentage degranulation following negative control
(basal) or calcium ionophore (concentration shown) challenge of
airway luminal mast cells (n=4). Challenge with 10~5M and 10"4M
calcium ionophore led to significant increases in degranulation
above basal levels (p<0.05). * denotes significant increase
compared with basal degranulation; horizontal lines denote
median values.
However, cell pellets from the 10~4M calcium ionophore challenges subjectively
appeared to be very fragile compared to the other cell pellets and were susceptible to
fragmentation and loss during the washing process. This would result in a reduced
cell pellet available for lysis and give an erroneously high degranulation value.
Therefore to interpret calcium ionophore challenge data avoiding this error,
supernatant tryptase content was compared among challenges. As equal numbers of
mast cells were used in each challenge, theoretically basal supernatant tryptase
content should be similar. However, considerable inter-horse variation was evident
but again, horses showed a similar trend in response to calcium ionophore challenge.
There was a significant difference in supernatant tryptase content among challenges
(p=0.006) with supernatant tryptase content significantly increased at the KP5M
































Fig. 6.4: Supernatant tryptase content (ng) following
negative control (basal) or calcium ionophore challenge
(concentrations shown). Challenge with 10"5M calcium
ionophore led to a significant increase in supernatant
tryptase above basal levels (p<0.01). * denotes
significant increase compared to basal levels; horizontal
lines denote median values.
6.5.1.3. Effect ofHDS on Tryptase ELISA
HDS markedly inhibited ELISA determination of equine tryptase in standards
containing 1 Ong/ml tryptase (table 6.2). This effect decreased with dilution of HDS,
until it was undetectable at a 1:10,000 dilution of HDS when tryptase quantification




Neat HDS + 1Ong/ml tryptase < scale
1:10 HDS + 1Ong/ml tryptase < scale
1:100 HDS + 1Ong/ml tryptase 3.0
1:1000 HDS + 1Ong/ml tryptase 3.6
1:10,000 HDS + 1Ong/ml tryptase 7.9
Table 6.2: ELISA tryptase determination of 1Ong/ml tryptase
diluted in equal volume with HDS dilutions. HDS significantly
interfered with tryptase determination of samples. < scale =
ELISA reading below the bottom of the standard curve.
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6.5.1.4. HDS Content ofSupernatant and Cell Pellet
Neat HDS (positive control) had high levels of P-hexosaminidase activity as
determined by sample absorbance. The majority of this P-hexosaminidase activity
was retained in the supernatant following centrifugation at 735g for 5min such that
very little activity remained in the pellet following washing 3 times with PBS (table
6.3).
Sample Mean Absorbance % of Neat HDS
Absorbance
Neat HDS 1.167 100
Neat HDS s/n 1.127 97
1:10 HDS s/n 0.116 10
1:100 HDS s/n 0.009 0.8
1:1000 HDS s/n 0.002 0.2
1:10,000 HDS s/n 0.004 0.4
Neat HDS pellet 0.008 0.7
1:10 HDS pellet 0.003 0.3
1:100 HDS pellet 0.002 0.1
1:1000 HDS pellet -0.001 -0.1
1:10,000 HDS pellet 0.003 0.2
PBS -0.001 -0.1
Table 6.3: P-hexosaminidase activity (absorbance) of neat HDS
and HDS dilution supernatants (s/n) and pellets following three
PBS washings. The majority of P-hexosaminidase activity was
retained in the supernatant.
6.5.2. HDS Challenge of Equine Airway Luminal Mast Cells
The percentage of negative control cell pellet tryptase remaining in calcium
ionophore or HDS challenged airway luminal mast cells is shown for individual
horses in fig. 6.5. Whilst the response to the positive control (10"5M calcium
ionophore) was highly variable among horses, neat HDS challenge of airway mast
cells decreased cell pellet tryptase in 4/6 control horses and 6/6 heaves susceptible
horses. The median and range of percentage negative control cell pellet tryptase
remaining following each challenge in control and heaves susceptible horses are
















Fig. 6.5: Individual horse data (control n=6, heaves
susceptible n=6) for mean percentage of negative control
(neg) cell pellet tryptase remaining following challenge









10' M Calcium Ionophore 82.1 8.5-154.2 69.5 30.3-116.0
Neat HDS 40.3 20.2-284.1 28.5 10.1-53.0
1:10 HDS 78.3 41.1-361.1 63.0 47.1-75.0
1:100 HDS 77.1 16.4-95.7 92.8 67.5-112.4
1:1000 HDS 94.5 66.1-108.0 107.7 70.1-123.8
1:10,000 HDS 85.9 39.7-126.0 95.7 67.8-122.3
Table 6.4: Median and range of cell pellet tryptase remaining in challenged cell
pellets from control (n=6) and heaves susceptible (n=6) horses expressed as a
percentage of negative control.
From fig. 6.5 it can be seen that control horse 5 is an obvious outlier in response to
challenge. Statistical analyses were therefore performed following exclusion of data
from this horse. There was a significant difference in the percentage cell pellet
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tryptase remaining following challenge in heaves susceptible horses (p<0.001) but
not control horses (p=0.09). However, as exclusion of control horse 5 resulted in
analysis of only 5 control horses, this non-significant result may be due to a restricted
sample size. Heaves susceptible horses had significantly decreased cell pellet
tryptase compared to the negative control following challenge with neat HDS
(75mg/ml) (p<0.01) and 1:10 HDS (7.5mg/ml) (p<0.05) (fig. 6.6). There was no
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Fig. 6.6: Percentage of negative control (neg)
tryptase remaining in 10"5M calcium ionophore (pos)
or HDS (dilutions shown) challenged cell pellets of
control (excluding control horse 5, n=5) and heaves
susceptible (n~6) horses. * denotes significantly
different to the negative control (p<0.05).
6.5.2.1. Cytotoxicity Assay
The majority of samples had very low absorbance values indicative of low LDH
values. There was no evidence of a dose response to HDS dilutions (fig. 6.7). These
low LDH values may be the result of cell losses during washing or cell death prior to


































Fig. 6.7: Individual horse data for cytotoxicity assays of
negative control (neg), calcium ionophore (pos) or HDS
(dilutions shown) challenged cell pellets for control (n=6)
and heaves susceptible (n=6) horses.
The relationship between cell pellet tryptase and LDH with different challenges was
investigated. If HDS had a cytotoxic effect, low tryptase and low LDH (OD) values
would be expected in neat HDS challenged cell pellets. In contrast, negative control
and low HDS dilution challenged cell pellets would have high tryptase and high
LDH giving a positive correlation between cell pellet tryptase and LDH. No clear
relationship between cell pellet tryptase and LDH was evident. There appeared to be
two populations of samples, however these were not defined by challenge (fig. 6.8)














Fig. 6.8: Scatterplot of cell pellet tryptase
content (ng) and OD (representing LDH
content) of samples.
Sample ODs were at the lower limit of sensitivity for the cytotoxicity assay and the
microplate reader. Therefore, as no consistent evidence of a cytotoxic effect was
apparent, further analysis of this data was not performed.
6.5.3. Tracheal Explant Challenge
6.5.3.1. Viability ofExplants
One explant from the 10"9M tryptase challenge in EXP2 became infected with micro¬
organisms at 48h and had to be discarded. All other explants maintained good
viability throughout the course of the experiment.
6.5.3.2. PAS Assay
There was no significant difference in mucus production, as measured semi-
quantitatively by PAS assay of explant washings, among explant systems (F2,53—1.7,
p=0.19) or among challenges (Fs,53=1.1, p=0.38) (fig 6.9). Furthermore, there was no
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Fig. 6.9: PAS assay relative OD (absorbance / mass of
epithelium) values for proteinase challenged explants.
Challenge concentrations are shown on x-axis. T = tryptase,
C = eq.MCP-1, SBTI = soy bean trypsin inhibitor
(lOOpg/ml), negative = DMEM challenged explants.
Horizontal lines denote median values.
6.5.3.3. MUC-5AC mRNA Expression
No RNA could be isolated from tryptase challenged explants. Inexplicably the RNA
appeared to have degraded prior to extraction.
For the limited number of samples available, neither explant experimental design nor
challenge with 1(T8M eq.MCP-1 had a significant effect on relative MUC-5AC
transcript expression (F2,i7=2.0, p=0.18 and Fij7=0, p=0.96 respectively) (fig. 6.10).























Fig. 6.10: LoglO relative expression (RE) of MUC-5AC in
tracheal explants (EXP 1-3) challenged with DMEM
(control) or 10"8M eq.MCP-1 (chymase). Horizontal lines
denote median values.
6.6. Discussion
6.6.1. Calcium lonophore Challenge of Mast Cells
Percentage degranulation data for equine airway luminal mast cells appeared to show
a dose dependent response to calcium ionophore with little degranulation in response
to 10~6M, but significant degranulation with both 10"5M and 10"4M challenges. In
contrast, cultured mouse mucosal mast cells showed pronounced degranulation
following 10~6M calcium ionophore challenge. These findings are consistent with
other reports of variation in optimal calcium ionophore concentrations for induction
of mast cell degranulation among species (Wardlaw et al., 1986; Sommerhoff et al.,
1989b; Hare et al., 1998). The percentage degranulation data for equine airway
luminal mast cells may be misleading however, due to an erroneously high
degranulation index for lO^M calcium ionophore challenge, which appeared to be
caused by cell pellet loss during washing, as described in section 6.5.1.2. Supernatant
tryptase content was therefore considered to more accurately represent degranulation
in response to calcium ionophore challenge. Using this data, significant
degranulation of equine airway luminal mast cells only occurred following challenge
with 10~5M calcium ionophore, in agreement with a previous study by Hare et al.
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(1999). This waning response to higher concentrations of calcium ionophore has
been previously reported and is suggested to be due to over-saturation of the adenyl-
cyclase pathway by calcium or the release of mast cell inhibitory agents from other
inflammatory cells (Wardlaw et al., 1986; Sommerhoff et al., 1989b; Hare et al.,
1998). For further experiments, challenge with 10~5M calcium ionophore was
therefore chosen as the positive control.
Levels of basal airway luminal mast cell degranulation were highly variable among
horses, however it is difficult to comment upon this due to the small sample size of
this pilot study. As horses used in this pilot study were clinical cases from the
R(D)SVS hospital, their management was unknown and may have been very varied,
possibly accounting for some of the inter-horse variability in basal degranulation.
However, horses used in the HDS mast cell challenge study, which all had identical
management, also displayed variable basal cell pellet tryptase content, which may
therefore reflect inherent individual variation in basal degranulation. This variability
appeared to be independent of heaves status.
The level of basal degranulation was considerably higher in equine airway luminal
mast cells compared to that of the cultured mouse mucosal mast cells. Airway
luminal mast cells are a dynamic, heterogeneous cell population which may be
responding to their surrounding microenvironment, and have undergone
physiological or immunological degranulation during their migration into the air
spaces, in contrast to cultured cells which represent a comparatively homogenous
and quiescent cell population. Furthermore, the presence of other cells in the mixed
airway luminal cell population may provide constant low level stimulation of mast
cells increasing their basal degranulation.
Response to 10"5M calcium ionophore was very variable among horses in the HDS
study with 5/12 horses (3 control, 2 heaves susceptible horses) showing no response
to this positive control challenge. In fact, all equine mast cells challenged appeared
relatively insensitive to calcium ionophore despite a significant dose dependent
effect being evident in the pilot study. Similarly, wide inter- and intra-horse
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variability in mast cell and basophil induced degranulation has been reported
previously (Kings and de Week, 1980; Hare et al., 1998) and is also apparent in other
species (Lichtenstein, 1975; Flint et al., 1985b; Wells et al., 1986). There was no
significant difference between control and heaves horses in their response to this 10"
5M calcium ionophore positive control challenge as previously reported by Hare et
al. (1999). Similarly, there is no significant difference in basal or calcium ionophore
induced BALF mast cell degranulation in mongrel (control) and innately hyper-
responsive Basenji greyhounds (Sommerhoff et al., 1989b), control and asthmatic
humans (Casolaro et al., 1989) or control and Ascaris suum sensitised monkeys
(Wells et al., 1986). In contrast however, other authors have reported increased
spontaneous (basal) and induced histamine release from human asthmatics compared
to control individuals (Flint et al., 1985a) and Basenji greyhounds compared to
mongrel dogs (Hirshman et al., 1986).
6.6.2. Effect of HDS on Tryptase ELISA
HDS had a dramatic effect on determination of tryptase concentrations by the
ELISA. Neat HDS and a 1:10 dilution of HDS rendered tryptase undetectable. This
effect decreased with serial dilution of HDS until tryptase quantification of a sample
mixed with a 1:10,000 dilution of HDS was equivalent to that of a sample diluted
with buffer.
The components interfering with the ELISA were retained in the supernatant
following centrifugation of HDS suggesting that soluble factors, rather than
particulates, are responsible for this effect. HDS has previously been found to
contain a 28kDa serine proteinase and 85 and 160kDA metalloproteinases (Pirie,
2002). Although it is unlikely that these proteinases competed with tryptase for
binding sites, they may have inactivated the capture antibody, degraded tryptase or
otherwise interfered with the ELISA. Alternatively, other HDS components may
have interfered with tryptase binding in some way.
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This interference made it impossible to quantify tryptase concentrations of mast cell
challenge supernatants. Instead, a measure of cell pellet degranulation was
determined by expressing the amount of tryptase in the challenged cell pellet as a
percentage of the control cell pellet tryptase.
The source of p-hexosaminidase activity in HDS is unknown. HDS contains fungal
spores, bacteria and storage mites (Pirie et al., 2002b) all of which contain numerous
enzymes (Childs and Bowman, 1981; Zakharova, 1998; Stewart et al., 1998). It is
therefore speculated that these mite, bacterial and/or fungal enzymes may have been
the main source of p-hexosaminidase activity in the HDS.
6.6.3. HDS Challenge of Mast Cells
This study is the first to report in vitro challenge of equine airway mast cells with
HDS. Prior studies have investigated in vitro fungal antigen challenge of equine
airway luminal mast cells, however in vivo studies have shown that these fungal
challenges do not fully represent the natural hay / straw challenge required to initiate
a heaves response (McGorum et al., 1993d). HDS challenge was therefore used to
more closely mimic in vivo natural challenge. Mast cells from both control and
heaves susceptible horses showed evidence of a non-cytotoxic degranulation in
response to HDS challenge. Significant degranulation was observed in airway mast
cells from heaves susceptible horses challenged with neat HDS (75mg/ml) and a 1:10
dilution ofHDS (7.5mg/ml). As similar dose response patterns were observed in both
control and heaves susceptible horses, the lack of significant degranulation in control
horses was considered likely to be the result of low sample size due to the exclusion
of control horse 5 as an outlier. Indeed, there was no significant difference between
control and heaves horses in their response to any challenge. This indicates that the
increased BALP concentrations of tryptase noted in heaves horses does not appear to
be due to mast cells from heaves horses having increased responsiveness to HDS.
Although challenge of equine airway luminal mast cells with HDS has not previously
been reported, the response of equine basophils to mould and dust extracts has been
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studied. Peripheral basophils from heaves horses showed degranulation and
histamine release at lower concentrations of mould extracts than those from control
horses (Gerber et al., 1982). However, extracts of hay and straw dust did not result in
significant basophil degranulation in either control or heaves affected horses
(Dirscherl et al., 1993). This lack of peripheral blood basophil response to hay and
straw dust extract does not preclude a compartmentalised airway mast cell response.
This is demonstrated by the fact that airway luminal mast cells from asthmatics show
increased histamine release with anti-IgE compared to controls in the absence of any
peripheral blood basophil response (Flint et al., 1985a). Alternatively, the dust
extract used by Dirscherl et al. (1993), for which details are not given, may not have
been appropriate and would ideally have been tested for its ability to evoke a positive
response in heaves susceptible individuals following inhalation prior to use in in
vitro challenge, as was performed in the present study.
Similar levels of mast cell response to HDS were observed in both control and
heaves susceptible horses in this study. However, in Chapter 4 it was determined that
heaves horses had significantly increased BALF tryptase concentrations compared to
controls. This apparent contradiction could be explained by the increased number of
intra-epithelial mast cells present in the airways of heaves horses (Chapter 5) such
that there are considerably more mast cells available to respond to challenge in
heaves horses. Alternatively, the in vitro HDS challenge may have been an
excessively severe, acute challenge compared to sub-acute or chronic lower level in
vivo challenges.
This similar responsiveness of mast cells from control and heaves susceptible horses
may also suggest that the observed HDS induced mast cell degranulation is unlikely
to be via allergen specific crosslinkage of IgE to high affinity receptors (FcsRI),
further questioning the role of type I hypersensitivity in equine heaves. However, it is
also possible that both control and heaves horses were sensitised to allergens in the
hay and straw and underwent IgE-mediated mast cell degranulation, but that
subsequent events differ between control and heaves horses such that controls do not
respond clinically. This dissociation between mast cell degranulation and clinical
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response has previously been described for adenosine challenge of control and
asthmatic subjects which caused similar mast cell mediator release in both groups,
but bronchoconstriction only in asthmatic individuals (Crummy et al., 2004).
In contrast to the current study, Hare et al. (1999) reported increased histamine
degranulation in heaves horses compared to controls following in vitro challenge of
airway luminal mast cells with extracts of fungi commonly found in hay and straw. It
is therefore possible that mast cells may be activated by multiple pathways by
different dust components. Although increased BALF levels of IgE to Faeni
rectivirgula and Aspergillus fumigatus have been reported in heaves horses
compared to controls (Halliwell et al., 1993; Schmallenbach et al., 1998),
fundamental verification of the involvement of type I hypersensitivity in the
pathogenesis of equine heaves is still lacking. There is some evidence from
immunohistochemical IgE staining of lung tissue from control and heaves horses to
suggest that different phenotypes of equine heaves may occur, such that IgE
mediated responses play a role in some individuals and not others (van der Haegen et
al., 2001). In further support of this hypothesis, increased serum IgE to grain dust
and grass pollen allergens has been reported in a proportion of heaves susceptible
horses (L. Monreal, personal communication). Considerable inter-horse variation in
response to in vitro equine airway luminal mast cell challenge with fungal antigens
(Hare et al., 1999) could also be explained by phenotypic diversity of heaves horses
with Type I hypersensitivity to fungal allergens existing in some heaves phenotypes.
It is now recognised that non-immunological mast cell degranulation may also result
from activation via neuropeptides, complement, endotoxin, bacterial lectins,
cytokines, adenosine, changes in osmolality and tryptase itself (Church et al., 1989;
Bingham and Austen, 2000; Holgate, 2000; Hart, 2001; Crummy et al., 2004). HDS
may therefore induce mast cell degranulation via one of these alternative pathways.
Although grain dust can activate complement (Olenchock et al., 1980), histamine
release from grain dust challenged human lung fragments was shown to be
independent of complement activation, cell cytotoxicity and endotoxin (Chan-Yeung
et al., 1987). Antigens ofFaeni rectivirgula are also able to activate complement via
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the alternative pathway and to induce pulmonary inflammation without antigen-
antibody interaction (Slauson and Hahn, 1980). Furthermore, some Faeni
rectivirgula antigens are proteolytic enzymes with a trypsin or chymotrypsin-like
effect which may have both a direct inflammatory and antigenic effect in the lung
(Slauson and Hahn, 1980).
The presence of other cells in the luminal airway mixed cell suspension certainly
allows the possibility of indirect mast cell degranulation requiring co-factors such as
cytokines from macrophages and lymphocytes, the predominant cells present due to
horses being either controls or heaves horses in remission. Indeed, grain dust has
been shown to indirectly enhance degranulation of guinea pig lung mast cells
stimulating the release of a mast cell degranulating factor from splenic cells
immunised against grain dust allergens (Alam et al., 1988). The fact that the pure
population of mouse mucosal mast cells failed to degranulate following incubation
with HDS may also support indirect mast cell degranulation. However, the mouse
mucosal mast cells may have been incapable of an IgE-mediated response simply
due to lack of prior exposure and hence sensitisation to allergens in the hay dust.
Mucosal mast cells should be representative of airway luminal mast cells which are
believed to be of the mucosal type (Wenzel et al., 1988), however they may not be
representative of fully functioning pulmonary mast cells further matured by their
microenvironment. Alternatively, species differentiation in mast cell susceptibility to
HDS may occur. Isolation of a pure population of mast cells from BALF would be
required to investigate the role of direct or indirect airway mast cell degranulation
further. While simian mast cells have been purified from BALF using density
gradient centrifugation (Wells et al., 1986), this technique was unable to resolve mast
cells from eosinophils and neutrophils. Similarly, attempts to isolate mast cells from
human lung digests (Alam et al., 1988) resulted in only 30% purity of mast cells,
which is insufficiently pure to allow study of mast cells without contamination of
other cells. Isolation of purified mast cells from equine BALF or lung tissue has not
been described.
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The mechanism by which dust can induce mast cell degranulation therefore remains
elusive. The current study and the reports cited suggest that at least part of the
response is likely to be via non-immunological means. Basic peptides (Shanahan et
al., 1984; Chan-Yeung et al., 1987) and the lectin-like activity of grain dust (Alam et
al., 1988) have been proposed as possible pathways but require validation. Further
attempts to elucidate the mechanism of FIDS-induced mast cell degranulation could
include investigation of response following fractionation of HDS or endotoxin
removal and the use of antibodies against IgE or cytokines such as TNF-a.
Grain dust stimulated mast cell degranulation has been investigated in several
occupational asthma models. Dose dependent degranulation occurred in guinea pig
lung mast cells following challenge with 0.03 to 0.25mg/ml grain dust (Alam et al.,
1988) and in lung fragments from control human subjects following 0.1-0.5mg/ml
exposure (Chan-Yeung et al., 1987). Grain dust challenge of occupational asthmatics
also results in enhanced basophil histamine release compared to controls with a dose-
dependent response observed from 0.01 to O.lmg/ml grain dust (Park et al., 1999).
These studies have reported significant mast cell degranulation at doses considerably
lower than the current study. Grain dust may be more potent than hay dust in
stimulating mast cell degranulation, or alternatively, preferential histamine
degranulation may mean that this index of degranulation, as measured in the
occupational asthma studies, is not reflective of tryptase degranulation. The
biological significance of in vitro dust induced mast cell degranulation is difficult to
speculate upon as dust concentrations encountered by airway luminal and intra¬
epithelial mast cells naturally in vivo are unknown. It is likely that natural challenge
in vivo presents a lower level challenge over a longer period of time, however
prolonged exposure to this environment may achieve similar dust concentrations in
the pulmonary airspace as those from acute, high concentration nebulisation or in
vitro HDS challenges. The aforementioned grain dust stimulated release of a mast
cell degranulating agent from splenic cells occurs at much lower concentrations than
direct dust induced mast cell degranulation. It has therefore been suggested that this
indirect influence on degranulation may have greater biological relevance.
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Increased serum neutrophil chemotactic activity is present in occupational asthmatics
following grain dust challenge (Park et al., 1999). This chemotactic activity has been
shown to consist of heat-stable and heat-labile components, with the mast cell
proposed to be the source of the heat-stable activity (Nagy et al., 1982). This is of
interest given that the primary cellular response in exacerbation of heaves is
neutrophil influx into the pulmonary airspace and, given the current findings of HDS
induced equine airway luminal mast cell degranulation, warrants further
investigation in the horse.
In Chapter 5 it was argued that BALF mast cells may be a senescent cell population
due to lack of upregulation of tryptase transcripts following a 48h hay / straw
challenge in heaves horses. However, equine airway luminal mast cells are clearly
capable of degranulation in response to non-specific degranulating agents such as
calcium ionophore and to HDS. Therefore, whilst it appears from the time-points
examined that these luminal mast cells may not be able to upregulate mRNA
transcripts in response to challenge, contribution to increased BALF tryptase
concentrations by degranulation could occur. As previously discussed, it is believed
that intra-epithelial mast cells may play a substantial role in response to inhaled
allergens and particulates and this contribution cannot be inferred by studying only
luminal mast cell responses. Despite these limitations in fully replicating an in vivo
challenge, this in vitro system demonstrated significant mast cell degranulation
following HDS challenge of mast cells. This system will therefore be useful for
further investigating the mast cell response to HDS challenge.
6.6.4. Tracheal Explant Challenge
No increase in mucus production or upregulation in mucin gene expression was
evident following proteinase challenge of tracheal explants as measured by PAS
assay or MUC-5AC transcript expression. All explants were derived from control
horses with no history of respiratory disease. It is possible, but unlikely, that mucus
cells in heaves horses may have exaggerated responses to secretagogues such that a
response was not observed with control subjects.
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Challenge with 4xlO"6M trypsin stimulates a three-fold increase in airway secretion
o
from tracheal ring organ culture in hamsters (Niles et al., 1986). In contrast, 10" M
tryptase had no effect on mucus secretion from cultured bovine submucosal gland
serous cells (Sommerhoff et al., 1989a). Although this divergence in response may
be related to a difference in challenge proteinase concentrations, it may also be
explained by the relative contributions of submucosal glands and goblet cells to
airway secretions in different species. Rodents have few submucosal glands and
primarily secrete mucus from goblet cells in the epithelial surface whereas, in
humans and most other mammals, the majority of airway secretion is submucosal
gland derived (Sommerhoff et al., 1989a). The horse is somewhat unusual in that
there are substantial contributions from both systems but goblet cell contribution is
reported to be greater than that of the submucosal glands in both control and heaves
horses (Nicholls, 1978; Hall et al., 1998). As goblet cells are located in the epithelial
compartment, it would be presumed that local proteinase concentrations should have
been high following lh submersion in challenge medium in EXP3. Furthermore, lh
challenge is reported to be sufficient to measure a mucus degranulation response
from goblet cells in a tracheal ring organ culture (Niles et al., 1986). The air-liquid
interface culture may not have provided a suitable model of the equine airway for
mucus production with other essential co-factors possibly being absent.
Alternatively, tryptase may have dissociated into inactive monomers following
reduction in salt concentration on dilution with DMEM or by the heparin scavenging
action of lactoferrin in the tracheal mucus.
Chymase markedly stimulates mucus secretion from cultured bovine airway
8 ...submucosal gland serous cells with a 10" M chymase solution increasing mucus
production by >1500% (Sommerhoff et al., 1989a). This secretory response had a
threshold of 10"10M, and was blocked by the chymase inhibitors soy bean trypsin
inhibitor and chymostatin. As such, chymase is the most potent secretagogue for
cultured airway gland serous cells identified so far with respect to both threshold
concentration and magnitude of response (Sommerhoff et al., 1989a). Although
chymase concentrations of 10"'°M to 10"8M stimulated dose-dependent mucus release
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from cultured airway gland serous cells, we observed no response with these
concentrations with equine tracheal explants. The chymase used by Sommerhoff et
al. (1989a) was an a-chymase and therefore may not be analogous to eq.MCP-1
which is a [3-chymase. An equine a-chymase homologue, which may have similar
secretagogue properties, has not yet been identified. Furthermore, application of
chymase directly to cultured cell monolayers as used in the study by Sommerhoff et
al. (1989a) will obviously result in high chymase concentrations local to the mucus
secreting cells, whereas use of the same concentrations in explants requires the
proteinase to pass through tissue to reach submucosal glands. Not only may this
passage through the tissues be a physical impediment, it may also result in much
lower local concentrations at the submucosal glands than those applied. Therefore
although air-liquid interface explant culture allows in vitro manipulation of airway
tissue in the most physiologically natural environment, this system does not allow
direct application of proteinases to the submucosal gland area. Consequently,
improved proteinase penetration of the tissues was attempted by removal of cartilage
in EXP2 and 3 and an initial lh submersion in challenge medium for EXP3.
However, even luminal challenge of explants requires the proteinases to pass through
the covering mucus layer which contains antiproteinases (Dixon, 1992) and therefore
may have inhibited proteinase activity. Suitable equine airway gland serous cell
culture lines, which would have allowed high local proteinase concentrations
possibly more representative of in vivo periglandular mast cell degranulation, are not
presently available.
6.7. Conclusion
This study has shown that HDS causes significant in vitro airway luminal mast cell
degranulation from heaves horses at challenge concentrations of 75 and 7.5mg/ml.
Control horses appeared to respond in a similar dose dependent manner, although
statistical significance was not achieved. Control and heaves horses did not differ in
their response to HDS and therefore this HDS induced luminal mast cell
degranulation is believed to be non-IgE mediated unless both populations of horses
were sensitised. Essential co-factors for degranulation may have been provided by
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macrophages or lymphocytes in the mixed luminal cell population. The availability
of a greater number of mast cells in the epithelial compartment may be the
determinant of increased BALF tryptase concentrations in heaves horses but not
controls. Alternatively, there may be divergence of mast cell mediator release and
subsequent inflammatory events.
We were unable to demonstrate a significant increase in mucin gene expression or
mucus production in tracheal explants following proteinase challenge. It is possible
that equine mucus secreting cells may not be responsive to mast cell proteinases.
However, it was considered more likely that insufficient concentrations of
proteinases were achieved locally at the mucus glands due to either poor tissue
penetration or inactivation of proteinases.
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Chapter 7: Concluding Addendum
This series of studies has investigated the role of mast cells and mast cell serine
proteinases in equine heaves and has provided evidence for their participation in the
pathogenesis of the pulmonary inflammatory response. The key findings are
summarised below.
Cloning and sequencing of equine tryptase allowed rationalisation of its trypsin-like
enzymic activity. Uniquely among tryptases, equine tryptase contains an alanine
substitution at residue 216, which confers increased arginine specificity. This finding
may have biological significance in inflammatory pathways, affecting its spectrum of
activity compared to tryptases in other species, for example by modifying cleavage
of fibrinogen-P chains. Determination of this tryptase cDNA sequence also enabled
design of molecular tools to probe transcription of equine tryptase in airway luminal
and tissue mast cells in control and heaves affected horses. Attempted cloning and
sequencing of eq.MCP-1 resulted in the sequencing of a novel chymase similar to
equine mastocytoma derived eq.MCP-1. As the cloned sequence shared strongest
identity with lymphocyte derived granzyme proteinases, the cellular origin of the
cloned proteinase could not conclusively be determined to be the mast cell.
Clinical heaves horses had significantly elevated BALF tryptase concentrations
compared to controls or heaves horses in remission, providing in vivo evidence for
mast cell degranulation in heaves horses following challenge. Horses with other
pulmonary diseases also showed evidence of mast cell degranulation suggesting that
this may be a general component of the equine pulmonary inflammatory response
rather than a response restricted to heaves. Very little eq.MCP-1 was detected in
BALF from any of the horses sampled. Likewise, whilst tryptase immunoreactive
mast cells were common in equine lung tissue and BALF cytospins, eq.MCP-1
immunoreactive cells were scarcely observed. Therefore the chymase eq.MCP-1
appears unimportant in the lungs of healthy or heaves affected horses. Histamine was
degraded in many BALF samples that had been archived and therefore could not be
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measured reliably. It appears that BALF histamine concentrations should be analysed
or stabilised immediately post collection to avoid this degradation, or alternatively,
other more stable mediators such as tryptase be used as a measure of mast cell
degranulation.
Increased numbers of tryptase positive mast cells were observed in the airway
epithelium of heaves horses compared to controls following exposure to hay and
straw. Total numbers of mast cells in the airway tissue remained the same and
therefore this appeared to be redistribution rather than recruitment of mast cells.
There was no difference between control and heaves horses in the number of tryptase
positive mast cells in the airway lumen such that elevated BALF tryptase
concentrations occur in heaves horses without a concomitant increase in the number
of luminal mast cells. Together, these findings suggest that intra-epithelial mast cells
may be an important source of BALF tryptase. As samples were not available from
heaves horses in full remission, it is unclear whether increased intra-epithelial mast
cells are a persistent feature of the heaves airway, or whether they are recruited to the
epithelium following inciting challenge. Similarly, whilst tryptase mRNA transcripts
in airway luminal cell pellets were not increased following challenge of heaves
susceptible horses, bronchiolar tissue transcripts were significantly down-regulated
in heaves horses in the early resolution phase of disease. This down-regulation of
tryptase transcripts following removal of challenge is likely to be at least partly
responsible for the decrease in BALF tryptase concentrations as heaves horses enter
disease remission, to values not significantly different from control horses. These
results again suggest that tissue mast cells are more important in response to
challenge than luminal mast cells. Enumeration of mast cells in epithelial brushings
from horses during heaves remission and at serial time points post challenge would
allow definition of epithelial mast cell population dynamics in response to challenge.
Furthermore, sequential measurement of tryptase transcript expression in airway
brushings or biopsies from control and heaves susceptible horses before, during and
post challenge would allow further clarification of the molecular response of tissue
mast cells to challenge.
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The number ofmast cells in control and heaves affected horses were not significantly
different in other airway tissue compartments, including airway smooth muscle. This
indicates that, in contrast to human asthma, appreciable mast cell recruitment to the
smooth muscle does not occur following challenge of heaves horses, at least within
the time period studied. Consequently, mast cell mediators may not play a significant
role in bronchospasm in equine heaves.
In vitro HDS challenge of mixed cell populations harvested from the airway lumina
induced significant mast cell degranulation in heaves susceptible horses following
challenge with concentrations of 75mg/ml and 7.5mg/ml HDS. However, there was
evidence of dose dependent degranulation in response to HDS in both control and
heaves susceptible horses. The increased number of intra-epithelial mast cells in
heaves horses available to respond to inhaled challenges may explain the divergence
ofmast cell responses in control and heaves horses to in vitro and in vivo challenges.
Alternatively, acute, severe in vitro challenges may represent an excessive challenge
compared to sub-acute or chronic lower level in vivo challenges. The presence of
other cells (predominantly macrophages and lymphocytes) in the challenged airway
luminal cell population did not allow differentiation between HDS-induced direct
and indirect mast cell degranulation. The use of isolated mast cell populations
purified from lung digests or airway luminal cell pellets would aid further
understanding of this degranulation response. Alternatively, depleting airway luminal
cells of other cell types prior to HDS challenge would potentially allow identification
of cells providing essential co-factors. The evidence of HDS-induced degranulation
in both control and heaves susceptible horses may suggest a role for non-IgE
mediated mast cell degranulation. However, it is possible that both IgE and non-IgE
mediated degranulation occur, with phenotypic diversity of heaves horses
modulating the role that type I hypersensitivity plays in their response to challenge.
Treatment of control and heaves susceptible horses with monoclonal anti-IgE
antibody during in vivo dust challenge may further elucidate the role of type I
hypersensitivity in equine heaves.
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The demonstration of mast cell degranulation in heaves susceptible horses following
in vivo challenge warrants further study into the potential role of mast cell
proteinases in the pathophysiology of equine heaves. Whilst we were unable to
demonstrate mucus hypersecretion or MUC-5AC gene upregulation following in
vitro proteinase challenge, this may reflect limitations in the in vitro model rather
than precluding proteinase induced mucus secretion in heaves. Other potential effects
of tryptase include smooth muscle spasm, airway remodelling, potentiation of airway
inflammation and direct and indirect neutrophil chemotaxis. Paradoxically,
neutrophil recruitment by mast cells may ultimately aid inactivation or clearing of
tryptase from the airway by the action of heparin scavenging neutrophil lactoferrin.
The use of specific tryptase inhibitors during in vivo dust challenge of control and
heaves susceptible horses may discern pathology with a significant tryptase
contribution, thereby allowing more targeted future research.
The role of not only mast cell serine proteinases, but also the many other
potent mast cell mediators, in the pathogenesis of the pulmonary
inflammatory response remains to be fully elucidated. However, this series
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